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„But who knows what she spoke to the darkness, alone, in the 
bitter watches of the night, when all her life seemed shrinking, 
and the walls of her bower closing in about her, a hutch to 
trammel some wild thing in?” 
 
John Ronald Reuel Tolkien, The Return of the King 
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 Signs of neurodegeneration are commonly found in schizophrenic patients, albeit still 
unclear, why they occur and whether they are a cause or rather an effect of schizophrenia. 
Although there are numerous studies supporting either theory, the working hypothesis of 
this thesis is that an overactivity of mesolimbic dopaminergic pathways leads to dopamine 
neurotoxicity in terms of an increased production of reactive oxygen species (ROS), in time 
leading to oxidative stress and thereby to so-called atypical neurodegeneration. This in turn 
negatively influences i.a. frontal glutamate neurotransmission, thereby linking the proposed 
schizophrenia-models of hyperdopaminergia and hypoglutamatergia.   
 A key player in the body’s antioxidant capacity is the peroxisome. This cell organelle 
is involved in both enzymatic (e.g. through the H2O2-degrading enzyme catalase) as well as 
non-enzymatic antioxidant metabolism. Its role in schizophrenia has, however, only been 
poorly examined, even though peroxisomes additionally are the only known source to-date 
of major enzymes for the degradation of cofactors of NMDA-receptors (including NMDA 
itself). Changes in peroxisomal metabolism and abundance therefore influence both the 
brain’s capacity to degrade ROS as well as the functionality of its NMDA receptors and vice 
versa. This thesis therefore examines the reactions of peroxisomes to increased dopamine. 
 Since peroxisomes are involved in a number of other metabolic functions apart from 
antioxidant defense, their enzyme content is highly heterogeneous. Catalase and ABCD3 are 
generally used as markers for peroxisomes. Their abundance is, however, highly dependent 
on metabolic demands and therefore varies extremely between as well as within different 
organs, tissues and cells. Especially in the brain, both catalase and ABCD3 are barely 
detectable, thereby leading to a marked underestimation of true peroxisomal abundance 
and distribution. 
 In the first part of this thesis it was therefore attempted to establish a new 
peroxisomal marker, peroxin 14 (Pex14p), which is part of a docking complex on the 
peroxisomal membrane relevant for import of all matrix proteins and therefore independent 
of individual peroxisomal metabolism. 
 Using various morphological methods in a large variety of organs, tissues and cell 
types from a number of different species it could be shown that Pex14p is indeed present in 
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the membrane of every healthy peroxisome and is expressed in similarly high levels in tissue 
sections and cell cultures of different organs and species.  
 As Pex14p is also highly suited as a peroxisomal marker in all neuronal tissue, post 
mortem brain sections of schizophrenic patients and controls were analyzed regarding the 
abundance and distribution of peroxisomes as well as catalase. The results were, however, 
inconclusive, wherefore the reactions of peroxisomes to increased dopamine were analyzed 
under more controllable conditions within the second part of this thesis. The effects of 
dopamine in vitro were examined using primary murine neuronal and astrocyte cell cultures 
and the in vivo-effects in a pharmacological mouse model (through subchronic systemic 
administration of the selective, non-competitive NMDAR-antagonist MK-801). 
 Analyses of gene expression patterns from the brains of the animals show i.a. an 
activation of antioxidant pathways in MK-801-treated animals compared to vehicle-treated 
controls as well as an increase in mRNA copies of enzymes involved in NMDAR-cofactor 
degradation. 
 Morphological experiments show that dopamine changes peroxisomal reactions and 
neuronal morphology specifically and only in intact neuron-astrocyte interactions, mimicking 
the atypical neurodegeneration found in schizophrenic patients. Additionally, increased 
levels of selected antioxidant enzymes were found to be increased in the brains of MK-801-
treated animals. 
 It can therefore be concluded that dopamine does indeed lead to increased ROS 
production in the brain, which is, however, initially still countered by an increase in 
antioxidant defense mechanisms. This strengthens the initial hypothesis that oxidative stress 
(i.e. the state of disequilibrium between ROS production and antioxidant defense) is an 
effect rather than a cause of schizophrenia. 
 Finally, the dopamine-related increase in the expression of genes encoding for 
enzymes degrading NMDAR-cofactors, thereby leading to a decrease of NMDAR-mediated 
neurotransmission, shows that hyperdopaminergia and hypoglutamatergia in schizophrenia 
are not separate entities, but rather influence, uphold and even exacerbate each other. This 
led to the proposition of a new integrative model of the etiopathogenesis of schizophrenia, 
linking both hyperdopaminergia and hypoglutamatergia together. 
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1. Introduction 
 
1.1 Schizophrenia 
 
 In the current version of the International Statistical Classification of Diseases and 
Related Health Problems, 10th Revision (ICD-10), subsection F (Classification of Mental and 
Behavioural Disorders) (World Health Organization, WHO, 2007,  p. 78) schizophrenia is 
described as “characterized in general by fundamental and characteristic distortions of 
thinking and perception, and by inappropriate or blunted affect. Clear consciousness and 
intellectual capacity are usually maintained, although certain cognitive deficits may evolve in 
the course of time.” The latter aspect of the WHO definition has particularly been scrutinized 
since increasingly more findings report cognitive dysfunction as a major symptom in 
schizophrenic patients (Kuperberg & Heckers, 2000; Mueser & McGurk, 2004; Ongur et al., 
2006; van Os & Kapur, 2009) often even in the prodromal phase of first episode patients 
before the emergence of psychotic symptom (Addington, Brooks & Addington, 2003; van Os 
& Kapur, 2009). Cognitive deficits are widely accepted to be more enduring than psychotic 
symptoms (Vinogradov, 2003; Mueser & McGurk, 2004; van Os & Kapur, 2009) and are 
considered a better predictor for clinical outcome than response to treatment. The current 
development presents a resurgence of interest regarding the cognitive alterations and 
decline over the course of the disorder as originally proposed by the dementia praecox 
model of Emil Kraepelin and refuted by the diagnostic model based on the concept of 
schizophrenia by Eugen Bleuler. Some schizophrenia researchers even suggest the idea that 
cognitive symptoms (rather than psychosis) may actually be the core feature of 
schizophrenia. 
 
1.1.1 Epidemiology and societal consequences 
 Reports in prevalence and incidence of schizophrenia are extremely heterogeneous 
(Goldner et al, 2002). The average incidence is reported between 0.02 and 0.2% per year. 
Due to the often chronic course of schizophrenia the prevalence is higher, being reported 
between 0.34 and 1%. The life time prevalence is estimated around 1% (Goldner et al., 2002; 
Mueser & McGurk, 2004; Austin, 2005; Picchioni & Murray, 2007; van os & Kapur, 2009). 
Data by the WHO estimated over 26 million cases of schizophrenia worldwide in 2004, 16.7 
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million of which were classified as a disabling condition. Schizophrenia therefore belongs to 
the most severe disability class (VII), alongside severe depression, severe migraine, 
quadriplegia and terminal cancer (WHO, 2008). Üstün et al. (1999) place schizophrenia third 
in their rank of disabling effect of health conditions by severity behind quadriplegia and 
dementia. The disorder causes 8.3/8.0 million years lost to disease (YLD), making up for 
2.8/2.6% of total YLD with values for males and females respectively (WHO, 2008). 
Compared to other diseases of similar disabling effects, but far higher prevalence, 
schizophrenia is one of, if not the major burden to society, requiring a disproportionate 
share of mental health services and leading to significant work place drop out. 
Approximately 25% of beds in psychiatric care facilities are occupied by schizophrenic 
patients, who also account for 50% of hospital admissions. The total costs of treating 
schizophrenia are high, estimated to be 44.9 billion dollars in the USA for the year 1994, 2.6 
billion pounds in the UK for 1996 and 2.35 billion Canadian dollars in Canada for the same 
year (Mueser & McGurk, 2004). The total direct and indirect economic annual burden 
caused by schizophrenia is estimated at roughly 1.2 trillion dollars in the US (Austin, 2005) 
The combined economic and social costs of schizophrenia place it among the world’s top ten 
causes of disability-adjusted life-years (DALY), accounting for an estimated 2.3% of all 
burdens in developed countries and 0.8% in developing economies (Mueser & McGurk, 
2004). The disorder is slightly more common in males than females (ratio approximately 
1.4:1), but has a definitive pattern of earlier onset, combined with more negative symptoms, 
worse clinical outcome and lower chance of full recovery in men compared to women 
(Hafner et al., 1993; Picchioni & Murray, 2007). Patients usually present with their first 
schizophrenic episode during late puberty to early adolescence. 
 
Fig. 1.1_1: Gender differences in age of onset of schizophrenia (modified from Hafner et al., 1993) 
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 Schizophrenia is also recognized (directly and indirectly) as a cause of excessive 
mortality in patients. Reasons here fore are often due to social withdrawal, lack of personal 
care, well-balanced eating habits and physical activity (e.g. inducing circulatory, digestive, 
endocrine, neurological and or respiratory diseases), side effects of antipsychotic medication  
as well as a significant increase in smoking-related deaths (Brown, Inskip & Barraclough, 
2000; Evins & Goff, 2008). The rate of successful as well as attempted suicides is also 
uncommonly high in schizophrenic patients (Caldwell & Gottesman, 1990; Radomsky et al., 
1999, Tandon, 2005). 
 
1.1.2 Signs and symptoms 
 Schizophrenic symptoms can generally be grouped into four categories: Positive, 
negative, cognitive and affective. Positive symptoms include delusions, hallucinations, 
thought and speech disorders and bizarre behavior. Negative symptoms are characterized by 
a reduction in normal psychophysical processes, e.g. alogia, avolition, asociality (not to be 
mistaken for antisociality) and catatonia. Cognitive deficits are common in schizophrenic 
patients and often predate the first florid psychotic episode (see introductory remarks to 
this chapter). Schizophrenic patients on average perform one standard deviation below the 
norm in various trials testing attention, processing speed, working and long-term memory, 
executive function and social cognition (van Os & Kapur, 2009) and their premorbid IQ, years 
before the onset of psychosis, is estimated on average at one-half of a standard deviation 
below that of healthy controls (Woodberry et al., 2008). Finally, affective disorders can range 
in both extremes from the norm (blunted affect & anhedonia vs. manic symptom) or involve 
so-called inappropriate affect, during which patients show affective responses not only 
incoherent with the socially accepted emotional expression (e.g. laughing upon receiving of 
bad news), but also sometimes not matching the emotion the patient “wants” to express 
(Davison & Neale, 1998). The model currently being able to best describe the congregation 
of such a broad array of (in part) seemingly unrelated symptoms is that of aberrant salience 
(Kapur, 2003). The inability of patients to discriminate between relevant and irrelevant 
stimuli at first leads to delusional ideas, which may then mature into full-blown positive and 
affective symptoms. Aberrant salience can also directly cause cognitive symptoms since 
patients will be incapable of adequate attention, sensorimotor gating including processing 
speed, stimulus perception and recognition as well as stimulus generalization, which is an 
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integral part of many learning processes. The added advantage of this proposed mechanism 
is that it also offers an explanation for the early onset as well as persistence of cognitive 
deficits, the ongoing mental decline observed in many patients as well as the high prediction 
value of cognitive impairment regarding the outcome of the disorder. Finally, aberrant 
salience may also present as lack of salience (because, in essence, all stimuli being processed 
as equally salient means that no stimulus is more salient than the others) thereby leading to 
negative symptoms, including blunted affectivity, anhedony and even post-schizophrenic 
depression. This can be illustrated nicely by a patient quotation from McGhie & Chapman, 
(1961, p. 106): “I can’t concentrate on television, because I can’t watch the screen and listen 
to what is being said at the same time. I can’t seem to take in two things like this at the same 
time, especially when one of them means watching and the other means listening. On the 
other hand I always seem to be taking in too much at the one time and then I can’t handle it 
and can’t make sense of it.” 
 
1.1.3 Diagnostic guidelines 
 Two major diagnostic manuals exist for psychiatric disorders, the aforementioned 
ICD-10 (mostly used in Europe) and the Diagnostic and Statistical Manual of Mental 
Disorders, 4th Edition, Text Revision (DSM-IV-TR) (American Psychiatric Association, APA, 
2000). The agreement between diagnoses derived from either system is reported to be very 
high (Jakobsen et al., 2005) (q.v. table 1.1_1). 
 Both manuals share the subdivisions paranoid schizophrenia, hebephrenic or 
disorganized schizophrenia, catatonic schizophrenia, undifferentiated schizophrenia and 
residual schizophrenia, whereby the developers of the DSM-V are contemplating on 
dropping these sub-classifications (www.dsm5.org). The ICD-10 additionally defines a post-
schizophrenic depression and simple schizophrenia, a slowly progressive form of the 
disorder consisting solely of negative symptoms and without any history of hallucinations, 
delusions or any other manifestations of an earlier psychotic episode.   
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Table 1.1_1: Diagnostic guidelines according to DSM-IV-TR and ICD-10  
Diagnostic criterion Description DSM-IV-TR ICD-10 
Characteristic 
symptoms (two or 
more during 1 month 
or more) 
Delusions – thought 
echo/insertion/withdrawal/ 
broadcasting 
+ 
(one during 1 
month if delusion is 
bizarre) 
+ 
(one during 1 
month, if very 
clear) 
 
Delusions – 
control/influence/passivity/ 
perception (referred to body, 
actions, sensations or thoughts) 
+ 
(one during 1 
month if delusion is 
bizarre) 
+ 
(one during 1 
month, if very 
clear) 
 
Delusions – persistent, culturally 
inappropriate and completely 
impossible 
+ 
(one during 1 
month if delusion is 
bizarre) 
+ 
(one during 1 
month, if very 
clear) 
 Hallucinations - auditory 
+ 
(one, if running 
commentary or two 
or more conversing 
voices) 
+ 
(one during 1 
month, if very 
clear) 
 
Hallucinations – persistent, of any 
other modality + + 
 
Incoherent/disorganized speech 
(resulting from breaks or 
interpolations in the train of 
thought) 
+ + 
 
Catatonic or grossly disorganized 
behavior (incl. negativism, mutism 
or stupor) 
+ + 
 Negative symptoms + + 
 
Significant and consistent changes 
in personal behavior (loss of 
interest, aimlessness, idleness, self-
absorbed attitude, social 
withdrawal) 
only if leading to 
social/ 
occupational 
dysfunction (see 
below) 
only for Simple 
Schizophrenia 
(duration of at 
least one year) 
Duration  
at least 6 months 
(including 
prodrome and 
residual) 
at least 1 month 
Social/occupational 
dysfunction 
 + 
possibly 
subclinical during 
prodrome 
Exclusion Affective/schizoaffective disorder + + 
 
Direct effects of substance 
intoxication/withdrawal + + 
 
Direct effects of general medical 
condition (includes brain 
disease/disorder, epilepsy, hyper-
/hypoglycemia etc.) 
+ + 
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1.1.4 Neurodegeneration in schizophrenia 
 Although not mentioned in either of the commonly used diagnostic manuals, 
schizophrenia is closely associated with neurodegenerative processes. Progressive reduction 
of brain total volume, enlargement of ventricles and loss of cortical as well as subcortical 
gray matter have been found in chronic and first-episode schizophrenic patients, whereby 
the exacerbation of neurodegeneration through antipsychotic pharmacotherapy cannot be 
excluded. The amount of neurodegeneration and loss of brain connectivity correlate with 
the severity of positive symptoms (Suzuki et al., 2005; Lui et al., 2009). The cause of 
neurodegeneration is still not clear, but could likely be due to oxidative damage caused by 
dopamine neurotoxicity (personal communication by Prof. Nancy Andreasen). Interestingly, 
the neurodegenerative processes appear to differ from those found in primary 
neurodegenerative disorders like Alzheimer’s disease, as there is no evidence of significantly 
increased neuronal death or reactive gliosis (Lieberman, 1999). It appears rather that 
schizophrenic patients show signs of atypical neurodegeneration, namely reduction of 
neuronal size resulting in secondary pathological features including loss of dendritic 
arborization and synaptic density, altered synaptic plasticity and increases in neuronal 
density (Benes et al., 1991a; 1991b; Browning et al., 1993; Daviss & Lewis, 1995; Selemon, 
Rajkowska & Goldman-Rakic, 1995; Arnold et al., 1996; Perrone-Bizzozero et al., 1996; 
Glantz & Lewis, 1997, Goldman-Rakic & Selemon, 1997; Zaidel, Esiri & Harrison, 1997;  
Rajkowska, Selemon & Goldman-Rakic, 1998). 
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1.1.5 Proposed causes of schizophrenia 
 Although the list of possible causes of schizophrenia is extensive, recent studies 
suggest a gene-environment interaction model (GxE), under which most of the commonly 
described ethiopathogenetic mechanisms can be subsumed (van Os & Kapur, 2009).  
 
 
Fig. 1.1_2: GxE-model of schizophrenia and related psychoses 
 
Many findings indeed show a significantly higher risk for schizophrenia as a result of 
environmental risk factors in patients carrying risk-alleles (van Os, Kenis & Rutten, 2010). 
 
 
Fig. 1.1_3: Carriers of “risk alleles” for schizophrenia (G+) are influenced more by environmental factors 
regarding schizophrenia-related symptoms and clinical admissions than non-carriers (G-). (modified from van 
Os, Kenis & Rutten, 2010) 
 
The following section shall therefore be divided into three aspects: (a) genetic risk factors, 
(b) environmental risk factors and (c) neurochemical mechanisms or alterations. 
 
1.1.5.1 Genetic risk factors: The genetic basis of schizophrenia is widely acknowledged. The 
risk of schizophrenia is extremely high in first degree relatives of schizophrenics, especially in 
monozygous twins (this effect is exacerbated due to common in-utero environment), very 
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high in second degree relatives and still considerably higher in third degree relatives than in 
the general population: 
 
Table 1.1_1: Rates of schizophrenia among relatives of schizophrenic patients  
Familial relationship 
Schizophrenia rates among relatives of schizophrenic patients 
Tsuang & Vandermey, 
1980 (approx. values) 
Gottesman, 1991 Rowe, 1994 
Siblings 9% 9% 7.3% 
Monozygotic twins 58% 48% 44.3% 
Dizygotic twins  17% 12.1% 
Siblings - neither 
parent schizophrenic 
8.5%   
Siblings - one parent 
schizophrenic 
14%   
Same sex siblings 12%   
Opposite sex siblings 6%   
Half-siblings 3.5% 6% 2.9% 
Nieces or nephews 2.5% 4% 2.7% 
Children 12% 13%  
Children - both parents 
schizophrenic 
37%  36.6% 
Children - one parent 
schizophrenic 
  9.4% 
Grandchildren 3% 5% 2.8% 
Parents 5% 6%  
Uncles or aunts 2.5% 2%  
First cousins 3% 2% 1.6% 
General 
population/spouses 
1% 1% 1% 
 
  
 The number of association studies published on potential genetic risk factors for 
schizophrenia borders on 2000, unfortunately with highly heterogeneous and often 
inconsistent results. In order to help with the interpretation of this wide array of results, 
Allen et al., created a regularly updated and publicly accessible online database (SzGene, 
www.szgene.org) of all genetic association studies for schizophrenia published in peer 
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reviewed journals and written in English (Allen et al., 2008). For eligible polymorphisms with 
genotype data in at least four case-control samples, continuously updated random-effects 
meta-analyses are presented. In the initial paper on the SzGene-database a total of 24 
genetic variants were found in 118 meta-analyses within 16 different genes (APOE, COMT, 
DAO, DRD1, DRD2, DRD4, DTNBP1, GABRB2, GRIN2B, HP, IL1B, MTHFR, PLXNA2, SLC6A4, 
TP53 and TPH1) that showed nominally significant effects with average summary odds ratios 
of approximately 1.23. By 2011 SzGene lists a total of 1727 eligible studies performed on 
1008 genes with 8788 polymorphisms in question. The number of meta-analyses is currently 
287. SzGene also currently incorporates the findings of 14 genome-wide association studies 
(GWAS) and 12 other large-scale studies (mostly fine-mapping studies and GWAS re-
analyses/follow ups). In all these studies, merely three protein-coding genetic loci were 
found in more than one study: ZNF804A and HIST1H2BJ (in two studies each) and NOTCH4 
(in three studies). As of 2009, Taylor et al. reviewed 63 mouse models with mutations or 
complete knockouts of various considered risk genes for schizophrenia. The validity of these 
mouse models is very heterogeneous. Any inferences from knockout animals should be 
drawn with great care, since the dysfunction of an entire gene does not represent the actual 
underlying genetic component found in schizophrenic patients. Even more so, the lack of any 
protein missing through the genetic knockout during ontogeny may have influences and 
repercussions on a wide variety of (neuronal) functions not directly involved with the 
protein/gene that has been knocked out, e.g. neuronal migration and growth, 
synaptogenesis, myelination or glial (especially astrocyte) development. Finally, the vast 
interconnectivity between neuronal pathways and transmitter systems and their 
interdependence during brain maturation and ontogeny may lead to false interpretations 
regarding immediate causality, e.g. a gene knockout in transmitter system A may lead to 
alterations in the development of basal activity of transmitter systems B which in turn 
influences systems C and D, whereof only D is involved in the etiopathogenesis of the 
disorder in question. Drawing the conclusion from the exemplary knockout that alterations 
in transmitter A activity in humans causes the disorder would therefore be highly 
questionable. The issue of critical time periods for the etiopathogenesis of schizophrenia will 
therefore be addressed in the following section. 
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In humans allelic variants of many schizophrenic candidate genes have also been shown to 
have an impact on schizotypy or endophenotypes of schizophrenia in the general population 
(Stefanis et al., 2007; Billino, Hennig & Gegenfurtner, 2011a; 2011b). 
 
1.1.5.2 Environmental risk factors: Amongst the more commonly discussed environmental 
factors or negative life events (nLEs) that are discussed as being causally involved in the 
development of schizophrenia are intra-uterine and perinatal complications (e.g. intra-
uterine growth retardation, viral infections, hypoxia, malnourishment), physical, 
psychological and sexual abuse, high expressed emotions in the family, social adversity, 
double bind relationships, migration, urbanicity, stress and drug abuse (especially 
cannabinoids, cocaine, amphetamine and phencyclidine/ketamine). 
 Two concepts appear to be of major importance regarding the influences of nLEs on 
the outbreak of schizophrenia: Sensitization and critical time periods. The concept of 
sensitization refers to the observation that multiple exposure to environmental risk factors 
(either multiple single exposures to different factors or repeated exposure to similar factors 
or a combination of both) leads to a greater increase in the development of phenotypical 
symptoms, eventually resulting in lasting schizophrenia (Collip et al., 2008) 
 
Fig. 1.1_4: The concept of sensitization; Person A (green) has ‘‘normal’’ developmental expression of subclinical 
psychotic experiences that are mild and transient. Person B (yellow) has similar expression but longer 
persistence due to additional but mild environmental exposure. Person C (red) has prolonged persistence due 
to severe and/or repeated environmental exposure and subsequent transition to clinical psychotic disorder, 
which can be repeatedly and easily triggered again at later time-points by relatively mild stressors. (based on 
Collip et al, 2008) 
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 Evidence for the validity of this concept could be shown i.a. in an animal study on 
intra-uterine growth retardation induced through low-protein diet of the pregnant mother 
C57Bl/6J mice (Vucetic et al., 2010). Results showed significant alterations in dopamine 
metabolism in the offspring in comparison to pups of mice fed with a control diet (in 
essence, increase in dopaminergic neurons in the midbrain, higher levels of mRNA 
expression of genes related to dopamine metabolism, altered methylation patterns of same 
genes, increase in dopamine abundance in combination with reduced dopamine 
degradadation etc.). In regards to behavioral patterns (locomotion patterns as commonly 
used as schizophrenia-phenotypical symptom expression in rodents), however, mice did not 
show differences compared to control animals. When a second environmental risk factor 
was introduced (high fat diet or cocaine administration), experimental animals did show a 
clear phenotype.  
 
Fig. 1.1_5: Animals with intrauterine growth retardation (IUGR) initially show no schizophreniform phenotype, 
despite various significant epigenetic, morphological and neurochemical alterations, until exposed to an 
environmental stressor like cocain or high-fat diet. (modified from Vucetic et al., 2010) 
 
 Similar results regarding sensitization were found in a large national cohort study 
performed on all children born in Sweden between 1963 and 1983 (n = 2.1 million). Among 
other results the authors showed that the risk of admission for schizophrenia rose with the 
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number of adverse social variables, leading them to attribute 20% of cases of schizophrenia 
to adverse social exposure (Wicks et al., 2005). 
 Various other animal models with a wide range of validity exist for schizophrenia that 
involve environmental challenges, including brain lesions, induced metabolite deficiencies, 
intra-uterine, peri- and postnatal physical or social stress, viral infections of the pregnant 
mother animal etc. (Taylor et al., 2009; published on schizophreniaforum.org). 
 Many of the inconsistencies regarding environmental influences on the outbreak of 
psychosis can be explained through critical life or time periods. These are sensitive periods 
of neuronal development during which the basal activities and the interconnections within 
and between neuronal pathways/transmitter systems are established. In this context it is 
important to note that, apart from primary intrauterine neural development, the brain 
continues to mature long after birth with significant changes in synaptic plasticity and 
neurotransmission occurring during puberty, most likely due to the influences of sex 
steroids. Gestational brain maturation studies comparing the consequences of maternal viral 
infections show significant correlations between schizophrenia and influenza during the 
second to early third, but not the first trimester (Mednick et al., 1988; Sham et al., 1992; 
Kunugi et al., 1995). Vice versa, maternal nutritional deprivation was fund to be a major risk 
factor during the first, but not the second or third gestational trimester (Susser & Lin, 1992; 
Susser et al., 1996; Hoek, Brown & Susser, 1998; StClair et al., 2005; Xu et al., 2009). Also, 
maternal stress during pregnancy, especially during months 3-5 and 9, was shown to be 
associated with increased risk of schizophrenia compared to paternal loss during the first 
year of life (Huttunen & Niskanen, 1978). Similar results regarding critical time periods can 
be found for the influences of drug abuse during puberty, whereof especially cannabis is 
considered a major risk factor. A vast number of animal and human studies using different 
methods conclude that schizophrenia is associated to cannabis use during puberty, but not 
in adults. This can be explained through several interconnections: (a) external stimuli are 
important for unique brain development. (b) Dopaminergic systems undergo critical 
refinement during adolescence. (c) Dopaminergic, glutamatergic and GABA-ergic system 
interact in the mature and developing brain with each other as well as the endocannabinoid 
system. (d) The immature brain contains many silent glutamatergic synapses, which have 
NMDA receptors, but lack AMPA receptors (see section on glutamate transmission). These 
silent synapses are converted into functional ones during critical time periods due to the 
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incorporation of AMPA receptors. (e) Neuronal activity during critical time periods changes 
the composition of NMDA receptors, which are made up of different subunits, whereby 
immature NMDA receptors are more sensitive to glutamate and therefore to glutamate 
excitotoxicity. Therefore binding of glutamate as well as influencing the NMDA receptor 
indirectly through cannabinoids during critical periods will have long-lasting effects (for an 
extensive review on brain maturation and cannabinoids, see Bossong & Niesink, 2010). Over 
all it can be said that there is a vast amount of evidence that the influence of environmental 
factors on the development of schizophrenia is not only dependent on repetitive events as 
shown through studies on sensitization, but also that the brain undergoes significant periods 
during which it is sensitive to the influence of specific life events but not others. Therefore 
the risk of schizophrenia being exacerbated through negative life events is not only inter-, 
but also intraindividually different, meaning the same life event may or may not lead to an 
outbreak of psychosis between as well as within persons. 
 The common link between genes, environment and neurochemistry is believed to be 
active methylation and/or demethylation of genes (especially within promoter regions). 
During DNA methylation a methyl group is transferred from S-adenosyl-L-methionine (SAM) 
to (preferably) cytosine bases/deoxycytidine nucleosides through the enzyme DNA 
methyltransferase (DNA MTase, DNMT). The alterations of DNA methylation interfere with 
binding of transcription factors to promoter regions of genes, thereby altering their 
expression patterns.  
   
1.1.5.3 Neurochemical mechanisms: Two major theories regarding alterations in 
neurotransmission have been proposed as causally related to schizophrenia: The dopamine 
and the glutamate hypotheses of schizophrenia. The dopamine hypothesis as well as the 
possibility of interactions between both theories shall be discussed in more detail in the 
following chapter on dopamine. 
 The theory of glutamate hypofunction in schizophrenia was first proposed by Kim et 
al. in 1980, due to findings of low glutamate levels in the cerebrospinal fluid (CSF) of 
schizophrenic patients. These results were fortified through findings that schizophreniform 
symptoms could be induced acutely through blockage of glutamatergic N-methyl-D-
aspartate receptors (NMDARs) in healthy controls (Javitt & Zukin, 1991; Krystal et al., 1994). 
The same groups of substances were also shown to induce longer (8-24 hrs) episodes of 
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psychosis in schizophrenic patients strikingly resembling symptoms during florid episodes of 
their illness (Lahti et al., 1995). Unlike other pharmacological substances, NMDAR blockers 
are able to induce both positive and negative symptoms of schizophrenia (Bowers & 
Freedman, 1966; Krystal et al., 1994) as well as cognitive symptoms and thought disorders 
similar to schizophrenic patients (Oye, Paulsen & Maurset, 1992; Malhotra et al., 1996; Adler 
et al., 1999).  
 Post mortem studies on schizophrenic patients show changes in glutamate 
metabolism and NMDAR subunit composition (Tsai et al., 1995; Clinton & Meador-Woodruff, 
2004), and a pilot SPECT-study found reduced NMDAR binding in the hippocampus of 
medication-free schizophrenic patients (Pilowsky et al., 2006). 
 Double-blind, placebo-controlled studies have shown significant improvement in 
positive and negative symptoms comparable to control groups treated with olanzapine in 
patients treated with an agonist of the metabotropic glutamate 2/3 receptor (mGlu2/3R), 
however, with prolactin levels, extrapyramidal motor symptoms and weight gain 
comparable to placebo-treated controls (Patil et al., 2007; Mosolov et al., 2010). Due to the 
nature of the NMDAR, being both ligand- and voltage-gated (see below), agonists of other 
glutamate receptors, like the mGLU2/3R, could enhance post-synaptic membrane 
depolarization and thereby NMDAR transmission. 
 Based on the aforementioned indication of glutamatergic involvement in the 
etiopathogenesis of schizophrenia many animal models have been established using 
selective non-competitive NMDAR blockers (reviews by Bubeníková-Valesová et al., 2008 or 
Carpenter & Koenig, 2008) - alternatively mouse models were established with mutations or 
knockouts of various genes encoding for proteins involved in NMDAR-transmission. The 
most common pharmacological models of NMDAR blocking use phencyclidine (PCP, street 
name “Angel Dust”), ketamine (street name “Special K”) or dizocilpine (MK-801). Ketamine is 
still used across the world, including Germany, during full anesthesia, but usually only in 
cases where patients present with risk of peri-operative circulatory collapse, as they often 
report vivid and frightening sensory perceptions and/or nightmares during anesthesia 
(personal communication from Dr. Andrea Mietens, anesthesiologist, Giessen, Germany). In 
this thesis the pharmacological MK-801 model was chosen in male pubescent C57Bl/6J mice. 
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Table 1.1_2: Some animal correlates of schizophrenia symptoms (modified from Arguello & Gogos, 2006) 
Symptom type Clinical manifestation 
Preclinical model/ 
animal correlate 
Positive Psychomotor agitation 
Hyperlocomotion in response to 
novelty or stress 
 
Psychostimulant 
supersensitivity 
Enhanced locomotor response to 
psychostimulants 
Negative Social withdrawal 
Decreased interaction with 
conspecifics 
 Anhedonia 
Decreased reinforcing properties of 
drugs of abuse und natural rewards 
Cognitive Memory deficits 
Delayed nonmatch to sample tasks, 
serial odor span 
 
Attentional deficits 
Latent inhibition, 5-choice serial 
reaction time tasks 
 
 
Executive dysfunction Attention set-shifting task 
 
 Glutamate is the major excitatory neurotransmitter found in the mammalian central 
nervous systems, especially in the forebrain. It is stored in synaptic vesicles and released into 
the synaptic cleft upon Ca2+-dependent exocytosis, when an action potential reaches the 
presynaptic button. Apart from the aforementioned metabotropic glutamate receptors 
(mGluRs) three major ionotropic receptors are known. They are named according to their 
major agonists: AMPA (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid), kainate 
and NMDA (N-methyl-D-aspartate) receptors. AMPA and kainate receptors are ligand-gated 
ion channels involved in fast excitatory synaptic transmission and lead to depolarization of 
the postsynaptic membrane (excitatory postsynaptic potential, EPSP). NMDA receptors, 
however, are blocked through a Mg2+-ion within the channel and are therefore not only 
ligand-, but also voltage-gated, as the Mg2+ only dissociates from within the pore, if the 
postsynaptic membrane has been sufficiently depolarized. Apart from the binding sites for 
NMDA/glutamate and Mg2+ the NMDAR also has several other binding sites for cofactors, 
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like D-serine, D-cycloserine and glycin, and antagonists like ketamine, PCP and MK-801. The 
open NMDAR is a channel for sodium, potassium and, importantly, also for calcium ions. 
 
Fig. 1.1_6: N-methyl-D-aspartate receptor (NMDAR); Gly: binding site for glycine, D-serine, D-cycloserine; 
NMDA: binding site for glutamate, D-aspartate, NMDA; PCP: binding site for phencyclidine (PCP), ketamine, 
dizocilpine (MK-801) (modified from Javitt, 2006) 
 
 Influx of calcium through the NMDAR pore leads directly and indirectly to the 
activation of various kinases, including Ca2+/calmodulin dependent (CaM) kinases, mitogen-
activated protein (MAP) kinases, tyrosine kinase and protein kinases A and C. This complex 
signal transduction cascade leads to the phosphorylation of a cyclic adenosine 
monophosphate (cAMP) response element binding protein (CREB), which then binds to the 
cAMP response element (CRE) in the promoter regions of various genes, e.g. for the 
expression of proteins for new AMPA receptor formation, thereby leading to alteration of 
the synaptic strength (synaptic plasticity). This process of neurotransmitter-induced gene 
expression, referred to as long term potentiation (LTP), is known for other transmitter 
receptors (e.g. dopamine receptors of the D1-family or the serotonin receptor 5-HT2A), but is 
best studied in NMDA receptors. 
 For NMDAR activation to work, a complex interplay between neurons and astrocytes 
is necessary, since both glutamate metabolism as well as the production of cofactors involve 
astrocytes. The important cofactor D-serine, for example, is produced in astrocytes from L-
serine through the enzyme serine racemase. It has been shown to effectively reduce 
positive, negative as well as cognitive symptoms in antipsychotic-resistant schizophrenia 
patients (Tsai et al., 1998; Heresco-Levy et al., 2005). Upon Ca2+-influx into the postsynaptic 
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neuron neuronal nitric oxidide synthase (nNOS) is activated producing NO, which then 
diffuses through the neuronal and astrocyte membranes and deactivates serine racemase, 
thereby functioning as negative feedback mechanism for NMDAR transmission. It has also 
been shown that NMDAR blockage using MK-801 leads to a rapid increase in expression of 
serine racemase mRNA (Yoshikawa et al., 2004a). In this thesis serine racemase expression 
induction was therefore chosen as an internal positive control for the action of MK-801. 
 
 
Fig. 1.1_7: Time course of changes in the levels of serine racemase mRNA in several brain areas of rat after 
systemic administration of MK-801 (0.4 mg/kg); St: striatum, Hip:hippocampus, Cx: cortex (modified from 
Yoshikawa et al., 2004a) 
 
 The alternative mechanism of termination of NMDAR transmission is through 
enzymes degrading amino acids of D-chirality, such as NMDA, D-serine and D-aspartate 
(which is also an NMDAR agonist). The currently only known enzymes to perform this 
function are the peroxisomal enzymes D-amino acid oxidase (DAAO) and D-aspartate oxidase 
(D-AspOx). Both enzymes have therefore also been discussed in the context of 
schizophrenia. Findings regarding the involvement of D-AspOx are few, but Errico et al. 
(2008) showed a reduction of a commonly used schizophrenic phenotype (prepulse 
inhibition, PPI) as well as an increase in hippocampal learning through unphysiological D-
aspartate increases in an MK-801 mouse model both after oral D-aspartate administration as 
well as in mice with a targeted deletion of the D-AspOx gene.  
 DAAO, on the other hand, is currently on 40th place on SZGene’s Top Results list since 
many studies have proposed links between polymorphic variations of the encoding gene and 
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schizophrenia (Chumakov et al., 2002; Liu et al., 2004; Schumacher et al., 2004; Wood, 
Pickering & Dechairo, 2007). Post-mortem studies show elevated DAAO activities and 
expression rates in brains from schizophrenic patients (Burnet et al., 2008; Madeira et al., 
2008), and increased levels of D-serine were found in patients’ CSF and serum (Hashimoto et 
al., 2003; 2005; Bendikov et al., 2007). 
 Interestingly, Yoshikawa et al. (2004b) found that inhibition of NMDAR trafficking 
through MK-801 leads to significant increases in DAAO mRNA expression. This process is, 
however, markedly slower than the aforementioned induction of serine racemase 
expression. A possible explanation is that the increase in D-serine would also lead to an 
increase in DAAO expression. Alternatively, sequences homologous to cAMP response 
elements (CREs) were found in the 5’-flanking region of the DAAO gene (Fukui & Miyake, 
1992). It is therefore possible that the increase in DAAO activity found in patients is not 
primarily the cause of schizophrenic symptoms, but could also be a side effect of transmitter 
system interactions (e.g. through activation of dopamine release and binding to certain D1-
like receptors involved in CREB phosphorylation). This side effect would in turn exacerbate 
rather than cause a schizophrenia phenotype. This is speculative, but other interactions 
between the glutamatergic and dopaminergic systems are better established, wherefore this 
argumentation would fit in line with a proposed model of hyperdopaminergia as a 
bottleneck within the etiopathogenesis of schizophrenia (q.v. the appropriate section in the 
next chapter). 
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1.2 Reactive oxygen species and antioxidant defense systems 
 
 Interestingly, oxygen was not originally found freely in earth’s atmosphere. Free 
oxygen, released from early obligate anaerobic prokaryotes during photosynthesis, was 
absorbed by minerals. Approximately 2.4 billion years ago, after the minerals had become 
saturated with oxygen, it began to accumulate freely in the atmosphere, thereby killing off a 
large portion of obligate anaerobics, an event known as the Great Oxygenation Event (GOE). 
Survival of organisms in this new toxic atmosphere made an evolutionary step necessary, 
which took place approximately 2 billion years ago through the endosymbiosis of what were 
to become mitochondria. These organelles are not only capable of enzymatically reducing 
and thereby detoxifying ROS, but also allowed archaebacteria, that had previously obtained 
their energy through glycolysis and fermentation, to use oxygen for respiration, thereby not 
only giving an evolutionary advantage, but ultimately allowing for life outside the ocean. 
Other theories state, that mitochondria were actually not the first endosymbionts, but were 
preceded by actinobacterial ancestors, which would then evolve into peroxisomes (Duhita et 
al., 2010). These indigestible parasitic invaders were also capable of degrading ROS, but 
could not generate energy through redox metabolism. 
 Even though oxygen now is an element vital for the survival of aerobic organisms, 
mainly during the generation of energy in form of adenosine triphosphate (ATP) through 
mitochondrial respiratory chain activity (ca. 80% cellular oxygen), it is also a highly reactive 
and potentially toxic molecule. The result of these reactions (removal of electrons from 
other molecules; oxidation) can lead to the formation of reactive oxygen species (ROS), 
which can be briefly divided into radicals and non-radicals. Accumulation of ROS can alter 
the intracellular redox balance and may lead to oxidation of cellular macromolecules like 
lipids, proteins or even nucleic acids. ROS are therefore usually combated by antioxidant 
defense mechanisms of the cells, which consist of enzymatic and non-enzymatic antioxidant 
mechanisms. A state of disequilibrium between pro- and antioxidant mechanisms is referred 
to as oxidative stress (Reddy & Yao, 1996). 
 
1.2.1 Oxygen chemistry, radicals and reactive oxygen species formation 
 Oxygen is the element with the atomic number 8 in the periodic table. It is 
represented by the abbreviation O and has an atomic weight of 15.994 u (Da; g/Mol). It has 
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eight protons in its core and eight electrons, whereof six are in its valence shell, making 
oxygen a potent electron acceptor (hence the term oxidization/oxidizing agent). Its major 
function in eukaryotes is therefore that of the being the most electronegative of all electron 
acceptors in the electron transport chain of mitochondrial respiration.  
 
 
Fig. 1.2_1: Illustration of a single oxygen atom undergoing a covalent bond with two hydrogen atoms to form 
molecular oxygen. Hereby the highly reactive oxygen receives two electrons to its outer shell transferring it into 
a non reactive state. (modified from Encyclopaedia Britannica) 
 The most common oxygen-allotrope, dioxygen (O2), usually exists in its ground state 
(triplet oxygen), since this form is least reactive. Of the eight electrons involved in the double 
bind between two oxygen atoms, two each occupy a molecular orbital alone. This makes 
dioxygen a diradical. In triplet oxygen, as opposed to the alternative state called singlet 
oxygen, however, both of these unpaired electrons have equal spins, wherefore triplet 
oxygen could only accept electrons from another reaction partner with two unpaired 
electrons of opposite spin to its own (Halliwell, 2006). Other electrons involved in double 
bonds are paired in an orbital with another electron of opposite spin, wherefore they would 
not be accepted by triplet oxygen. Through energy input it can occur that one of the 
unpaired electrons inverts its spin, thereby changing triplet oxygen into the highly reactive 
singlet oxygen, which can occur during photosensitization reactions or during lipid 
peroxidation (Halliwell et al., 2006) as is also used by the immune system amongst other 
reactive oxygen species for killing of bacteria (Wentworth et al., 2002). Singlet oxygen exists 
in two possible configurations: either both opposing electrons continue to occupy one 
molecular orbital each or they pair up in one molecular orbital leaving the other completely 
empty. 
 Since dioxygen has both the character of a double bound molecule (as shown 
through the skeletal formula <O=O>) as well as that of a radical (as shown through the 
skeletal formula ·O  -O  ·) the most accurate description of the molecules nature through a 
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skeletal formula would be <O÷O>. It can be reduced through either receiving 4 electrons 
alongside 4 protons, as is the case during mitochondrial respiration, to form water (O2 + 4 H
+ 
+ 4 e-  >  2 H2O) or, receive only 2 electrons and 2 protons to form hydrogen peroxide (O2 + 2 
H+ + 2 e-  >  H2O2). This step is often a byproduct of enzymatic activity (e.g. during 
degradation of dopamine through monoamine oxidases). Although dioxygen is not a primary 
cause of oxidative damage in its triplet state, it can lead to autoxidation of other molecules. 
Especially in the brain, reaction of O2 with several aromatic neurotransmitters and their 
precursors or metabolites leads to the formation of quinones and semiquinones. These 
strong oxidizing agents consist of cyclic dione structures with two double bonded oxygen 
atoms. They no longer have aromatic character and can react with neutrophilic 
macromolecules to form other ROS. 
 
 
Fig. 1.2_2: Formation of a quinone through autoxidation of dopamine (modified from Stokes et al., 1999) 
 Dioxygen is, however, not directly the major font of intracellular ROS formation. Most 
oxidative damage comes from electron leakage during mitochondrial respiratory chain 
activity. Under physiological circumstances, electrons are transported along the inner 
mitochondrial membrane through a series of redox reactions, whereby the electrons are 
always passed on to a more electronegative redox-partner. The most electronegative 
molecule is dioxygen, which is reduced as described above by cytochrome c oxidase 
(complex IV) to water. Approximately 80% of the bodies inhaled oxygen is used in this 
pathway, which is therefore also referred to as cellular respiration (Halliwell, 2006). Through 
the energy won through these redox reactions protons are pumped from the mitochondrial 
matrix into the intermembrane space, thereby causing a proton gradient over the 
membrane, which in turn powers an ATP synthase. 
 Even under physiological conditions, however, there is a leak of electrons from this 
transport chain, mainly at complexes I and III. These free electrons then react with dioxygen 
within the mitochondrial matrix as well as the intermembrane space to form the superoxide 
radical (full name: superoxide radical anion; O2
°-). Since these electrons come one at a time, 
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molecular dioxygen can accept them even as triplet oxygen. The rate of leakage is usually 
less than 5 %, but can increase during hyperoxia (Halliwell, 2006). 
 
 
Fig. 1.2_3: Schematic illustration of the electron transport chain along the inner mitochondrial membrane 
showing common sites of electron leakage and superoxide radical anion (O2
°-) formation 
 The superoxide radical is usually not highly reactive, despite its “super” name, as it 
has only one unpaired electron left compared to dioxygen (Halliwell, 2006). It is usually 
reduced through the so called dismutation reaction (2 O2
°- + 2 H+  >  H2O2 + O2), which can 
occur spontaneously or be enzymatically catalyzed through superoxide dimutases (SODs; see 
section on antioxidant enzymes) (Maier & Chan, 2002), but also reacts with nitric oxide (NO°) 
to form peroxynitrite (ONOO-), linking the production of ROS to equally toxic reactive 
nitrogen species (RNS). The resulting hydrogen peroxide from the dismutation is then often 
broken down during Fenton reaction (H2O2 + Fe
2+  >  Fe3+ + OH° + OH-), whereby the hydroxyl 
radical (OH°) is formed. OH° is one of the most reactive chemical species known and can 
damage cellular macromolecules by oxidizing them (Maier & Chan, 2002). 
 Another major source of hydrogen peroxide and potential hydroxyl radicals is as a 
byproduct of enzymatic oxidation (e.g. through xanthine oxidase, NADPH oxidases or 
cythochromes P450). Especially relevant thereof in this context is the enzymatic degradation 
of monoamines through monoamine oxidases (MAOs). Hereby the monoamine is converted 
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into an aldehyde with H2O2 and ammonia as byproducts (RCH2NH2 + O2 + H2O  >  RCHO + 
H2O2 + NH3) (Halliwell, 2006). 
 Apart from the aforementioned, other molecules can turn into ROS, often through 
contact with another ROS (radical chain reaction) or as a byproduct of enzymatic 
catalyzation.  
Table 1.2_1: List of common reactive oxygen species (ROS) (modified from Halliwell, 2006) 
Free radicals Non-radicals 
Superoxide O2°
-
 Hydrogen peroxide H2O2 
Hydroxyl OH° Hypobromous acid HOBr 
Hydroperoxyl HO2° Hypochlorous acid HOCl 
Carbonate CO3°
- Ozone O3 
Peroxyl RO2° Singlet oxygen 
1 g 
Akloxyl RO° Organic peroxides ROOH 
Carbon dioxide radical CO2°
- Peroxynitrite ONOO- 
Singlet oxygen O2 
1 g+ Peroxynitrate O2NOO
- 
 Peroxynitrous acid ONOOH 
 Peroxomonocarbonate HOOCO2
- 
 Nitrosoperoxycarbonate ONOOCO2
- 
 
1.2.2 Antioxidant defense mechanisms and oxidative stress 
 The primary defense mechanisms of aerobic organisms against oxidative damage can 
be divided into two categories: antioxidant enzymes (AOEs) or non-enzymatic reducing 
agents. Both systems act in synergy with each other and overlap at the glutathione system. 
Additionally it is discussed, whether a subgroup of ether lipids (plasmalogens) could be 
involved in antioxidant defenses by acting as radical scavengers within cellular membranes. 
Antioxidant defense is mainly carried out within the cytoplasm, but also in cellular 
organelles; mainly in mitochondria and peroxisomes. The main group of AOEs consists of 
superoxide dismutases (SODs), catalase (CAT) glutathione peroxidase (GPx) and its synergist 
glutathione reductase (GR). The expression of genes encoding for most antioxidant enzymes 
is regulated through the transcription factors nuclear factor (erythroid-derived 2)-like 2 
(Nrf2) and peroxisome proliferator-activated receptors (PPARs). 
 There are, however, a variety of other enzymes that are important in antioxidant 
pathways, such as different peroxidases, oxidases and reductases (Matés, 2000). A group of 
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peroxidases that have been the center of attention regarding brain antioxidant defenses are 
peroxiredoxins, which reduce both molecular hydrogen peroxide as well as organic 
peroxides (RO=OR), by offering a reducing SH group which is oxidized by the peroxide to 
sulfenic acid (SOH), thereby turning the organic peroxide into an alcohol. Some 
peroxiredoxins (2-Cys) have two SH groups, whereby the other reacts with the SOH groups 
forming a disulfide bond which in turn is now reduced by thioredoxin. Peroxiredoxins have a 
lower catalytic rate compared to other peroxide reducing enzymes, like CAT or GPx, although 
this is compensated for by large concentrations and low Michaelis constant for H2O2. A 
problem with peroxiredoxin pathways is that the enzymes are inhibited and also readily 
oxidized by hydrogen peroxide, whereby low levels of H2O2 can be cleared by 
peroxiredoxins, but increasing amounts will inhibit the detoxifying enzymes. This is probably 
due to the fact that H2O2 is also used in cellular signaling as well as in the immune system, 
wherefore acute increases in intracellular concentrations of hydrogen peroxide should not 
necessarily be degraded immediately. H2O2 then activates the expression of various 
antioxidant genes, including peroxiredoxin coding genes, leading to an increase in enzyme 
production to make up for the inhibited and oxidized base content, whereby H2O2 can now 
be degraded after having “done its job”. This mechanism, however, backfires during 
excessive and prolonged hydrogen peroxide increases, making the peroxiredoxin defense 
mechanism suboptimal during oxidative stress (Halliwell, 2006). 
 The bulk of ROS is degraded through SODs, CAT and GPx, whereby SODs form the 
first of a two step degradation and CAT and/or GPx the second. SODs are metalloproteins 
and are classified depending on the metal ion in their active centers. Manganese- containing 
superoxide dismutases (MnSOD; SOD2) are found within the mitochondrial matrix, whereas 
SODs with copper and zinc (CuZnSODs) are found either in the cytoplasm and mitochondrial 
intermembrane space (SOD1) or in the interstitium (SOD3). SODs have also been reported in 
peroxisomes of rats (Wanders & Denis, 1992; Kira, Sato & Inoue, 2002) and humans (Kira, 
Sato & Inoue, 2002), while other papers refute these findings in both species (Kobayashi et 
al., 1993; Liou et al., 1993). In plants the results are clearer, since many species appear to 
have peroxisomal SODs, like peas (del Río et al., 2003), peppers (Mateos et al., 2003), 
tomatoes (Kuzniak & Sklodowska, 2005) and watermelons (Sandalio et al., 1997; Rodríguez-
Serrano et al., 2007).  
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 As mentioned before the action of SODs is to enzymatically combine superoxide 
radicals in order to form hydrogen peroxide (dismutation reaction), thereby converting one 
reactive oxygen species into another. It is therefore necessary for healthy antioxidant 
capacities that cells have SODs as well as hydrogen peroxide degrading enzymes. Out of 
these catalase is limited only to H2O2 degradation and does not peroxidize organic peroxides 
(Aebi, 1984). It is one of the most efficient enzymes known to exist, being able to catalyze 
over 40 million molecules each second (Goodsell, 2004) and therefore being unable to be 
saturated with its substrate (Lledías et al., 1998). Catalase is a homoquadromer heme-
containing metalloprotein which converts hydrogen peroxide into dioxygen and water (2 
H2O2  >  2 H2O + O2). This two-step reaction starts with a reduction of the first hydrogen 
peroxide molecule to water, whereby the second O-atom is transferred to the heme-
containing region of the enzyme. Hereby the Fe3+ is converted through the loss of its 
electron and the addition of O to Fe4+=O, wherefore the heme is now a cation radical, which 
may now oxidize the second H2O2 molecule, turning over the O-atom and being reduced 
back to its original state in the progress. 
 The alternative mechanism of H2O2-degradation is the glutathione system, which 
also degrades organic peroxides. Hereby the tripeptide glutathione (GSH) functions as a 
reducing agent and is reduced itself in a second enzymatic reaction to its original state. The 
reduction of glutathione to glutathione disulfide (GSSG) through a donation of an electron to 
the peroxide substrate is catalyzed through selenium-dependent glutathione peroxidase 
(GPx) and produces water or an alcohol (ROH). GSSG is then reduced back to GSH through 
glutathione reductase (GR), whereby an electron is transferred from NADPH (Dringen, 
Pawlowski & Hirrlinger, 2005). 
 
Fig. 1.2_4: Degradation of hydrogen peroxide (A) and organic peroxides (B) through catalase and the 
glutathione system; GR: glutathione reductase, GPx: glutathione peroxidase, GSH: glutathione, GSSG: 
glutathione disulfide ( modified from Dringen, Pawlowski & Hirrlinger, 2005)  
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 Apart from enzymatic antioxidant defense, many reducing agents exist in most cells. 
Major examples hereof are vitamins A (retinol), C (ascorbic acid) and E ( -tocopherol), b-
carotene, melatonin, uric acid, NADPH and coenzyme Q10 (ubiquinol) as well as 
metallothionein, polyamines, adenosine, urate, polyphenols, flavonoids, phytoestrogens, 
cysteine, homocysteine, taurine, methionine, s-adenosyl-L-methionine, resveratrol, 
nitroxides & plasmalogens (Matés, 2000). The role of plasmalogens in this list is insofar 
extraordinary as they are not soluble molecules, but rather a group of etherlipids which 
make up between 20 % and 55% (tissue dependent) of biological membranes. They contain a 
vinyl ether at the sn-1 position of their glycerol backbone and are therefore highly targeted 
by ROS. It has been argued that this functions as a radical scavenging system to protect the 
integrity of membranes as well as membrane proteins. This interpretation is, however, 
highly controversial, since a reduction of plasmalogens through ROS does not break the 
chain of oxidative damage, but rather leads to the formation of other highly toxic ROS. It is 
therefore not clear, whether or not plasmalogens actually have antioxidant properties 
(Lessig & Fuchs, 2009).  
 
 
Fig. 1.2_5: Overview of the major ROS generating and degrading pathways (based on Bellance, Lestienne & 
Rossignol, 2009) 
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 Under normal physiological circumstances there is a constant production of ROS, 
which are degraded through cellular antioxidant mechanisms. If this equilibrium is, however, 
shifted in a way that either the ROS production overcomes the antioxidant systems, the 
latter underfunction and cannot cope with “normal” intracellular ROS-levels or elevated ROS 
levels lead to an underfunction of antioxidant defense, in any case the result is a chronic 
shift towards prooxidant conditions in the body. This state of disequilibrium is referred to as 
oxidative stress (Reddy & Yao, 1996; Matés et al., 2000; Emerit, Edeas & Bricaire, 2004; 
Dringen, Pawlowski & Hirrlinger, 2005). Oxidative stress is assessed through the 
measurements of (by)product of peroxidation of lipids, proteins and/or DNA. Lipid 
peroxidation is classically measured through quantification of malondialdehyde (MDA) 
through a ThioBarbituric Acid Reactive Substances (TBARS) assey during which the resulting 
red fluorescent derivative is detected spectrophotometrically. Aldehydes like MDA or 4-
hydroxynonenal (4-HNE) often react with proteins leading to the formation of protein 
carbonyl groups. These are made to react to hydrazones in a 2,4-dinitrophenylhydrazine 
(DNPH) assey, which can be quantified through fluorescence measurements or using 
spectrophotometry (Castegna, et al. 2003). Finally DNA also reacts with MDA which leads to 
the adduction of the carcinogenic molecule pyrimido[1,2-a]purin-10(3H)-one (M1G). 
Different assays for M1G can be performed based on mass spectrometry or immunochemical 
techniques (Marnett, 1999a; 1999b). 
1.2.3 Pro- and antioxidant metabolism in the brain 
 Since the mammalian brain is by far the most extremely oxygenated of all organs it is 
highly susceptible to oxidative damage. Making up only approximately 2% of the body’s 
weight in humans, the cells of brain utilize 20% of the consumed oxygen (Clarke & Solokoff, 
1999). The main reason for this high oxygen turnover is the extraordinary amount of ATP 
needed for the regulation of cellular membrane potentials via Na+/K+-ATPases. As previously 
mentioned, ATP is won primarily through mitochondrial respiratory chain activity. In neurons 
this means that a high risk for the formation of superoxide radicals through electron leakage 
exists. Since all areas of the brain contain SODs, the superoxide radicals can be dismutased 
leading to the production of H2O2. But also others of the aforementioned fonts of ROS are of 
high importance in neuronal tissue. First of all, since neurons and astrocytes are 
metabolically very active cells, they produce a major amount of intracellular hydrogen and 
organic peroxides through enzymatic activity.  On the one hand there are neurotransmitter-
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degrading enzymes like monoamine oxidases, which produce both H2O2 as well as 
aldehydes. On the other hand enzymes like cyclooxygenases or lipoxygenases produce 
specific organic peroxides (Dringen, Pawlowski & Hirrlinger, 2005). High oxygenation also 
leads to increased levels of autoxidation of aromatic compounds to quinones (Stokes et al., 
1999).  
 Apart from these previously mentioned mechanisms of ROS production the brain also 
has specific risks which make it especially vulnerable to oxidative stress: (a) Brain tissue is 
highly saturated in polyunsaturated fatty acids (PUFAs) which are common targets of 
membrane tissue peroxidation (Kuhn & Borchert, 2002). (b) Neurons suffer from the 
neurotransmission-linked Ca2+-influx, both in presynaptic buttons, where Ca2+ enters the 
neurons due to voltage-gated channels that open upon an action potential in order to allow 
for Ca2+-dependent fusion of vesicular and presynaptic membranes during exocytosis, as well 
as postsynaptically in NMDAR-expressing neurons, since the NMDAR is also a Ca2+-channel. 
Ca2+ activates neuronal nitric oxide synthase (nNOS). Aditionally the brain produces NO° 
through endothelial NOS (eNOS) as well as inducible NOS (iNOS) from activated microglia. 
NOS and superoxide radicals from the highly toxic ROS peroxynitrite (ONOO-) (Emerit, Edeas 
& Bricaire, 2004). (c) Some areas of the brain, like substantia nigra, caudate, putamen and 
pallidum, are rich in metal ions like iron, which increase the risk of ROS formation (Schenck & 
Zimmerman, 2004). Also many brain proteins contain iron, such as hemoglobin, 
cytochromes, ferritin, aconitases, non-heme iron proteins in the mitochondrial electron 
transport chain, cytochromes P450, and tyrosine and tryptophan hydroxylases (Halliwell, 
2006).  
 In contrast, the antioxidant capacities of the brain are relatively poorly developed. 
Neurons have extremely low levels of catalase (Arnold & Holtzman, 1978; Holtzman, 1982), 
which even decrease with maturation (Ahlemeyer et al., 2007). Most catalase in the brain is 
located in astrocytes which play an important part in maintaining the brain’s redox 
homeostasis (Ahlemeyer et al., 2007; Fisher, 2010). The brain’s most common mechanism of 
enzymatic peroxide degradation appears to be through peroxi- and thioredoxins, which are, 
however, probably not suited for detoxification of severely increased H2O2 levels as may 
occur in the brain (see above; Halliwell, 2006). The degradation of H2O2 through 
GSH/GpX/GR appears to be the major means of preventing oxidative stress under normal 
brain-physiological conditions, but is has been shown that, as is the case for catalase, 
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neurons contain relatively low amounts of GSH, which is mainly found in astrocytes 
(Halliwell, 2006). Over all, calculation of a specific H2O2-detoxification rate constant (D = p
-1 x 
t1/2
-1; p, protein content in mg; t1/2, half-time in min; calculated for the detoxification of 100 
M H2O2) showed that neurons have the lowest peroxide disposal rate compared to other 
cells in the nervous system (Dringen, Pawlowski & Hirrlinger, 2005). 
 
 
Fig. 1.2_6: Comparison of specific H2O2-detoxification rate constants (D) between different cell types in nervous 
tissue; A: astrocytes, N: neurons, M: microglia; O: oligodendrocytes (modified from Dringen, Pawlowski & 
Hirrlinger, 2005) 
 
 Due to this high vulnerability for redox disequilibrium in the brain, oxidative stress 
has been reported in a number of neurodegenerative diseases. Examples hereof are 
Parkinson’s (Jenner, 2005; Chinta & Andersen, 2008), Huntington’s (Emeric, Edeas & Bricaire, 
2004), Alzheimer’s diseases (Moreira et al., 2005a; 2005b; 2005c; 2005d) and schizophrenia 
(see following chapter). 
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 Since dopamine trafficking is widely considered to play an important role in the 
aethiopathogenesis of schizophrenia and since it is elemental to the argumentative line of 
this thesis, it as well as several aspects of its neurochemistry, -anatomy and -
(patho)physiology shall be discussed in the following chapter. Aim of the chapter is to build 
argumentative bridges between the metabolism and neurotransmission of dopamine and 
possible neurotoxic effects of (hyper)dopaminergia as well as interactions with the 
glutamatergic system. 
1.3.1 Dopamine metabolism - synthesis and degradation:  
The biogenic monoamine dopamine was first described as a proper neurotransmitter, 
rather than only a precursor to noradrenalin, under the name of 3-hydroxy-tyramine by 
Arved Carlsson in 1958 (Carlsson et al., 1958) as was reaffirmed shortly after as an 
endogenous neurochemical agonist independently distributed of its derivative noradrenalin 
(Bertler & Rosengren, 1959a; 1959b).  
Dopamine is mainly synthesized in the CNS and to a lesser extent in the 
postganglionic neurons of the sympathetic nervous system, including the chromaffine cells 
of the adrenal medulla, from the aromatic amino acid tyrosine. Like 
noradrenaline/norepinephrine and adrenaline/epinephrine it therefore belongs the group of 
catecholamines. The pseudo-essential amino acid tyrosine can either be taken up into the 
body through food or can be synthesized in the liver from the essential amino acid 
phenylalanine by the enzyme phenylalanine hydroxylase. It is taken up into 
catecholaminergic neurons and chromaffine cells and then converted through cytoplasmic 
tyrosine hydroxylase (TH) to 3,4-dihydroxyphenylalanine (DOPA). This is the rate-limiting 
step in catecholamine synthesis. It is very common to refer to DOPA, slightly more 
accurately, as L-DOPA or levodopa. Since, however, all biologically active enantiomers of the 
catecholamine synthesis (as well as most other bioactive substances in humans) share the L-
chirality, for reasons of simplicity, unless otherwise stated, e.g. as in D-serine, all 
enantiomers are of L-chirality. 
DOPA, unlike dopamine, is able to cross the blood brain barrier and is therefore 
commonly used in the pharmacotherapy of Parkinson’s disease. It is, whether if given as a 
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supplement or synthesized endogenously, converted in the cytoplasm into mature 
dopamine through the enzyme DOPA-decarboxylase (DDC). Dopamine is then taken up into 
synaptic vesicles through the amine/proton antiporter vesicular monoamine transporter 2 
(VMAT2), also known as solute carrier family 18, member 2 (SLC18A2) (Eiden et al., 2004). In 
dopaminergic neurons, and also to a low percentage in the sympathetic nervous system and 
adrenal medulla, it is stored here and secreted during action potential controlled Ca2+-
dependent exocytosis. In (nor-)adrenergic cells it is converted further through the vesicular 
emzyme dopamine- -hydroxylase (DBH) into noradrenaline.  
Apart from the conversion into noradrenaline through DBH, dopamine is degraded in 
homovanillic acid (HVA) through a two-step reaction by the enzymes catechol-O-
methyltransferase (COMT) and monoamine oxidase (MAOA and MAOB) in synergy with 
aldehyde dehydrogenase (AD). Hereby enzymatic degradation first through COMT leads to 
the intermediate product 3-methoxytyramine (3-MT), whereas MAOs/AD convert dopamine 
into 3,4-dihydroxyphenyl acetic acid (DOPAC) (Eisenhofer, Kopin & Goldstein, 2004).  
 
 
Fig. 1.3_1: Enzymatic dopamine metabolism  
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1.3.2 The dopaminergic synapse 
The storage of dopamine within synaptic vesicles is mainly regulated through VMAT2, 
which is essential for the stability of the transmitter as well as the health of the 
dopaminergic neurons due to reduced toxicity of dopamine within the vesicle (Miyazaki & 
Asanuma, 2008; Sulzer & Zecca, 1999), whereby there is a constant equilibrium between 
dopamine uptake and diffusion into the cytoplasm (Eisenhofer et al., 2004; 2008). The 
disruption of this equilibrium is thought to be involved in increased dopamine neurotoxicity 
and shall be discussed in a later chapter. 
Upon an action potential reaching the axonic terminal button (or the chromaffine cell 
through a preganglionic sympathetic cholinergic neuron) there is an influx of Ca2+ through 
voltage-gated channels which leads to the fusion of the vesicular and the target SNAREs 
(soluble N-ethylmaleimide-sensitive factor attachment protein receptors) which in turn 
allows for the exocytotic fusion of the vesicular membrane to the presynaptic membrane of 
the terminal button (Drenckhahn, 2003) and the release of dopamine into the synaptic cleft. 
Dopamine binds to one of five types of dopamine receptors (numbered D1 through 
D5 and encoded for by the genes DRD1 through DRD5), whereby the dopamine receptors D1 
and D5 form the D1-like family and the receptors D2 through D4 form the D2-like family 
(Girault & Greengard, 2004). All dopamine receptors are G-protein coupled metabotropic 
transmembrane proteins working through the adenyl cyclase (AC), cyclic adenosine 
monophosphate (cAMP) & protein kinase A (PKA) second messenger system, whereby D1-
like receptors activate AC through the Gs alpha subunit and the D2-like receptors inhibit AC 
through the Gi alpha subunit (Civelli et al., 1991a; 1991b; Neves at al., 2002). Most dopamine 
receptors are found postsynaptically, however, the D2-receptor has two isoforms - a long 
and a short form, differentiated through a sequence of 29 amino acids - (Civelli et al., 
1991b), whereby the short form acts as a presynaptic autoceptor (Castellano et al., 1993; 
Elsworth & Roth, 1997; Jomphe et al., 2005).  
Dopamine action is terminated primarily through removal of the transmitter from the 
synaptic cleft through the dopamine active transporter (DAT), also known as the solute 
carrier family 6, member 3 (SLC6A3). It is a Na+ and Cl- (2:1 per dopamine molecule) co-
transporter powered through an ion concentration gradient generated through a Na+/K+-
ATPase. After reuptake into the presynaptic neuron via the DAT dopamine is either restored 
into vesicles through VMAT2 or enzymatically degraded through MAOs/AD (Eisenhofer, 
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Kopin & Goldstein, 2004). In the postsynaptic neuron dopamine is degraded by both COMT 
and MAOs/AD into homovanillic acid, whereas remaining dopamine in the synaptic cleft is 
katabolised through postsynaptic membrane-bound COMT (Elsworth & Roth, 1997). In the 
prefrontal cortex (PFC) neurons express significantly less DAT in comparison to those in the 
nucleus accumbens (NAcc) or the striatum. In these cases it has been shown in knockout 
mice that dopamine is taken up into postsynaptic neurons by the norepinephrine 
[noradrenalin] transporter (NET) (Morón et al., 2002). 
An important part of the dopaminergic synapse is the astrocyte, since astrocytes 
have been repeatedly shown to express DAT, COMT and both MAOs (Fisher, 2010). 
 
 
Fig. 1.3_2: Dopaminergic synapse; 3-MT: 3-methoxythyramine, AD: aldehyde dehydrogenase, COMT: catechol-
O-methyl transferase, DA: dopamine, DAT: dopamine active transporter, DDC: DOPA decarboxylase, DOPA: 3,4-
dihydroxyphenylalanine, DOPAC: 3,4-dihydroxyphenylacetic acid, HVA: homovanillic acid, MAO: monoamine 
oxidase, TH: tyrosine hydroxylase, VMAT2: vesicular monoamine transporter 2 
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1.3.3 Dopaminergic pathways in the mammalian brain 
Dopamine synthesis not only occurs in terminal buttons of dopaminergic neurons, 
but also in their somata, where it is stored into vesicles which are then anterogradely 
transported by kinesine along axonal microtubules to the synaptic terminals. These long 
axon bundles form the dopaminergic neuronal pathways. The exact number of these 
pathways depends upon different nomenclatures, but most authors consider two to three 
major systems in which dopamine acts as a neurotransmitter (nidrostriatal and mesolimbic 
[sometimes divided into mesolimbic and mesocortical]) and one in which it has hormonal 
function (tuberoinfundibular) (Civelli et al., 1991a; Van den Heuvel & Pasterkamp, 2008).  
The tuberoinfundibular system is very clearly defined as a group of hypothalamic 
neurons in the arcuate nucleus of the tuber cinereum that project to the median eminence 
and infundibulum where they secrete dopamine into the hypophyseal portal vein. It is 
transported via the bloodstream to the mammotropic acidophilic cells of the anterior 
pituitary and here inhibits the secretion of the somatotropic hormone prolactin, wherefore 
dopamine in this pathway is also referred to as prolactin inhibiting hormone (PIH). 
The first of the classical dopamine neurotransmitter systems is the nigrostriatal 
(sometimes called mesostriatal) pathway, which consists of different subpathways 
emanating from the paranigral and retrorubral nuclei and mainly the substantia nigra pars 
compacta, running in the median forebrain bundle (MFB) and terminating in the caudate and 
putamen (dorsal striatum) (Standring (ed.), 2008, Gray’s Anatomy). It is involved in the 
modulation of striatal gating and is underfunctioning in patients suffering from Parkinson’s 
disease. 
The mesolimbic and mesocortical (sometimes referred to as mesolimbocortical or 
just mesolimbic) dopamine pathways begin in the ventral tegmental area of the midbrain 
(VTA) and terminate inter alia in the nucleus accumbens (NAcc) and the prefrontal cortex 
(PFC) respectively. Since they are both considered essentially dysregulated in patients 
suffering from schizophrenia (dopamine hypothesis of schizophrenia) (Howes & Kapur, 
2009), they shall be discussed in more detail in the following section.  
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Fig. 1.3_3: Schematic illustration of the nigrostriatal (black) and mesolimbic (red) dopamine systems (modified 
from Nieuwenhuys, Voogd & van Huijzen, 2007) 
1.3.4 The mesolimbic dopamine pathways - Specific motivation and Incentive Salience 
The mesolimbic and mesocortical dopamine pathways connect the mesencephalic 
ventral tegmental area (VTA) with structured of the limbic lobe or the areas of the neocortex 
involved in limbic functions, expressiv verbis the accumbens nucleus (NAcc), amygdala, 
hippocampus (Hp) and the prefrontal cortex (PFC) (Van den Heuvel & Pasterkamp, 2008). 
Since the discovery of specific rodent behavior shown when given the opportunity of 
electrically stimulating their own mesolimbic structures, intracranial self-stimulation, ICSS 
(Olds & Milner, 1954), it has often been described as the reward pathway of the mammalian 
brain. Mapping the rat midbrain by using electric self-stimulation revealed that most of the 
neurons giving rise to ICSS-behavior when stimulated were located in the VTA. Their axons 
travel into the lateral hypothalamus, form part of the medial forebrain bundle and terminate 
within a variety of structures of the forebrain. Self-stimulation was described as a rate of at 
least 500 responses per h for 15 minutes in different trials (Crow, 1972). 
Fundamentally in the field of neuroscience these findings clearly established the 
NAcc and the mesolimbic dopamine pathway as involved in appetitive or specific motivation 
and positive reinforcement (Salamone, 1994). The specificity of this stimulus-dependent 
reward pathway sets it apart, both anatomically and functionally, from the unspecific 
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motivation system ascending from the nucleus basalis MEYNERT within the substantia 
innominata of the basal forebrain. While the nucleus basalis MEYNERT projects diffusely into 
the entire cortex and is responsible for curiosity, drive and showing behavior out of one’s 
own volition (Duncker, 1999), the mesolimbic system consists of distinct pathways involved 
in the positive reinforcement of and approach towards specific conditioned stimuli.  
The NAcc is located bilaterally of the septal area and forms part of the ventral 
striatum. It can morphologically and functionally clearly be distinguished as consisting of two 
regions - NAcc core and NAcc shell, each with distinctive chemoarchitectural properties as 
well as different afferent and efferent connections. The NAcc core merges dorsally with the 
caudate nucleus and the putamen and bears morphological resemblance to these regions. It 
has therefore been suggested by Haber et al. (1990) that the nucleus accumbens cannot be 
distinguished from other parts of the striatum. This does not, however, seem to be 
corroborated by the fact that the dorsal and ventral parts of the striatum receive individual 
dopaminergic input from different regions within the midbrain (Niewenhuys, Voodg & van 
Huijzen, 2008). 
 The main efferents of the NAcc include projections to the PFC via the ventral 
pallidum and the dorsal thalamus. It also has decending connections to the striatum and 
substantia nigra and the pontine aspects of the reticular formation, thereby leading to 
disinhibition of approach behavior. The mesolimbic dopamine system has therefore been 
described as the Behavioral Activation System (BAS) within the Reinforcement Sensitivity 
Theory of personality by Jeffery Gray et al. (1982; 1987; Gray & McNaughton, 2000, 
Pickering & Gray, 2001; McNaughton & Corr, 2004) alongside projections to the PFC from 
the NAcc and directly from the midbrain (Depue and Collins, 1999; Pickering and Gray, 2001; 
Knutson and Cooper, 2005). It has also been associated with drug seeking behavior and with 
both positive as well as negative reinforcement during the development and the 
maintenance of addiction, since almost every recreational drug has been shown to lead to 
an increase of DA-signaling to the NAcc (Di Chiara et al., 2004). Since the NAcc also 
communicates directly with the amygdala and the hippocampus it is apparently involved in 
emotional learning and positive as well as negative reinforcement during operant learning in 
a sense of association formation regarding the prediction of future rewards. This was shown 
in studies on learning in rats with destroyed VTA and NAcc. These animals were still capable 
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of learning, but showed a lack in motivation to perform reward-bringing behavior (Berridge, 
2007).  
Importantly, however, during learning a shift in the firing pattern of the nucleus 
accumbens neurons occurs. Initially the NAcc is activated by unpredictable rewards. If these 
rewards are however coupled with a specific stimulus, the NAcc will be activated by the now 
conditioned reward-predicting stimulus, but no longer upon receiving the reward. This 
reflects the acquired incentive salience of the conditioned stimulus. If the reward-predicting 
stimulus is presented (and the NAcc activated), but is not followed by a reward, the firing 
rate of the NAcc is reduced exactly at the time the reward was expected to occur (Schultz, 
Dayan & Montague, 1997). 
 Finally it has been shown that repeated stimulation of the NAcc through the same or 
strongly similar stimuli (e.g. during addiction behavior) leads to a decrease of DA release as 
well as post-synaptic activation, explaining the so called b-process of hedonic dynamics and, 
in the clinical context, many of the various symptoms associated with withdrawal. This also 
leads to an increase in wanting or craving for a specific stimulus of growing incentive 
salience (Young, Gobrogge & Wang, 2011). 
The consequences of mesolimbic hyperfunction will be discussed further under the 
aspect of the dopamine hypothesis of schizophrenia. 
 
1.3.5 The dopamine hypothesis of schizophrenia 
 According to Oliver Howes and Shitij Kapur (2009) the evolution of the dopamine 
hypothesis of schizophrenia underwent three distinct evolutionary steps. The first 
involvement of the dopaminergic system was suggested as a result of pharmacological 
studies showing the discovery of antipsychotic drugs (Delay, Deniker & Harl, 1952) and their 
effects on dopamine metabolism (Carlsson & Linqvist, 1963). The fact that dopamine 
antagonists alleviated psychosis (Carlsson, Linqvist & Magnusson, 1957; Seeman & Lee, 
1975; Creese, Burt & Snyder, 1976; Seeman et al., 1976), whereas dopamine agonists, like 
amphetamine, could induce psychotic symptoms (Lieberman, Kane & Alvir, 1987), suggested 
an underlying hyperactivity at dopaminergic synapses in patients suffering from 
schizophrenia. This first dopaminergic hypothesis focused on the dopamine receptor 
(Snyder, 1976), but did not link hyperdopaminergia to specific regions of the brain. It could 
also not explain differences between positive or negative symptomatology or explain the 
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mechanism, by which an increase of dopaminergic activity could lead to the symptoms 
observed in schizophrenia (Howes & Kapur, 2009). 
 A “modified dopamine hypothesis of schizophrenia” was published in 1991 by Davis 
et al. addressing various issues that had been at odds with the dopamine receptor 
hyppothesis. Firstly it was shown in many schizophrenic patients that metabolites of 
dopamine in the cerebrospinal fluid were not generally elevated. Secondly, the fact that 
clozapine, a drug that has rather low affinity for and occupancy at the D2-receptor, was 
superior in treating psychotic symptoms in some patients, combined with post-mortem and 
PET-studies on D2- and D3-receptors in humans, conflicted heavily with the receptor-
centered model. Thirdly, findings on differential distribution of various dopamine receptor 
subtypes, namely higher levels of D1-receptors in the cortex compared to higher levels of D2-
receptors in the striatum and NAcc, suggested regional differences in erroneous dopamine 
signaling. The final straw were PET studies showing decrease of prefrontal blood flow and its 
correlation to schizophrenic symptoms. Davis therefore proposed that schizophrenia 
resulted as a combination of cortical hypodopaminergia and subcortical hyperdopaminergia, 
a model that was suggested to explain the occurrence of positive (through striatal 
hyperfunction) as well as negative (through frontal hypofunction) symptomatology. This 
model therefore no longer focused on the causal involvement of dopamine receptors, but 
rather on the transmitter itself. The hypothesis did not, however, explain the origins of 
dopaminergic abnormalities (Davis et al., 1991). 
 A third version of the dopamine hypothesis was proposed by Howes and Kapur in 
2009 and was called the “final common pathway”-hypothesis by the authors. Instead of 
focusing singularly on the mesolimbic pathway the authors propose that schizophrenia 
results from dysfunctions of multiple neuronal systems that lead to cognitive deficits and 
negative symptoms on the one hand and to hyperactivity of the mesolimbic pathway on the 
other, this being the cause of psychosis. It has been noted by the authors that this 
hypothesis should therefore more poignantly be called the “dopamine hypothesis of 
psychosis-in-schizophrenia”.  
 The underlying idea behind the “final common pathway”-model is that mesolimbic 
hyperactivity will lead to a state of aberrant salience, namely that the VTA neurons would 
fire not only with respect to incentively salient stimuli, but rather indiscriminately to a 
variety of (often completely irrelevant) stimuli. The human mind’s need to make sense of 
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these abnormally salient stimuli or combination of stimuli would then lead to either 
delusions or hallucinations, whereby the latter would be interpreted as reflection of actual 
experiences with regard to the aberrant salience. “Thus, dopamine, which under normal 
conditions is a mediator of contextually relevant saliences, in the psychotic state becomes a 
creator of saliences, albeit aberrant ones” (Kapur, 2003, page 15). During early onset of 
schizophrenic episodes (the prodromal phase) patients will often describe noticing stimuli in 
their environment as more clearly or keenly or with greater awareness. Alternatively this 
beginning psychosis is often described as an increase in sensory sharpness or brain activity. 
Colors are described as brighter and more saturated, music is perceived as more meaningful 
and patients often describe feelings of anticipation, foreboding or even premonition. Finally, 
irrelevant stimuli are explained cognitively in a “top-down” fashion dependent on the 
experiences and psychologically relevant themes of each individual, thereby explaining the 
cultural differences in delusion and hallucination types as well as contents. As soon as an 
individual has come up with his or her “psychotic explanation” of the aberrantly salient 
stimuli, new information will be integrated into the preexisting fabrication and new stimuli 
confirming this fabrication will be specifically sought out according to the patient’s frame of 
mind. Through this, a patient may experience entire theoretical buildings of aberrant 
conclusions and fabrications. In many cases these are perceived as acoustic phenomena 
either in the own voice or in a third voice (Kapur, 2003; Kapur, Mizrahi & Li, 2005). The latter 
situation is found in extremis in patients who report thought disorders like thought removal, 
disruption or inputting.  
 Subclinical disinhibition of incentive salience and mesolimbic dopaminergic action 
could likely explain early onset cognitive impairment in patients long before the first 
schizophrenic episodes, but also endophenotypes that focus on failures in sensorimotor 
gating, e.g. reduction of prepulse or latent inhibition (PPI, LI) or deficiencies in oculomotor 
efficiency. 
 In an attempt to integrate many of the various models of the aethiopathogenesis of 
schizophrenia with the dopaminergic systems and the hypothesis of aberrant insentive 
salience, the author proposes another dopamine hypothesis of schizophrenia, that, rather 
than place mesolimbic hyperdopaminergia at the end of the pathogenetic cascade, puts it in 
the middle and could therefore be coined the “mesolimbic bottleneck theory” of 
schizophrenia. This model depends upon a number of assumptions: 
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- Risk factors or vulnerabilities (like genes, substance abuse, social adversity, obstetric 
complications or infant viral infections etc.) can cause mesolimbic hyperactivity via 
mechanisms that are both unknown and most likely relatively idiosyncratic. 
- Mesolimbic hyperactivity causes cognitive deficits, endophenotypes and full blown 
psychotic symptoms in schizophrenia through the mechanism of aberrant incentive 
salience as proposed by the “final common pathway”-model. 
- Hyperdopaminergia leads to dopamine neurotoxicity (in form of oxidative stress). 
- Dopamine neurotoxicity in turn exacerbates cognitive deficits and causes structural 
deficits on the molecular, cellular and macroscopic levels (like loss of dendritic 
arborisation, reduced synaptic connectivity, atypical neurodegeneration, changes in 
laterality, loss of gray matter volume and cortical glutamate hypofunctionality). 
- The reduced glutamatergic activity (primarily through NMDAR hypofunction or even 
loss of NMDAR transmission in certain neurons or populations of neurons) will in turn 
lead to further disinhibition of the mesolimbic dopamine pathway turning the 
neuronal impairments to a self-sustaining vicious cycle. 
 
Fig. 1.3_4: Integrative “mesolimbic bottleneck theory” of schizophrenia; left hand side: possible GxE-
interactions leading to mesolimbic hyperdopaminergia; right hand side: signs and symptoms caused by 
hyperdopaminergia, in some cases sustaining mesolimbic hyperactivity 
 
Since the proposed model hinges mainly on the latter aspects, namely that 
hyperdopaminergia leads to dopamine neurotoxicity and dopamine induced oxidative stress 
and that reduced NMDAR activity in the forebrain in term leads to mesolimbic 
hypodopaminergia, they shall be discussed in more detail in the following sections. 
1.3 Dopamine - Metabolism, transmission and neurotoxicity 41 
 
 
1.3.6 Dopamine neurotoxicity and dopamine induced oxidative stress 
 Dopamine neurotoxicity depends widely on dopamine stability and abundance. While 
dopamine is prone to auto-oxidation in the intra- and extracellular spaces, it appears 
relatively stable within the presynaptic storage vesicles (Riddle, Fleckenstein & Hanson, 
2006). This mechanism is due to differential pH inside the vesicles (pH ca. 5.5) as compared 
to outside (pH ca. 7.5) (Rudnick & Clark, 1993; Eiden & Weihe, 2011). Substances belonging 
to the amphetamine family act as potent dopamine releasers from both the synapse and the 
vesicles, by interacting with both the DAT and VMAT2, being taken up into the presynaptic 
terminal and vesicles and then reversing the flow-direction of both transporters (Sulzer & 
Rayport, 1990; Fleckenstein et al., 2007). Dopamine is therefore found in large abundance in 
the cytoplasm and the synaptic cleft, where is begins to form reactive oxygen species (ROS) 
not only through auto-oxidation (Riddle, Fleckenstein & Hanson, 2006), but also through 
enzymatic degradation. The brains of humans or other mammals abusing or treated with 
amphetamines can therefore be considered as pivotal in vivo models for neurotoxicity and 
oxidative stress caused by hyperdopaminergia. The ability of amphetamines to release 
dopamine in the human brain has been shown in methamphetamine users (Laruelle et al., 
1995, Wilson et al., 1996; Moszczynska et al., 2004). And indeed, post-mortem gas 
chromatography-mass spectrometry studies showed significantly elevated levels of 
malondyaldehyde and 4-hydroxynonenal, both products of oxidative damage, in the 
caudate, frontal cortex and cerebellum of chronic methamphetamine users compared to 
controls (Fitzmaurice et al., 2006). The direct connection between these two findings has 
been examined in animal studies. Reviews suggest that methamphetamine leads to damage 
of dopaminergic synaptic terminal buttons caused by excessive oxidative stress possibly 
related to the formation on dopamine-derived oxidation products (Davidson et al., 2001). 
 Dopamine-induced oxidative stress was also reported in astrocyte cultures 
(Hirrlinger, Schulz & Dringen, 2002). In vitro neuronal cultures exposed to dopamine show 
oxidative stress as well as a significant decrease in dendritic spines (Grima et al., 2003).  
The activation of antioxidant genes through treatment with 6-Hydroxydopamine in vitro and 
in vivo was demonstrated in mice by Jakel et al. (2005), whereas more recent studies have 
shown dopamine to induce activity of Nrf2 (nuclear factor 2), a transcriptional factor that 
activates the expression of various antioxidant defense pathways by binding to the 
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antioxidant response element (ARE) in the promoter regions of antioxidant genes, through 
formation of ROS (Shih, Erb & Murphy, 2007). 
 The neurotoxicity of dopamine injections into the rat striatum, as measured through 
death of tyrosine hydroxylase-positive neurons as well as measurements of oxidation 
products of dopamine, were attenuated by equimolar injections of antioxidants like ascorbic 
acid or glutathione, which makes the oxidative capacity of excess dopamine more than likely 
(Hastings, Lewis & Zigmond, 1996). 
 In a pharmacological model of chronic Parkinson’s disease, part of the symptoms of 
which are generally considered to be caused by dopamine neurotoxicity and dopamine-
induced oxidative stress (Chinta & Andersen, 2008), even showed significant reduction of 
morphological, biochemical and behavioral Parkinson’s markers, when mice were pretreated 
with rosiglitazone, a PPAR  (peroxisome proliferator active receptor )-agonist and activator 
of antioxidant transduction pathways (Schintu et al., 2009). PPAR-agonists have since been 
suggested as therapeutic targets in the treatment of Parkinson’s (Chaturvedi & Beal, 2008). 
Similar results were found when Parkinson’s animals were treated with various cannabinoids 
of different receptor selectivity, also suggesting that the antioxidant capacity of these plant-
derived agents protect neurons against dopamine neurotoxicity (Lastres-Becker et al., 2005).  
 The biochemical mechanisms of dopamine neurotoxicity are auto-oxidation on the 
one hand and formation of ROS byproducts during enzymatic degradation on the other. 
 Dopamine has been shown to form highly reactive quinones through enzymatic 
action, presence of metal ions and spontaneous auto-oxidation, thereby causing damage to 
intracellular macromolecules like lipids, proteins or even nucleic acids (Stokes et al., 1999, 
Sulzer & Zecca, 1999). The quinone formation and therefore the cytotoxic potential is higher 
in dopamine compared to other catecholamines, due to the fact that dopamine oxidizes to 
quinones faster and reduces back more slowly (Graham, 1978; Graham et al., 1978). 
 Dopamine degradation through MAOs leads to the formation of the byproduct H2O2 
(Maker et al., 1981), which has high potential of producing ROS like hydroxyl radicals (OH°) 
through the Fenton reaction (Stokes et al., 1999). These in turn increase the rate of auto-
oxidation of dopamine to dopamine-quinone (Nappi et al., 1995) creating a vicious cycle of 
positive reinforcement between these two pathways of dopamine neurotoxicity through 
ROS formation. 
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Fig. 1.3_5: Biochemical mechanisms of dopamine neurotoxicity and dopamine induced oxidative stress 
(modified from Stokes et al., 1999) 
 
1.3.7 Oxidative stress in schizophrenia 
 Albeit prone to fall victim to oxidative damage, not only through dopamine 
neurotoxicity, the brain is poorly equipped with antioxidant defense mechanisms (Halliwell, 
1992, 2006). It is therefore not overly surprising that many researchers attribute various 
neuropathologies to oxidative stress. Especially for Parkinson’s disease and schizophrenia 
countless papers have linked these disorders of dopaminergic neurotransmission to 
dopamine neurotoxicity and oxidative stress.  
 Several studies have been published over the last thirty to forty years showing 
alterations of antioxidant enzyme levels and activities in blood cells of patients suffering 
from chronic schizophrenia (Glazov & Mamzev, 1976; Golse et al., 1978; Abdalla et al., 1986; 
Reddy et al., 1991; Mukherjee et al., 1996) as well as increases in plasma lipid peroxidation 
products (Prilipko, 1984; Peet at al., 1993; Mahadik et al., 1995; 1998) or both (Ranjenkar et 
al., 2003; Zhang et al., 2006). More recent studies even found significant correlations 
between antioxidant enzyme activities and levels of lipid peroxidation products in the blood 
of schizophrenic patients and measures of psychopathology (Li et al., 2006; Zhang et al., 
2006).  
 Addressing the issues of inferences of blood data on CNS metabolism, these findings 
have been corroborated through studies on post-mortem brain samples taken from 
schizophrenic patients and compared to matched controls. Results show membrane 
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phospholipid abnormalities, altered glutathione redox state and increased nitric oxide 
radicals (Yao, Leonard & Reddy, 2000; 2004; 2006) and overall impairments of the fatty acid 
composition (Horrobin et al., 1991; McNamara et al., 2007). Examinations of levels of 
thiobarbituric acid reactive substances (TBARS), another harmful lipid peroxidation product, 
also revealed elevated levels in the CSF of schizophrenic patients (Pall et al., 1987; Lohr et 
al., 1990). 
 Overall, although there are many findings that suggest significant oxidative damage 
or oxidative stress in schizophrenic patients, there are major confounding factors like typical 
vs. atypical neuroleptical therapy, schizophrenia type, age of onset and duration since onset. 
It is therefore difficult to find clear correlations between schizophrenic symptoms and 
oxidative stress. Furthermore the question of causal relationship - the chicken and the egg 
issue - cannot be answered through status quo analyses of schizophrenic patients. 
 Research therefore calls for different approaches to this topic, like endophenotype 
research in healthy and/or subclinical subjects or animal studies in which schizophreniform 
phenotypes can be induced specifically and controlled regarding the emergence of oxidative 
damage or antioxidant responses. 
 The two most common pharmacological models for schizophrenia in rodents are the 
amphetamine- and NMDAR-antagonist-models. Since the mechanism of amphetamine-
induced hyperdopaminergia (as described above) is less representative of likely metabolic 
alterations in the human schizophrenic brain, the model of NMDAR-antagonists seems the 
more internally and externally valid, since it appears to lead to an increase in endogenous 
dopamine pathway activity. Furthermore it mirrors the concept of schizophrenia being 
described as “dopaminergic noise and glutamatergic silence” (conference statement by 
Bernd Gallhofer, 2010), thereby allowing for a possible combination of two of the major 
described schizophrenia-theories into one conjoint model. The advances of this model and 
the most-likely connection between the glutamatergic and dopaminergic systems shall 
therefore be described in the next paragraph. 
 
1.3.7.1 NMDAR blockage leads to an increase in mesolimbic dopamine release: The 
associations of the glutamatergic system, especially the NMAR linked neurotransmission, to 
schizophrenic symptoms are observed clearly in humans, non-human primates and other 
mammalian species. Firstly, drugs blocking the NMDAR, like Ketamin, Phencyclidin 
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(Phenylcyclohexylpiperidin, PCP) and Dizocilpine (MK-801) lead to a specific 
schizophreniform phenotype both observed in overt behavior and in endophenotypical 
research (e.g. PPI-inhibition) (Luby, 1959; Long, Malone & Taylor, 2006). Secondly, patients 
with a past history of schizophrenia exhibit pronounced and sustained relapses after taking 
NMDAR-blockers (Domino and Luby, 1981; Braff, Geyer & Swerdlow, 2001; Yui et al, 1999a; 
1999b; 1999c). 
 This does not, however, answer the question whether this is an independent 
mechanism or whether there is a neuronal connection between NMDAR-transmission and 
mesolimbic dopamine release in a direction that blocking the NMDAR leads to an increase in 
dopamine in the striatum (especially the NAcc) and other regions of the forebrain. 
 PCP was shown to be a potent blocker of the NMDAR in the early 1980s, by when it 
had become a major recreational drug since its availability for this purpose under the name 
“angel dust” in the 1960s (Lodge & Anis, 1982). MK-801 was identified as another NMDAR-
antagonist shortly thereafter (Coan, Saywood & Collingridge, 1987). 
 An increase of dopamine was observed in microdialysis studies after NMDAR-blocking 
using MK-801 in different regions of the rat brain, namely the striatum and the NAcc 
(Loscher, Annies & Hönack, 1991; Mathé et al., 1996) as well as the medial PFC (Kuroki et al., 
1999). Apart from its role in NMDAR-antagonism, PCP was also shown to block dopamine 
reuptake (Pechnick, Bresee & Poland, 2006), although it was shown clearly that the increase 
of dopamine in the medial PFC, unlike in the striatum, is not mediated through blocking of 
dopamine reuptake, but rather through increasing dopamine flow to the mPFC from 
subcortical or even subprosencephalic regions (Nishijima et al., 1996). A similar conclusion, 
namely that the mechanism of dopamine increase is independently of reuptake-inhibtion 
was drawn for MK-801 (Wolf et al., 1994). It can therefore be assumed that NMDAR-
antagonists activate the mesolimbic and mesocortical dopamine pathways, rather than only 
inhibit the reuptake of dopamine in the forebrain. These findings from animal studies are 
also observed in imaging studies performed on human subjects (Kegeles et al., 2000; 
Laruelle, Kegeles & Abi-Dargham, 2003; Narendran et al., 2005).  
 Pharmacological influences on PCP- or MK-801 induced hyperdopaminergia as well as 
disruption of PPI and LI have been described for 1-adrenoceptor ligands (Mathé et al., 
1996; Takahashi, Horikomi & Kato, 2001), 5-HT2A/2C-receptor agonists and antagonists 
(Kuroki et al., 1999), lithium carbonate (Umeda et al., 2006) as well as cannabidiol (Long, 
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Malone & Taylor, 2006). Unpublished data from PsychoGenics showed attenuation of PCP- 
or MK-801 induced schizophreniform symptoms in rodents through olanzepine, clozapine, 
haloperidol and aripiprazole (www.psychogenics.com/pdf/Psychosis.pdf).  
 It is commonly suggested that neuronal pathways involved in mesolimbic 
disinhibition through blocking of NMDARs would have to be modulated through GABAergic 
interneurons which attenuate dopamine production in the VTA as well as release in the 
NAcc, when activated through the glutamatergic efferents. Upon blockage of NMDARs on 
these glutamatergic neurons, GABAergic neurons projecting onto mesolimbic dopaminergic 
neurons would no longer be activated, leading to a disinhibition of the mesolimbic pathway.  
 
 
Fig. 1.3_6: Interactions between the (frontal) glutamatergic and the mesolimbic dopamine system showing the 
mechanism of NMDAR-antagonist induced mesolimbic hyperdopaminergia; inhibition of NMDA-receptors leads 
to a reduction of GABAergic attenuation and thereby to disinhibition of dopaminergic neurons in the VTA and 
their axon terminals in the NAcc. 
 
1.3.7.2 Oxidative stress in pharmacological models of schizophrenia using NMDAR-
antagonists: Results regarding the influences of selective NMDAR-antagonists are few, but 
ambiguous. Some studies report antioxidant effects of treatment with NMDAR-blockers in 
cases of otherwise induced oxidative stress (Drian et al., 1991; Kalonia et al., 2009; da Cunha 
et al., 2011; Noh et al., 2011), probably through inhibition of glutamatergic excitotoxicity 
(Gao et al., 2007; Cheng et al., 2008; Sun et al., 2010). Other groups showed that MK-801 
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could enhance activity of antioxidant enzymes (Harkany et al., 1999; Selakovic, Janac & 
Radenovic, 2010), which can be interpreted in line with the argumentation that NMDAR-
blocking has alternative prooxidant effects which in turn would activate antioxidant 
defenses, since no direct interaction between NMDAR-antagonists and antioxidant signal 
transduction has been reported. A study by Bondy & Guo (1996) strengthens this hypothesis 
by showing that protective effects of MK-801 could not be attributed to antioxidant 
substance effects. 
 Experiments in which NMDAR-blockers were given not in combination with other 
prooxidant treatments showed that these drugs actually induce oxidative damage when 
given alone (Sharma et al., 1997; Rajdev, Fix & Sharp, 1998; Alva, Palomeque & Carbonell, 
2006; Zuo et al., 2007; de Oliveira et al., 2009; da Silva et al., 2010; Radonjic et al., 2010; 
Wang et al., 2010). These studies often also report subsequent increases in antioxidant 
defense mechanisms and are therefore in agreement with the interpretation that possible 
protective mechanisms of NMDAR-blockers are not only mediated through inhibition of 
glutamate excitotoxicity, but also induce antioxidant systems through their own prooxidant 
capacities. This supposition is strengthened further by showing that oxidative damage from 
MK-801 could be attenuated through antioxidant supplements (Ozyurt et al., 2007a; 2007b; 
Willis & Ray, 2007). Finally, Nasr, Carbery & Geddes (2009) found that NMDAR-antagonists 
had moderate to no protective effects on striatal degeneration induced through 3-
nitropropionic acid (3NP) injections, but rather exacerbated motor deficits caused by 3NP 
administration. Taken into account that ketamine, PCP and MK-801 are known to decrease 
sensorimotor gating and induce motor deficits, most likely through mesolimbic dopamine 
release, these findings seem so support the argumentation on the pro- vs. antioxidant 
effects of selective NMDAR-blocking.   
 Taken together, the ambiguity of results could be explained through the assumed 
interaction between the glutamatergic and dopaminergic systems. It can therefore be 
assumed that NMDAR-antagonists activate the mesolimbic and mesocortical pathways and 
thereby induce oxidative damage, which in turn leads to increases in antioxidant defense 
mechanisms. The MK-801-model of psychosis in animals and the activation of antioxidant 
metabolism as a measure for the extent of dopamine neurotoxicity can therefore be 
considered internally valid and shall be used in this thesis. 
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1.4 Peroxisomes 
 
 Peroxisomes are single lipid bilayer membrane organelles found in almost all 
eukaryotic cells including plant cells. They were first described by Rhodin (1954) in the 
proximal tubule of the mouse kidneys and referred to by him as microbodies. The name 
“peroxisome” was given by Christian de Duve (de Duve & Baudhuin, 1966), who was the first 
to isolate peroxisomes from rat liver and identify them as cell organelles (de Duve, 1969). 
The name was chosen due to his findings of various oxidases as well as a peroxidase 
(catalase) within the peroxisome. The phylogenic origins of peroxisomes are still unclear, 
although the fact that peroxisomal proteins are mostly formed on free ribosomes and 
imported into the organelles post-translationally, fully folded, oligomeric and co-factor-
bound directly from the cytoplasm (Léon, Goodman & Subramani, 2006) suggests a certain 
degree of (semi)autonomy as found in endosymbionts like mitochondria and chloroplasts. 
The fact that peroxisomes have no DNA and only a single membrane could be explained by 
the theory that peroxisomes preceded mitochondria in the phylogenic timeline, which could 
also explain why, unlike mitochondria, peroxisomes have the capability of degrading ROS 
and very long chain fatty acids (VLCFAs), but cannot generate ATP (q. v. chapter 1.2). These 
suggestions have been criticized (Gabaldón & Capella-Gutiérrez, 2010) and other 
mechanisms of peroxisomal biogenesis involving the ER have been discussed (Hoepfner et 
al., 2005; Kim et al., 2006; Titorenko & Mullen, 2006). Studies on peroxisomal ontogeny 
suggest that these finding do not, however, necessarily exclude the possibility of 
endosymbiotic peroxisomal origins (see following section). 
 
1.4.1 Peroxisomal ontogeny and metabolism 
 Out of the over 80 genes encoding for peroxisomal proteins found in Homo sapiens, 
roughly three quarters encode for metabolic enzymes, whereas the other 20 are involved in 
peroxisomal ontogeny, proliferation and maintenance (Schrader & Fahimi, 2008). The group 
of proteins expressed from these genes is referred to as peroxins and numbered 
continuously (e.g. peroxin 1, Pex1p; encoded by the PEX1 gene). 
 Preperoxisomal vesicles are generated both through division of existing peroxisomes 
as well as through budding off of the ER (South & Gould, 1999, Kim et al., 2006; Titorenko & 
Mullen, 2006). 
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Fig. 1.4_1: Peroxisomal biogenesis in plants and mammals (modified from Titorenko & Mullen, 2006) 
 The import of Pex16p into the membrane of this organelle precursor then turns the 
vesicle into a nascent peroxisome, which may then, upon import of members of the peroxin 
11 family, divide further to form new nascent peroxisomes. This mechanism is also relevant 
during the duplication of mature peroxisomes (South & Gould, 1999). Thereby new 
peroxisomes may proliferate both from pre-existing peroxisomes or be synthesized de novo. 
 
Fig. 1.4_2: A model of peroxisome biogenesis in the absence (top) and presence (bottom) of preexisting 
peroxisomes (adapted from South & Gould, 1999) 
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 Apart from Pex16p other perosisomal membrane proteins (PMPs) are then imported 
through mechanisms that are not clearly understood. PMPs that are synthesized on free 
polyribosomes contain a membrane targeting signal (mPTS) and are bound and shuttled to 
the nascent peroxisome by Pex19p and recruited into the membrane through binding to 
Pex3p. Pex16p is required for this machinery in mammals, although its exact function is not 
clear. Lack of all or either of these proteins therefore leads to complete absence of 
detectable peroxisomes (Schrader & Fahimi, 2008).  
 Peroxisomal progeny from preexisting parent organelles includes three steps: 
Elongation of parent peroxisomes, constriction leading to a “pearls on a string” appearance 
and, finally, fission into new daughter organelles. Elongation is thought to be controlled 
through members of the Pex11p family, fission through dynamin-like GTPases (DLPs), which 
are recruited from the cytosol to the dividing peroxisome through fission 1 protein (Schrader 
& Fahimi, 2008). 
 
Fig. 1.4_3: Pex11p-dependent peroxisomal proliferation (modified from Schrader & Fahimi, 2008) 
 Import of enzymes into the peroxisomal matrix requires the presence of a docking 
complex within the peroxisomal membrane. This complex is made up of the peroxins 13, 14 
and 17. Matrix proteins contain specific targeting signals (sequences of amino acids) either 
at the C-terminus (peroxisomal targeting signal 1, PTS1) or the N-terminus (PTS2) which are 
bound by Pex5p and Pex7p respectively and shuttled through these to the nascent 
peroxisome, where they interact with the docking complex described above. The actual 
dissociation and translocation into the matrix probably involves peroxins 2, 8, 10 and 12, 
leaving Pex5p and Pex7p to be recycled back into the cytoplasm. The exact method of 
transport through the peroxisomal membrane is unclear, since peroxisomes do not have 
pores unlike the nucleus, through which matrix proteins could be imported (Schrader & 
Fahimi, 2008). 
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Fig. 1.4_4: Peroxisomal matrix protein import 
1.4.2 Peroxisomal metabolism 
 Peroxisomes are involved in a majority of metabolic pathways, including ROS 
metabolism, -oxidation of VLCFAs, -oxidation of branched chain fatty acids, ether lipid 
synthesis and D-amino acid degradation. In the context of this thesis emphasis shall only be 
laid on ROS- and D-amino acid-metabolism. For a full list of peroxisomal functions see table 
1.4_1 (from Schrader & Fahimi, 2008). 
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Table 1.4_1: List of peroxisomal functions (modified from Schrader & Fahimi, 2008) 
Peroxide metabolism (catalase and H2O2-generating oxidases), ROS/NOS metabolism 
Lipid biosynthesis (i.a. ether phospholipids/plasmalogens, bile acids & cholesterol) 
Fatty acid -oxidation (i.a. VLFCAs, branched chain fatty acids, unsaturated fatty acids) 
Fatty acid -oxidation 
Long chain and VLCFA activation 
Regulation of acyl-CoA/CoA ratio 
Protein/amino acid metabolism (i.a. D-amino acid degradation, transamination, proteases) 
Catabolism of purines 
Glyoxylate and dicarboxylate metabolism 
Hexose monophsphate pathway 
Glycerol synthesis 
Nicotinate and nicotinamide metabolism 
Retinoid metabolism 
 
 Peroxisomes contain a number of enzymes that generate as well as others that 
degrade ROS, mainly in the form of hydrogen peroxide. The importance of peroxisomal 
antioxidant defense can be shown through incubation of cultured cells in UV radiation or 
with H2O2, whereby peroxisomes are shown to elongate, which is the first step in 
peroxisomal progeny. This effect is clearly linked to the detoxification of ROS as it could be 
attenuated through pre-incubation with the antioxidant N-acetylcysteine (Schrader, 
Wodopia & Fahimi, 1999). Cells successively adapted to increasing levels of dioxygen where 
shown to not only be able to survive in excessive O2-concentrations (99%), but also shown 
twice the amount of peroxisomes, both compared to control cells (van der Valk et al., 1985). 
H2O2-incubation has also been shown to increase the expression of various peroxin-encoding 
genes (Lopez-Huertas et al., 2000; Desikan et al., 2001). Finally, ROS induction also increases 
activity of peroxisomal AOEs (van der Valk et al., 1985; Dhaunsi et al., 1993). A full overview 
of peroxisomal ROS-metabolism is described in Schrader & Fahimi (2004; 2006). 
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Table 1.4_2: List of ROS-producing and -degrading peroxisomal enzymes (modified from Schrader & Fahimi, 
2006) 
 
Enzymes in peroxisomes that generate ROS 
 
Enzyme Substrate ROS 
Acyl-CoA oxidases 
Long chain fatty acids, methyl 
brachend fatty acids, bile acid 
intermediates 
H2O2 
Urate oxidase (not in 
hominoids) 
Uric acid H2O2 
Xanthine oxidase Xanthine H2O2, O2°
- 
D-amino acid oxidase D-amino acids H2O2 
Pipecolic acid L-pipecolic acid H2O2 
D-aspartate oxidase D-aspartate, NMDA H2O2 
Sarcosine oxidase Sarcosine, pipecolate H2O2 
L-alpha-hydroxy acid oxidase Glycolate, lactate H2O2 
Poly amine oxidase N-Acetyl spermine/spermidine H2O2 
Nitric oxide synthase L-Arginine H2O2 
Plant sulfite oxidase Sulfite H2O2 
 
Enzymes in peroxisomes that degrade ROS 
 
Enzyme Substrate Enzyme also present in 
Catalase H2O2 
Cytoplasm (e.g. erythrocytes) 
and nucleus 
Glutathione peroxidase H2O2 All cell compartments 
MnSOD O2°
 Mitochondria 
CuZnSOD O2°
 Cytoplasm 
Epoxide hydrolase Epoxides ER and cytoplasm 
Peroxiredoxin 1 H2O2 
Cytoplasm, mitochondria, 
nucleus 
PMP20 H2O2  
Plant ascobate-glutathione 
cycle 
H2O2 plants only 
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 Fig. 1.4_5: Schematic overview of peroxisomal ROS metabolism (adapted from Schrader & Fahimi, 2006) 
 
 A noteworthy aspect of peroxisomal enzymatic content and metabolism is the 
phylogenic and inter-species difference in the activity of pathways involved in purine 
metabolism. Important peroxisomal enzymes hereof are xanthine oxidase and urate oxidase 
(aka uricase). Compared to other mammals certain primates, namely prosimians and Old 
World monkeys (Catarrhini), have generally lower levels of urate oxidase activity. In 
extremis, all genera of hominoids (comprised of hominids (Hominidae): Pongo, Gorilla, Pan 
and Homo,  and gibbons (Hylobatidae): Hylobates, Hoolock, Nomascus and Symphalangus) 
as well as a few species of New World monkeys (Platyrrhini) express absolutely no urate 
oxidase due to several mutations found in various regions of the encoding gene (Oda et al., 
2002). Although there appears to be an adaptive decrease in the activity of xanthine oxidase 
(Xu, LaVallee & Hoidal, 2000), which produces uric acid, the substrate of urate oxidase, 
especially in humans the amount of uric acid in the body is substantially elevated compared 
to that of other primate and mammalian species (Johnson et al., 2005). These differences 
have been suggested as essential in hominid and especially human evolution, since the 
antioxidant and anti-inflammatory capacity of uric acid is believed to be responsible for 
these species’ longevity, increased brain complexity and therefore intelligence. Since 
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intelligence and cognitive capacity are closely linked to the form of phenotypical symptoms 
of schizophrenia, this mutation may play a pivotal role in explaining the differences between 
expressed behavioral, cognitive and perceptional abnormalities in various animal models of 
the disorder. The inability to degrade uric acid is also the cause of gout, a disease which is 
only found in the aforementioned primate species. 
 
Fig. 1.4_6: Uric acid levels in primates (adapted from Johnson et al., 2005) 
 
1.4.3 Peroxisomes in the nervous system 
 The role of peroxisomes in the brain and other neuronal tissues is but poorly 
examined. A first description of the organelle’s abundance and distribution in nervous tissue 
was published by Gail Arnold and Eric Holtzman (Arnold & Holtzman, 1978; Holtzman, 1982), 
who found different populations of peroxisomes dependent on enzyme content. One 
population was rich in catalase and poor in D-amino acid oxidase (DAAO), whereas the other 
was oxidase-poor and catalase-rich. These populations of peroxisomes were differentially 
distributed between neuronal cells, in essence between neurons and glial cells, as well as 
between different brain regions. In general, both groups were found both in higher 
abundance and of larger size in glial cells compared to neurons. Largest quantities of 
peroxisomes were found in astrocytes and oligodendrocytes as well as in ependyma, 
suggesting the neuroprotective functions of these cells with regard to ROS metabolism. 
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Within neurons, peroxisomes were most abundant in the perikarya and the large dendrites 
and only very sparse in axons and synaptic terminals.  
 Regarding differential distribution between various brain regions, Holtzman 
emphasizes the lack or low abundance of catalase-containing peroxisomes in Purkinje cells, 
cerebrocortical neurons as well as dorsal root ganglion cells. In contrast he found relatively 
larger populations of catalase-positive bodies in catecholaminergic cells, with the exception 
of the adrenal medulla. He does, however, warn about the overinterpretation of negative 
cytochemical results. 
 Apart from differences between cells and regions, Holtzman also described 
ontogenetic differences within the same cells and regions. Whereas catalase is found in 
relatively high levels in developing neurons, including in synaptic terminals, as well as in 
oligodendrocytes during myelination, the amount of catalase is reduced drastically during 
the later stages of ontogeny. This is explained by a possible involvement of peroxisomes in 
membrano- and myelogenesis, which would be in line with previously described findings 
that peroxisomes are involved in ether lipid synthesis, of which there is a large concentration 
in neuronal and glial membranes.  
 Further investigations regarding the distribution of D-aspartate oxidase (D-AspOx) 
were performed by Kurt Zaar and coworkers (Zaar et al., 2002) on rat and human brain 
sections using immunohistochemistry, immunoelectronmicroscopy and in-situ hybridization. 
Findings indicate that D-AspOx is located solely in peroxisomes, widely distributed in the CNS 
and mainly localized in neurons and astrocytes.  
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Fig. 1.4_7: Cellular and subcellular distribution of D-aspartate oxidase in (a) rat kidney, (c) human hippocampal 
overview, (d) granule cells and (e) multipolar cells of the human dentate dyrus, (m) interneurons and astrocytes 
in the stratum lacunosum-moleculare of the human cornu ammonis and (h) Purkinje cell of the human 
cerebellar cortex; IEM: immunoelectron microscopy, IHC: immunohistochemistry, PO: peroxisome ( modified 
from Zaar et al., 2002) 
 
 A study using indirect immunofluorescence on mouse brain sections showed similar 
findings to Holtzman in that a significant down-regulation of catalase abundance and 
immunoreactivity was observed between postpartum days 2 and 38 and that catalase 
immunoreactivity was markedly different between neurons and glial cells with highest levels 
found in astrocytes. Moreover peroxisomal abundance was evaluated independently of 
enzymatic content through the usage of a novel peroxisomal marker protein, peroxin 14 
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(Pex14p, q.v. section on problems in labeling peroxisomes), which showed that the decrease 
in catalase immunoreactivity was not mirrored by the decrease in peroxisomal abundance 
(Ahlemeyer et al, 2007). These findings were corroborated through examination of various 
other peroxisomal proteins, catalase-activity assays and through Western blotting. The latter 
also clearly showed that, while catalase content decreases continuously throughout early 
ontogeny, Pex14p-levels remain stable after a global reduction of peroxisomal protein levels 
between postpartum days 2 and 15. These findings stress the importance of peroxisomes in 
the developing brain, not only during neuronal growth and myelination, but also during the 
transition from the hypoxic environment in utero to postnatal hyperoxia. 
 
 
Fig. 1.4_8: Distribution of Pex14p and catalase in the early and late developing mouse neocortex; I-V: 
neocortical laminae, CP: cortical plate, fCx: frontal cortex, IZ: intermediate zone, LV: lateral ventricle, P2/38: 
postpartum days, pCx: parietal cortex, PVZ: periventricular zone (modified from Ahlemeyer et al., 2007) 
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Fig. 1.4_9: Western blotting shows differential regulation of catalase and Pex14p during murine brain 
development (modified from Ahlemeyer et al., 2007) 
 
 The importance of intact peroxisomal function is also shown through marked 
neurological deficits, neuronal migration retardation and abnormal neurogenesis in all 
different knockout-models of various peroxisomal biogenesis proteins and metabolic 
enzymes (Baes et al., 1997 [Pex5p KO]; Faust et al., 1997; 2001; 2003 [Pex2p KO]; Li et al., 
2002 [Pex11 p KO]; Maxwell et al., 2003 [Pex13p KO]; Huyghe et al., 2006 [peroxisomal 
multifunctional protein 2, MFP-2 KO]).  
 
Fig. 1.4_10: Retardation of neuronal migration in the neocortex of the PEX5 knockout mouse; CP: cortical plate, 
GZ: germinative zone, IZ: intermediate zone (modified from Baes et al., 1997) 
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 Since these animals all show signs of a storage disease as is found in the human 
peroxisomal disorder “Zellweger syndrome” (see section on peroxisomal disorders) and 
neural migration is dependent on more than functional peroxisomes solely in the brain 
(Janssen et al., 2003; Krysko et al., 2007), owing to multiorgan peroxisomal dysfunction in 
these mouse models, they are not well suited for analysis of intrinsic roles of peroxisomes in 
the brain. This unsuitability is further underlined by the obvious conclusion that peroxisomal 
function in the developing brain is not equal to that in the adult brain. 
1.4.4 Peroxisomal disorders 
 Peroxisomal disorders can be divided into two groups: Peroxisomal biogenesis 
disorders (PBDs) on the one hand and single peroxisomal enzyme deficiencies (PEDs) on the 
other. The PBDs consist of rhizomelic chondrodysplasia punctata, type 1 (RCDP1), which is 
caused by a mutation in the PEX7 gene and the disorders of the so-called Zellweger 
spectrum, which include infantile Refsum disease, neonatal adrenoleukodystrophy and 
Zellweger syndrome. Disorders of the Zellweger spectrum, of which Zellweger syndrome is 
the most severe, are usually caused by multiple genetic mutations in a variety of PEX genes. 
The disorders are named after Hans Zellweger, who first described the disorder as 
cerebrohepatorenal syndrome, due to the multi-organ involvement. Patients exhibit 
symptoms of a storage disorder since their lack of functional peroxisomes inhibits 
degradation of VLCFAs and branched chain fatty acids. Patients also show decreased levels 
of plasmalogens and hypomyelination. This accompanied by neuronal migration and 
neurogenesis defects accounts for severe muscular hypotonia, seizure, apnea and inability to 
swallow. For a full description of the syndrome see Zellweger et al., 1988. There is currently 
no known curative treatment for Zellweger syndrome. Palliative measures involve 
pneumonia and asphyxiation prophylaxis as well as artificial nutrition. Patients usually die 
within their first year of life (Steinberg et al., 2006). 
 Peroxisomal enzyme deficiencies are far more numerous and can affect any of the 
peroxisomal metabolic pathways (see table 1.4_3). The most commonly known PED is 
probably X-linked adrenoleukodystrophy (X-ALD), a dysfunction of the peroxisomal fatty acid 
transporter ABCD1. The palliative treatment, Lorenzo’s oil, is a 4:1 mixture of glycerol 
trioleate and glycerol trierucate, developed and named by Augusto and Michaela Odone 
after their son Lorenzo, who suffered from X-ALD. 
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Table 1.4_3: List of the single peroxisomal enzyme deficiencies (modified from Wanders & Waterham, 2006) 
Peroxisomal pathway 
affected 
Defect 
enzyme 
Disease 
Ether phospholipid synthesis DHAPAT Rhizomelic chondrodysplasia punctata Type 2 (DHAPAT deficiency) 
Peroxisomal beta-oxidation ADHAPS Rhizomelic chondrodysplasia punctata Type 3 (alkyl-DHAP synthase) 
 ABCD1 X-linked adrenoleukodystrophy 
 ACOX1 Acyl-CoA oxidase deficiency 
 DBP D-bifunctional protein deficiency 
 AMACR 2-MethylacylCoA racemase deficiency 
 SCPx Sterol carrier protein X deficiency 
Peroxisomal alpha-oxidation PHYH/PAHX Refsum disease (phytanoyl-CoA hydroxylase deficiency) 
Glyoxylate detoxification AGT Hyperoxaluria Type 1 
H2O2-metabolism CAT Acatalasaemia 
 
1.4.5 Problems in labeling peroxisomes 
 The most common marker for the localization of peroxisomes in morphological or cell 
culture studies is catalase, an enzyme endogenous to peroxisomes and commonly found in 
eukaryotes. Its function is the decomposition of hydrogen peroxide to water and oxygen, 
thereby protecting the cell from oxidative damage. This organelle-specific cytochemical 
staining became available for light and electron microscopy due to the introduction of the 
alkaline 3,3’-diaminobenzidine (DAB) reaction for endogenous catalase (Fahimi, 1968; 1969; 
Novikoff & Goldfisher, 1969). It was originally believed that catalase was ubiquitously 
expressed in all animal cells (Hruban et al, 1972), but since catalase has the highest turnover 
numbers in all enzymes, it is therefore not present in all cell types and tissues in equal 
amounts at the same time, since one molecule of catalase can decompose millions of 
hydrogen peroxide molecules per second (Goodsell, 2004). Although all of the mechanisms 
for the Nrf2-dependent induction of catalase-expression are not yet completely understood, 
it is shown to be dependent on different factors like maturation (Ahlemeyer, 2007) or the 
amount of reactive oxygen species (ROS) in the respective cell. ROS are produced during 
subcellular metabolism, e.g. in mitochondrial respiratory chain, wherefore intracellular 
catalase-concentration is directly dependent on specific cellular ROS metabolism and only 
indirectly on peroxisomal abundance. Since a major part of ROS is produced during 
mitochondrial respiration, ROS-release and thereby mitochondrial amounts of manganese-
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superoxide dismutase (SOD2) also influence the levels of catalase. In general it can therefore 
be ascertained that the enzyme content of peroxisomes is highly heterogeneous, not only 
between cell types or tissues, but also within cell types and tissues depending on the stage 
of ontogeny (Baumgart, 1997, Baumgart et al, 2003, Luers et al., 2006). In the brain, for 
example, it has been shown that catalase is highly expressed in neurons during the 
embryonic development of the mouse central nervous system, but is then significantly 
downregulated and can, in adult animals, mainly be found only in glial cells (Arnold & 
Holtzman, 1978; Ahlemeyer et al. 2007). Similar intercellular differences in catalase-
concentration between male germ cells, different somatic cell types of the testis or the cells 
of the alveolar epithelium could be shown in mice (Nenicu et al, 2007; Karnati & Baumgart-
Vogt, 2008).  Therefore positive peroxisomal localization by using antibodies against catalase 
or by the cytochemical alkaline 3,3'-diaminobenzidine- (DAB)-reaction (Fahimi et al., 1976) 
turns out to be imprecise and heavily dependent on the metabolism of the respective cell 
type. 
The supposed low abundance of peroxisomes in neurons was shown to be incorrect 
by staining morphological samples from rat and human brain for other enzymes known to be 
found only in peroxisomes, namely D-amino acid oxidase (Holtzman, 1982) or D-aspartate 
oxidase (Zaar et al., 2002). Since these enzymes are, however, common to neuronal tissue, 
their capabilities as peroxisomal markers in other tissues and organs are limited. 
A similar statement can be made about another commonly used peroxisomal marker, 
namely adenosine triphosphate-binding cassette sub-family D member 3 (ABCD3), a 70-kDa 
peroxisomal membrane protein (formerly PMP70). This ABC-transporter is a major 
component of the peroxisomal membrane and is involved in transport of lipid derivatives 
through the peroxisomal membrane (Kamijo et al, 1992). ABCD3 expression is also highly 
dependent on cell metabolism. Due to its involvement in the initial steps of peroxisomal lipid 
metabolism, namely the bringing of the metabolites into the peroxisome, its expression 
pattern differs highly in some tissues from that of catalase.  
It is therefore necessary to find another peroxisomal marker, which is capable of 
labeling peroxisomes in all tissues and cell types independently of metabolic changes. The 
likelihood of finding an optimal ubiquitous peroxisomal marker is highest within the group of 
peroxisomal biogenesis proteins (peroxins) that are part of the organelle membrane such as 
the members of the docking complex for the import of matrix proteins are ideal for this 
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purpose. First attempts were done with antibodies against peroxin 13 (Pex13p) and peroxin 
14 (Pex14p: Distel et al., 1996) in testis and lung (Nenicu et al., 2007; Karnati & Baumgart-
Vogt, 2008), whereof Pex14p showed better and more uniform results, probably due to the 
better accessibility of the antigen compared to that of Pex13p.   
In this thesis the peroxin 14 is therefore presented as the optimal peroxisomal 
marker. Pex14p is a peroxisomal biogenesis protein (peroxin) involved in the docking of both 
PTS1- and PTS2-linked peroxisomal matrix enzymes (Albertini et al, 1997), present within 
every intact peroxisomal membrane and found in similarly high levels in distinct cell types 
and organs. To show this, a large variety of tissues and organs as well as primary cultured 
neurons and mouse and human hepatoma cells were compared regarding their distinct and 
individual abundance of catalase, ABCD3 and Pex14p. In order to compare levels of catalase 
with those of antioxidant enzymes in other organelles parallel tissue sections were also 
stained for SOD2. In addition to standard localization of the anti-Pex14p antibody with 
immunofluorescence, peroxidase-based immunohistochemistry and immunogold-labeling 
QuantumDots (Qdots) were used for localization of peroxisomes in cultured cells. The 
unique capabilities of this new peroxisomal marker for morphometric purposes can 
furthermore be shown through experiments on cells treated with the peroxisome-
proliferator ciprofibrate. 
Apart from the cell biological advantages of Pex14p as a peroxisomal marker, the 
temporal stability of the epitope, its sensitivity to different fixation techniques as well as the 
cross-species applicability of our self-created antibody were also examined. For this purpose 
labeling of peroxisomes in tissues from mouse, cat, Sacred Baboon (Papio hamadryas) and 
human was attempted, using samples from freshly perfused animals, samples taken from 
field studies almost 15 years ago, human autopsy samples as well as biopsies from body 
donors to the gross anatomy course of the Institute for Anatomy and Cell Biology (JLU 
Giessen). These samples were fixed in aqueous formaldehyde (formalin), pH-buffered 
formaldehyde solution (Lilie’s formol), pH-buffered paraformaldehyde- (PFA)-solution or in 
Bouin’s fixative.  
This is additionally the first attempt of localizing Pex14p in the human brain, which in 
and of itself makes localization of peroxisomes especially problematic. In classical 
immunohistochemical staining peroxisomes is complicated by diffusion artifacts of the 
reaction products into the surrounding cytosol. Since neuronal tissue is known to have very 
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few and exceptionally small peroxisomes this method is definitely inferior to 
immunofluorescence staining. This approach will be shown to work more than adequately in 
cultured cells and animal tissues, but comes with its own setbacks in the human brain, due 
to the accumulation of lipofuscin granules, which fill almost the entire cytoplasm of neurons. 
Since lipofuscin is made up of various lipid-containing residues of lysosomal digestion it 
autofluoresces in all emission wavelengths and brightly outshine specific 
immunofluorescence signals. Therefore, attempts were made to quench lipofuscin 
autofluorescence through pre-staining with a lipid staining agent (Sudan Black B), which in 
turn, however, also reduces the signal of the fluorochromes and leads to unspecific 
background fluorescence.  
 Nevertheless, this thesis suggests that Pex14p is the ideal standard marker protein for 
the localization of peroxisomes, allowing for reliable studies regarding abundance and 
distribution of peroxisomes, thereby giving accurate numerical values which would not be 
obtainable through catalase or ABCD3 stainings due to strong intra- and intercellular 
differences. 
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1.5 Aims and schematic overview 
 
 The primary aim of this thesis is to examine the role of oxidative stress and dopamine 
neurotoxicity in the etiopathogenesis of schizophrenia and attempt to integrate many 
preexisting models into one. Since the role of peroxisomes has not been researched 
extensively a special emphasis shall be laid on the involvement of this organelle. 
 
 
Fig. 1.5_1: Flow chart of the experiments performed within the first part of the thesis 
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The first part of this thesis shall therefore be an attempt of localizing peroxisomes 
ubiquitously and independently of metabolism and enzyme content using a new marker 
protein, peroxin 14 (Pex14p). Labeling of peroxisomes shall be attempted in various tissues 
and cell types of different species, including human (with special emphasis on human brain), 
through different methods, including immunohistochemistry, immunofluorescence and 
immunoelectronmicroscopy (see fig. 1.5_1). 
 
 
Fig. 1.5_2: Flow chart of the experiments performed within the second part of the thesis 
In the second part, the newly established marker shall be used to measure 
peroxisomal reactions to increased dopamine in vivo and in vitro. Additionally the expression 
levels and protein content of various enzymes involved in antioxidant defense and dopamine 
metabolism shall be analyzed alongside selected proteins believed to be relevant for the 
interaction between dopamine and glutamate neurotransmission and peroxisomal 
metabolism, e.g. D-amino acid oxidase, D-aspartate oxidase and serine racemase. Analyses 
shall be performed on post-mortem brain sections from schizophrenic patients, cultured 
murine astrocytes and neurons as well as male pubescent C57Bl/6J mice treated with the 
selective non-competitive NMDAR antagonist dizocilpine (MK-801) (see fig 1.5_2). 
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2. Materials and methods 
 All experiments were performed in accordance to international ethical standards of 
the Justus-Liebig-University, Giessen (Germany). Human tissues were taken from donors 
who testamentarily donated their bodies to the Institute of Anatomy and Cell Biology (JLU 
Giessen). Animal testing was approved through the regional board (animal research proposal 
“MK-801 und (anti-)oxidativer Stoffwechsel”, Geschäftszeichen V 54 - 19 c 20-15 (1) GI 20/23 
Nr. 05/2010, Feb. 25 2010), in accordance with § 8 paragraph 1, German Protection of 
Animals Act (TSchG). 
 For reasons of conciseness, the methods performed in this thesis shall only be 
described briefly in this section. For detailed information see appendix A. 
 
2.1 Animal treatment with MK-801 
 Animals used were male pubescent wild type C57Bl6/J mice, obtained from Charles 
River, Germany. Each experiment consisted of three animals, whereof one was treated with 
a vehicle (0.9% saline) and the other two with MK-801. The selective NMDAR-antagonist MK-
801 (dizocilpine, (5S,10R)-(+)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-
imine maleate, Tocris Bioscience) was given in a final concentration of 0.5 mg per 1 g body 
weight. A 20x stock solution was prepared by dissolving 10 mg MK-801 (337.37 g/Mol) in 5 
ml sterile 0.9% saline solution. Aliquots of 10 ml were stored at -80°C, thawed prior to use 
and 190 ml of sterile 0.9% saline solution were added, where after the solution was sterilized 
using a sterile filter. Each animal was weighed and 5 ml of the MK-801 solution or a vehicle 
per g body weight were injected intraperitoneally to reach the final treatment amount of 0.5 
mg per 1 g body weight. 
 Animals were either treated once and sacrificed after 1 h or were treated once every 
24 hrs and sacrificed one hour after the final injection. Treatment durations were 25 hrs (2 
treatments), 49 hrs (3 treatments) or 73 hrs (4 treatments). Method of sacrifice was cervical 
dislocation. 
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2.2 Tissue preparation for morphological methods 
2.2.1 Tissue acquirement 
2.2.1.1 Mouse tissue: Animals used for the comparative morphological analyses were 
anaesthetized with isoflurane and subsequent intraperitoneal injection of a mixture of 
ketamine/xylazine/Sedastress®. After a short rinse with 0.9% NaCl to remove blood cells, 
animals were perfused anterogradely via the left ventricle with 4% depolymerized 
paraformaldehyde (PFA) in phosphate buffered saline (PBS, pH 7.4) containing 2% sucrose 
for light and immunofluorescence analyses or with 4% PFA in 0.1% phosphate buffer (PB) for 
electron microscopy, after which organs were individually removed and immersion fixed 
over night in the respectively same fixative. 
Animals used in the studies on MK-801-induced dopamine neurotoxicity were 
sacrificed through cervical dislocation. 
 
2.2.1.2 Rat tissue (liver): Tissues were obtained with kind permission of Dr. Wiebke Moebius 
(MPI Göttingen, Germany), fixed in 4% PFA and 0.2% glutardialdehyde (GDA) in 0.1% PB. 
 
2.2.1.3 Cat and Sacred Baboon: Sections were taken from paraffin blocks which were 
prepared for use in our histology course up to 20 years ago. Fresh tissue was dissected from 
the cadavers and fixed in Lilie’s formol. Samples were then refixed in Bouin’s fixative over 
night in the same fixative.  
 
2.2.1.4 Human tissue: Brain samples were taken from human autopsy-materials, kindly 
provided by Prof. Dr. Klaus Kuchelmeister (at that time: Department of Neuropathology, 
University of Giessen, Germany). Brains were removed from the bodies during postmortem 
and, after initial inspection, immersion fixed in 4% formaldehyde in tap water for at least 
three weeks. After thorough fixation, brains were dissected and small samples (ca. 2x2cm) 
were cut for paraffin embedding. 
 Samples from human submandibular glands were acquired from body donors to the 
Institute for Anatomy and Cell Biology’s gross anatomy course. Bodies were cooled over 
night and perfused retrogradely via the femoral artery with a fixation solution containing 5% 
phenoxytol, 66% ethanol 9% formaldehyde and 20% water.  
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2.2.2 Embedding and processing for light and fluorescence microscopy 
 Samples were dehydrated through a graded alcohol series (50%, 70%, 80%, 96% and 
2x99%) and embedded in paraffin in an automated vacuum infiltration tissue processor 
(Leica TP 1020). Two micron sections were cut on a standard rotation microtome (Leica RM 
2135) with a block cooling system and collected on precoated SuperFrost Plus microscope 
slides (Menzel). 
 
2.2.3 Embedding and processing for electron microscopy 
 Samples were recut into approximately 1x1x1mm blocks. Some of the blocks were 
then embedded in either LR White resin (polymerization at 50°C) or in Unicryl resin (UV-
polymerization at 4°C). Blocks were neither refixed in glutardialdehyde nor in osmium 
tetroxide in order to preserve maximum antigenicity. Semithin and ultrathin (silver to gray 
interference colored) sections were cut with glass and diamond knives (Diatome ultratrim) 
on a Reichert Ultracut ultramicrotome. Ultrathin sections were collected on 100 mesh nickel 
grids coated with 1% formvar and dried at room temperature.  
 Other blocks were not embedded into synthetic resins, but infiltrated with 2.3M 
sucrose in 0.1% phosphate buffer (PB) according to the Tokuyasu method for cryo-
ultramicrotomy (Tokuyasu, 1973). After infiltration, blocks were mounted on T-pins and 
quick-frozen in boiling liquid nitrogen. Blocks were introduced into a Reichert Ultracut-S 
ultramicrotome with a Reichert FC R cryo-chamber and trimmed into a mesa with a glass 
knife at -80°C. Ultrathin sections (gold to gray interference colored) were then cut with a 
cryo-diamond (Diatome cryo immuno) at between -80 and -120°C (according to tissue 
consistency) and picked up onto formvar-coated nickel grids using a mixture of 2.3M sucrose 
and 2% methyl cellulose. 
 
2.3 Cell culture 
 
2.3.1 Mixed primary murine neuronal cultures 
2.3.1.1 Preparation of primary neuronal cultures of the medial neocortex of newborn mice:  
Primary cultures from the medial neocortex of newborn C57BL/6J mice were prepared as 
previously described (Ahlemeyer and Baumgart-Vogt, 2005). For a detailed description see 
appendix A, section A.1.1. 
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2.3.1.2 Peroxisome proliferator (ciprofibrate) treatment of primary neuronal cultures: 
Ciprofibrate was added to primary cortical neurons 4 h after seeding until day 6 at a final 
concentration of 100 µM, whereas controls received vehicle only. 
 
2.3.1.3 Dopamine and haloperidol treatment of murine primary neuronal cultures: On the 
seventh day of cultivation 20 ml of a vehicle (medium) or a sterile dopamine or haloperidol 
solution of defined concentration (100x of final concentration) were added to reach final 
concentrations of 0 (vehicle), 10, 25, 50, 100 or 200 mM. Cells were treated with dopamine 
or haloperidol for 24 hrs, where after the solution was removed by pipetting. Cells were then 
washed three times briefly with warm PBS and then fixed in 4% PFA in PBS for indirect 
immunofluorescence labeling.  
 
2.3.2 Primary astrocytes cultures 
2.3.2.1 Preparation of primary astrocyte cultures of the neocortex of newborn mice: 
Astrocytes were cultivated using the neocortices of entire litters of newborn C57Bl/6J mice. 
For a detailed description see appendix A, section A.1.2. 
 
2.3.2.2 Dopamine treatment of murine primary astrocyte cultures: On the third day after 
passaging the medium was changed and 60 ml of a vehicle (medium) or a sterile dopamine 
solution of defined concentration (100x of final concentration) were added to reach final 
concentrations of 0 (vehicle), 0.1, 1, 10, 50, 100, 200, 500 mM. Cells were treated for either 
24, 48 or 72 hrs, resulting in a 3x8-design. 
 
2.3.3 Mouse and human hepatoma cells 
 Hepa 1-6 cells (from DSMZ, Braunschweig, Germany) were cultured on Petri dishes 
containing a coverslip in DMEM supplemented with sodium pyruvate and 20% FCS. Semi-
confluent cultures at passages 13-15 were used for the experiments. 
HepG2 cells (from ATCC, HB-8065, delivered by Promochem, Wesel, Germany) were 
cultured on collagen-coated Petri dishes containing a coverslip in DMEM supplemented with 
sodium pyruvate, non-essential amino acids and 20% FBS. Semi-confluent cultures at 
passages 98-100 were used for the experiments.  
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2.4 Morphological staining techniques 
 
2.4.1 Histological staining 
2.4.1.1 Modified Kluver-Barrera staining: Sections were stained for 1.5-2 hrs at 60°C in luxol 
fast blue and differentiated in 0.1% NaOH (aq). Counterstaining with acidophilic cresyl violet 
was performed at RT for 8-15’. Kluver-Barrera stains myelin sheaths blue, nuclei, nucleoli 
and Nissl bodies (rER) violet and neuropil cyan. For a detailed description see appendix A, 
section A.2.1.1. 
 
2.4.1.2 Sudan Black B (SBB) staining: SBB staining was used in combination with subsequent 
indirect immunofluorescence staining in order to quench unspecific fluorescence from 
lipofuscin granules (Schnell, Staines & Wessendorf, 1999).  
 Sections were incubated over night at 60°C followed by 3 changes of xylene (5’ each) 
to remove the paraffin. Afterwards sections were rehydrated through a descending series of 
ethanol (2 x 99%, 1 x 96°; 90%, 80%, 70%; 5’ each) and then introduced into a solution of 
0.1% SBB in 70% ethanol for 10’. Thereafter rehydration of sections was continued using 
50% ethanol and ultrapure water for 5’ each. Hydrated sections were then used for indirect 
immunofluorescence labeling (see below). 
 
2.4.2 Indirect Immunohistochemistry (IHC), Immunofluorescence (IF) and 
ImmunoGoldLabeling (IGL) 
2.4.2.1 IHC on paraffin-embedded tissue sections: Stainings for Pex14p, catalase, ABCD3 as 
well as mitochondrial Mn-superoxide dismutase (SOD2) were carried out according to a 
standardized protocol for indirect immunofluorescence on formalin-fixed paraffin-
embedded (FFPE) tissues (based on Grabenbauer et al., 2001 and Baumgart et al., 2003).  For 
a detailed description see appendix A, section A.2.2.2. 
 
2.4.2.2 IF on paraffin-embedded tissue sections: The protocol was similar to that for IHC-
labeling (see above), but without H2O2-incubation or adding of avidin and biotin to the 
respective solutions. Secondary donkey antibodies against rabbit were coupled with 
AlexaFluor 488 fluorophore (Molecular Probes/Invitrogen) and diluted 1:300 in 1% PBSA 
with 0.05% Tween 20. Nuclei were counterstained with Hoechst 33342 (Sigma) and TOTO-3 
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iodide (Molecular Probes) diluted in PBS. All washing steps and incubation procedures 
(except for antigen retrieval) were performed at room temperature. Slides were mounted 
with Mowiol mounting medium (Polysciences) mixed two parts to one with n-propylgallate 
(Sigma) as fading agent.  
 
2.4.2.3 Multiplex IF on human and murine brain tissue sections: Main steps were the same 
as described above. Apart from a primary rabbit antibody against Pex14p, catalase or ABCD3 
further primary antibodies against MAP2 (neuronal marker) and GFAP (astrocyte marker), 
raised in different animals) were used simultaneously and visualized with respective 
secondary antibodies carrying green (for Pex14p, catalase, SOD2), red (for GFAP) and blue 
(for MAP2) fluorophores. For a detailed description see appendix A, section A.2.2.3. 
 
2.4.2.4 Multiplex IF on murine primary neuronal and astrocyte cultures: Labeling protocols 
were similar to those described above for human and murine brain sections. For a detailed 
description see appendix A, section A.2.2.4.   
 
2.4.2.5 IF using QuantumDots® on mouse and human hepatoma cells: Labeling cells and 
tissues with secondary antibodies coupled to QuantumDots® was performed using the 
standard protocols described above and in appendix A, however, without success. The 
labeling protocol was therefore carefully adapted stepwise by the author, until satisfactory 
results were obtained. For a detailed description of the final protocol for IF on cells using 
QuantumDots® see appendix A, section A.2.2.5.  
 
2.4.2.6 IGL for electron microscopy: All washing and incubation steps were performed on 
drops pipetted onto a specially cast rubber panel. Primary antibodies against Pex14p and 
catalase were visualized through nanogold-Fab’-probes with silver or gold enhancement. For 
a detailed description see appendix A, section A.2.2.6. 
 
2.5 Reverse transcription polymerase chain reaction (RT-PCR) 
 
Prior to RNA extraction all surfaces and gloves were treated with chaotropic agents 
(RNaseZap, Sigma) to avoid RNase contamination. Metal tools (scissors, tweezers and 
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scalpels) were incubated for 60’ in 70% ethanol. RNA extraction were performed using 
appropriate kits from Qiagen (RNeasy Mini Kit for cells and tissues; RNeasy Protect Animal 
Blood Kit for blood samples), wherefore buffer compositions cannot be described. Buffer 
names are those given by Qiagen. 
 
2.5.1 RNA extraction protocols 
2.5.1.1 RNA extraction from animal tissues: Excised organs were immediately placed into a 
stabilizing agent and flash frozen in liquid nitrogen for storage. RNA extraction was 
performed according to the RNeasy Mini Kit (Qiagen) protocol. For a detailed description see 
appendix A, section A.3.2.1. 
 
2.5.1.2 RNA extraction from primary murine astrocyte cultures: Dopamine- or vehicle-
containing medium was removed by pipetting and cultures were washed in cold RNase free 
PBS (4°C). Each Petri dish was incubated with 350 l buffer RLT + 3.5 l -ME for 30’ at room 
temperature to lyse the cells and reduce protein disulfide bonds. The cell lysate was then 
pipetted onto the QIAshredder spin column and centrifuged for 2’ at >8000 g. The 
subsequent steps were identical to those described for tissues in appendix A, section A.3.2.1. 
In the final step RNA was eluted with 43 l RNase-free water. 
 
2.5.1.3 RNA extraction from animal whole blood: After collection blood was mixed with an 
appropriate volume of RNA Protect Animal Blood Reagent (Qiagen), incubated for 2 hrs at RT 
and frozen in liquid nitrogen for storage. RNA extraction was performed according to the 
RNeasy Protect Animal Blood Kit (Qiagen) protocol. For a detailed description see appendix 
A, section A.3.2.2. 
 
2.5.2 RNA denaturation, quantification and quality control 
 All RNA eluates were denatured through incubation for 5’ at 65°C and quantified 
using a spectrophotometer (BioRad Smart SpecTM 3000). RNA-integrity was additionally 
controlled through a denaturing agarose-MOPS/FA-gel electrophoresis. For a detailed 
description see appendix A, section A.3.3. 
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2.5.2.1 DNase digestion: DNase digestion was either performed on column or prior to First 
Strand Synthesis. For a detailed description see appendix A, section A.3.3.1. 
2.5.3 First Strand Synthesis (FSS)  
 FSS was performed according to the SuperScriptTM II reverse transcriptase 
(Invitrogen) protocol. For a detailed description see appendix A, section A.3.4. 
2.5.4 Primer Design 
 Primers for cDNAs of the mRNAs of 28S rDNA, PEX14, CAT, SOD2, ABCD3 & GFAP 
were taken from the primer stock of the Division of Medical Cell Biology (Institute for 
Anatomy and Cell Biology, JLU Giessen). All other primers were self-designed using the 
Primer Basic Local Alignment Search Tool (Primer-BLAST) online program (NCBI, 
www.ncbi.nlm.nih.gov/tools/primer-blast). Primers were designed to be separated by at 
least one intron on the corresponding genomic DNA so that possible amplification products 
of contaminating genomic DNA could be detected and differentiated from the intended cDNA 
amplificates. Primers were only searched for in the species Mus musculus. PCR product size 
was set at default (70-1000 base pairs). Optimum primer melting temperatures were initially 
set at 59°C-61°C. Primer specificity stringency was set at at least 4 mismatches to 
unintended targets, including 4 mismatches within the last 7 base pairs at the 3’end.  
Maximum self complementarity and maximum 3’ end complementarity was set at 4 and 2 
respectively. 
 In cases were no primers matched the aforementioned criteria, these were loosened 
progressively until suitable primers were found. For a complete list of primers used for PCRs 
and nested PCRs see appendix B. 
 Primers were ordered as lyophylisates from Operon and diluted with PCR clean water 
(aqua ad iniectabilia, AAI, Braun) for 10’ at 37°C on a thermo-shaker set at 700 rpm to create 
stock solutions (100 pmol/ l), which were stored at -20°C. Before use, portions of the stock 
solutions were diluted 1:10 with AAI in RNase- and DNase-free reaction tubes. Ready-to-use 
primer solutions were also stored at -20°C. 
 Several primer-pairs for each template were tested in temperature graded PCRs (5 
temperature steps) with various numbers of PCR cycles until the best primers and the 
optimal conditions for each template (regarding cDNAs transcribed from cell-, tissue- or 
whole blood-RNA) and each primer pair were found (see appendix B).  
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2.5.5 Polymerase Chain Reaction (PCR) 
 PCRs were pipetted and run in DNase-free PCR-softstrips (0.2 ml, Biozym). Pipetting 
steps were all carried out either on crushed ice or PCR cool blocks. PCRs were run in an 
iCycler thermal cycler (BioRad). 
 PCR single reaction volume was 25 l, consisting of 5.2 l master mix, 1 g (0.5 g for 
samples taken from whole blood) cDNA (X l) and an appropriate volume of AAI (19.8-X l). 
For each primer pair a control samples was run containing just 5.2 l master mix and 19.8 l 
of AAI with the omission of cDNA. 
 For detailed information on the composition of master mixes as well as PCR protocols 
see appendix A, section A.3.5. 
 
2.5.5.1 Nested PCR: In the cell culture experiments the expression of specific templates 
(DAO, DRD1, DRD2, DRD3, DRD4, DRD5, COMT1t3 and DAT) appeared to be very low, 
wherefore the signal/noise-ratio of the PCR products was considered insufficient. In these 
cases nested PCRs were run. Here for a second (nested) primer pair was designed, whereby 
the nested primers lay farther towards the 3’-end of the amplicon in comparison to the 
original primers. The product of the first PCR run with the respective first primer pair was 
then amplified again, but using the nested primer pair. Thereby the target template was 
amplified even more, whereas unspecific noise was reduced simultaneously. For nested 
primer pairs see appendix B. 
 
2.5.5.2 Agarose-Gel Electrophoresis: PCR amplification products were mixed with 2ml DNA 
loading dye (Blue/Orange 6x loading dye, Promega) and analyzed through electrophoresis 
using a 1% agarose-gel. For detailed descriptions see appendix A, section A.3.5.1. 
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2.6 Imaging 
 
 Light and fluorescence microscopical images were taken with a Leica fluorescence 
microscope (Leica DMRD with a Leica DC 480 digital camera) and a confocal laser scanning 
microscope (Leica TCS SP2, setting at airy 1, average of 16 scans). 
 Gel pictures were taken in a BioRad GelDoc 2000 with QuanityOne® software (version 
4.3.0, BioRad) 
 EM pictures were taken at 80 kV with a LEO906 electron microscope (Zeiss, Wetzlar). 
 All ex post facto modifications of images were performed with Adobe® Photoshop® 
CS2 version 9.0 or Adobe® Photoshop® Elements version 9. 
 
2.7 Statistical Analyses 
 
 All statistical analyses were performed with the Statistical Package for the Social 
Sciences (SPSS), different versions.  
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3. Results 
 
In order to find an optimal ubiquitous marker for peroxisomes independently of 
metabolism, cell and tissue type or species the general abundance and distribution of 
catalase, ABCD3 and Pex14p was compared in a large variety of organs, tissues and cell types 
of different embryonic origin. Results show that a more accurate picture of the abundance as 
well as inter- und intracellular distribution of peroxisomes is given through Pex14p rather 
than catalase, which is the generally used maker enzyme (Hruban et al., 1972). Catalase and 
ABCD3 are metabolically dependent enzymes which are present in many cell types, but vary 
strongly regarding their abundance and distribution, whereas Pex14p is found in every 
healthy and intact peroxisomal membrane and can therefore be used as a general marker.  
With the new Pex14p-labeling it is therefore possible to localize peroxisomes in 
various species, different tissues and distinct cell types in all different stages of ontogeny. 
 
3.1 Establishing Pex14p as the optimal peroxisomal marker for comparative 
and experimental morphology 
 
3.1.1 Specificity of the self-created antibodies against catalase and Pex14p 
 Western blotting for catalase and Pex14p performed and published by co-workers 
shows the specificity of both antibodies. The specificity of the catalase antibody was also 
further established through preabsorption with bovine liver catalase. The incubated antibody 
was centrifuged and the supernatant was used for immunostaining on formalin fixed and 
paraffin embedded (FFPE) sections as described above for the IF technique. In these control 
experiments no signal for catalase could be detected (Ahlemeyer et al., 2007). 
 Additionally, the specificity of both antibodies was examined in immunogold-EM 
experiments, showing specific binding of both antibodies with a negligible amount of 
unspecific background. Pex14p-staining in electron microscopy has not been achieved before 
and could not be performed successfully on epoxy resins, even after etching with H2O2 or 70% 
ethanolic sodium hydroxide (data not shown here). In acrylic resins immunogold labeling of 
Pex14p was achieved, but labeling densities and signal/noise ratios were considered relatively 
unsatisfactory. Therefore labeling was attempted in cryo-ultrathin sections with markedly 
better results.  
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Pex14p as a membrane protein can be clearly shown around the perimeter of peroxisomes 
comparable to immunogold-labeling for ABCD 3 (Baumgart, 1997), whereas the functional 
enzyme catalase is located in the peroxisomal matrix (Fig. 3.1_1). The abundance of catalase 
is striking, especially in comparison to other matrix enzymes like acyl-CoA oxidase, enoyl-CoA 
hydratase (Litwin & Beier, 1988), D-amino acid oxidase, multifunctional protein 1 (Baumgart, 
1997) or D-aspartate oxidase (Zaar et al., 2002). The density of catalase labeling is also 
markedly increased in cryo-ultrathin sections compared to resin ultrathin sections (both in rat 
liver, e.g. Baumgart, 1997) showing that immunogold labeling using cryo-ultramicrotomy is far 
superior even than acrylic resin embedding, albeit more difficult during cutting and handling. 
The ultrastructural tissue preservation is, however, obviously superior in resin-embedded 
ultrathin sections.  
As peroxisomes are less abundant and smaller in the brain compared to the liver, 
enhancement times for the immunogold particles was increased, wherefore the particles 
surrounding two peroximes (probably in axons) are not round, but unevenly shaped. The 
areas devoid of catalase in the two larger peroxisomes are most likely caused by urate 
oxidase crystals, which are present in peroxisomes of most mammalian species, but not in 
hominoids (q.v. chapter 1.4.2). 
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Fig. 3.1_1: Immunogold labeling of Pex14p in acrylic resin (top row) and cryo (bottom rows) ultrathin sections; 
er: rough endoplasmic reticulum, gly: glycogen fields, m: mitochondria 
 
3.1.2 Specificity of secondary antibodies and peroxidase substrate reaction 
  Unspecific binding of secondary antibodies or unspecific reaction of the peroxidase 
substrate as well as adequate quenching of endogenous peroxidases was control for through 
sections which were incubated parallel to and in the same fashion as regular sections, but 
with omission of the primary antibodies. In these control sections no signal was ever 
observed. An example shall be given of catalase, Pex14p and the appropriate negative control 
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in the developing murine abdomen. Not only can the differential distribution of catalase and 
peroxin 14 be illustrated, but it can also be shown that the specificity of secondary antibodies 
and the peroxidase substrate reaction is given in all different tissues and organs (Fig. 3.1_2). 
 
 
 
3.1.3 Peroxisomes in epithelial cells of mesodermic and endodermic origin 
 Epithelia are known for their functional, structural and metabolic diversity. Their major 
functions are the lining of the body, the forming of a barrier to the outside world (also within 
the respiratory, gut and urinary organs) as well the endo- and exocrine secretion. 
 The epithelia of different organs with distinct functions were therefore examined 
regarding their peroxisome content and the differences in abundance and distribution of 
catalase (CAT), ABCD3 and Pex14p. Duodenum and kidney were chosen as examples for 
epithelial lining of different parts of the viscera with endodermic and mesodermic origin 
respectively. Epithelia serving a glandular function were investigated in the endocrine and 
exocrine pancreas as well as the serous, mucous and duct cells of the submandibular gland.  
 Due to the findings of coworkers in testis (Nenicu et al, 2007) epithelial cells involved 
in steroid hormone production were also examined more closely. 
Fig. 3.1_2: Immunohistochemical stainings of the 
developing mouse gut for Pex14p, catalase and an 
exemplary negative control under omission of any 
primary antibody 
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3.1.3.1 Kidney (Fig. 3.1_3): The distribution of peroxisomes within the different parts of the 
renal nephron is dichotomous. Pex14p is found in all cells of the renal corpuscle, the distal 
(marked by the macula densa) and intermediary tubules as well as the collecting ducts in 
similar abundance. There is, however, a marked increase in peroxisomal density within the 
proximal tubules, identifiable through the urinary pole. This dichotomy in the expression 
patterns is also found in ABCD3- and catalase-stainings. Both of the latter stainings, however, 
do not show peroxisomal distribution consistent to the staining for Pex14p. In ABCD3-
labeling, the renal corpuscle has less positive signals within the glomerulum and the parietal 
layer of Bowman’s capsule is completely negative. This would allow the supposition that the 
signals within the glomerulum are found within the endothelial cells of the blood vessels, 
while the podocytes of the visceral layer of Bowman’s capsule and maybe also the 
intraglomerular mesangial cells show no signal for ABCD3, which would explain the weaker 
and not as evenly distributed signal for ABCD3 compared to Pex14p. 
 Catalase is found in high abundance within the proximal tubules, which is concurrent 
with findings in electron microscopy and in situ hybridization (Baumgart, 1997), but catalase 
is found only very sparsely within the glomerulum. Again, similar to the staining for ABCD3, 
the parietal layer of Bowman’s capsule appears negative for catalase, wherefore it is again 
likely that the sporadic signals within the glomerulum are also within endothelial 
peroxisomes. The distal tubules are hardly stained for catalase. The distribution of catalase 
was therefore compared to that of mitochondrial SOD2, in order to assess whether catalase is 
expressed in high amounts within cells with high mitochondrial antioxidant activity. As 
expected, SOD2 is found in all cells of the renal duct system, but with markedly higher levels 
within the proximal tubules, whereas the renal corpuscle is mainly devoid of signal. This 
difference can also be seen in standard fluorescence microscopy in serial sections of the same 
renal corpuscle and macula densa in stainings for Pex14p and catalase. 
 The results from the FFPE-sections taken from a freshly perfused mouse were 
replicable in sections from the kidney of a Sacred Baboon, immersion fixed in Lilies’s formol 
and refixed in Bouin’s fixative in the year 1984 as part of our regular histology course for 
medical and dentistry students. 
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Fig. 3.1_3: Immunofluorescence labeling of Pex14p, catalase, ABCD3 and SOD2 in sections of mouse and baboon 
kidney; dt: distal tubule, g: glomerulum, md: macula densa, pt: proximal tubule, up: urinary pole 
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3.1.3.2 Endocrine pancreas: Whereas the exocrine pancreas shows a similar distribution of 
Pex14p as well as catalase as is found in other exocrine glands of endodermic origin (see next 
section), the exocrine cells in the islets of Langerhans differ markedly regarding both 
peroxisomal as well as catalase abundance. While the number of peroxisomes is extremely 
high within the exocrine cells, catalase appears to be almost absent and only traceable in 
what appear to be peroxisomes of endothelial cells (Fig 3.1_4). This would suggest a role of 
peroxisomes in pancreatic hormone metabolism that is independent of H2O2-degradation.  
 Multivariate analyses of the morphometric quantification of various parameters of 
fluorescence signal intensity (ratios signal/area, signal/nucleus and signal area/whole area) 
for Pex14p and catalase immunolabelings (n=29) showed significant differences between 
protein content (F = 21.76, p < .001; F = 25.42, p < .001; F = 10.00, p = .004) as well as 
between endocrine and exocrine pancreas (F = 24.25, p < .001; F = 63.9, p < .001; F = 6.78, p = 
.016). A principle component analysis (PCA with Varimax-rotation and Kaiser-normalization) 
of all items measuring the ratios signal/area & signal area/whole area revealed a two-factor 
solution (factor 1: endocrine pancreas, factor 2: exocrine pancreas) explaining for 76.1% of 
variance. The ratio signal/nucleus was excluded from PCA, due to the fact that the size and 
abundance of cells differ substantially between endocrine and exocrine pancreas, wherefore 
the aforementioned ratio was considered unsuitable in this context.    
 
 
Fig. 3.1_4: Immunofluorescence labeling for Pex14p and catalase in the mouse pancreas; left and middle images 
show an endocrine islet surrounded by exocrine acini. The right image shows an excretory duct in the exocrine 
part of the pancreas. 
 
3.1.3.3 Exocrine cells of mouse pancreas and submandibular gland (Figs. 3.1_4 & 3.1_5): The 
distribution of peroxisomes in the serous glandular cells of both the submandibular gland and 
the pancreas is quite comparable. Peroxisomes are found in moderate abundance throughout 
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the cytoplasm. In the serous part of the gland the abundance of peroxisomes in duct cells is 
markedly higher as is their distribution herein clearly perinuclear. Mucous cells of the 
submandibular gland exhibit higher numbers of peroxisomes within their cytoplasm, even 
higher than the adjacent duct cells. They appear to be displaced to the basal part of the cell.  
 Catalase is found in similar distribution within the serous cells of the submandibular 
gland and the pancreas, albeit in lesser amount. In duct cells, however, catalase is significantly 
increased both in pancreas and in the submandibular gland. In the larger ducts of the 
submandibular gland an unexpected catalase-pattern was found, which was not punctuate as 
usual, but appeared in the basal cell layer to be evenly distributed throughout the entire 
cytoplasm. This phenomenon was observed in different ducts, different sections and through 
different labeling techniques, suggesting that basal cells of the submandibular duct truly 
possess physiologically cytoplasmic catalase. 
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Fig. 3.1_5: Immunolabeling of Pex14p and catalase in serous, mucous and duct cells (arrows) of the mouse 
submandibular gland and in the duodenum (bottom two images on the right). In the middle left image the 
mucous part is on the left hand and the serous part on the right hand side of the image. The bottom two images 
on the left show higher magnifications of excretory ducts. 
 
3.1.3.4 Exocrine cells of the human submandibular gland (Fig. 3.1_6): Apart from the 
question of conservation of peroxisomal membrane protein expression and abundance 
between mouse and human, another question regarding this tissue sample was also, whether 
the protein was still detectable in samples that had not been prepared specifically for 
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laboratory research, thereby giving insight into the stability of the Pex14p-antigen as well as 
the sensitivity of the Pex14p-antibody.  
 Tissue was taken from body donors to the gross anatomy course and was therefore 
already in a state of beginning decay, as can be seen by the beginning autolysis of the 
glandular tissue. The labeling for Pex14p, however, is consistent with that achieved in 
samples taken from freshly perfused animals that had immediately been transferred into 
immersion fixation solution. Apart from the identical localization of the signals in the 
glandular ducts and parenchyma, the excellent quality of the staining (albeit in relatively poor 
quality of tissue preservation) shows the advantages of both the Pex14p-antigen as well as 
the high quality of the antibody.  
 
 
Fig. 3.1_6: Two sections of a human submandibular gland in an advanced stage of autolysis stained for Pex14p 
 
3.1.3.5 Duodenum (Fig. 3.1_5): Catalase-staining clearly allows a distinction between the 
epithelia of the villi and those of the krypts, as the positive signals on both sides of the nuclei 
of krypt-cells are markedly reduced in comparison to those of the villi. The amount of catalase 
within the lose connective tissue of the lamina propria is also highly reduced and barely 
detectable. Pex14p-staining, however, shows that peroxisomes are actually more or less 
evenly distributed in the epithelia of both villi and crypts. They are found around the nucleus 
and towards both ends of the cell with, however, relatively larger amounts towards the 
luminal/apical side of the duodenal epithelium. Peroxisomes are also found randomly 
throughout the lose connective tissue of the lamina propria within the villus. 
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3.1.4 Follicular development in the ovary (Figs. 3.1_7 & 3.1_8) 
 Oxidative stress is one of the key mechanisms in X-linked adrenoleukodystrophy (X-
ALD) (Powers et al., 2005; Fourcade et al., 2008), a rare inherited disorder leading not only to 
adrenal dysfunction, but in 80% of male patients to impairment of testicular functions 
(Powers, 1985). Male germ cells have just recently been shown to contain a large number of 
small peroxisomes, whereof some have very low levels of catalase. Additionally it was also 
shown in the same paper that the peroxisomal compartment undergoes drastic alterations 
and clustering in the cytoplasm of elongated spermatids during spermiogenesis (Nenicu et al., 
2007).  
 The peroxisomal abundance and distribution during the maturation of the oocyte 
within follicular development was therefore examined. Similarly to male germ cells (Nenicu et 
al., 2007) oocytes show little to no signal for catalase. Also the amount of traceable catalase 
in the surrounding corona radiata and granulosa epithelia is quite low, albeit that theca cells 
and cells of the corpus luteum exhibit extremely high levels of catalase.   
 
 
Fig. 3.1_7: Immunohistochemical stainings of a mouse ovary for Pex14p (left column) and catalase (right 
column); cl: corpus luteum 
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 To evaluate possible differences in the content of antioxidant enzymes between the 
various cells of the ovary a labeling for mitochondrial SOD2 was performed, showing a similar 
pattern of the enzyme to that of catalase, however with higher intensity in each instance. Low 
levels of SOD2 are found within the oocyte, medium levels in the follicular epithelia and the 
highest levels in the theca cells. ABCD3 and Pex14p are distributed in a comparable manner in 
the ovary, as can be seen by differential staining of the same tertiary follicle.  
 
 
Fig. 3.1_8: Immunofluorescence labeling of serial sections of the same tertiary follicle for Pex14p, catalase, 
ABCD3 and SOD2; cr: corona radiata, gc: granulosa cells, o: oocyte, tc: theca cells, asterisks mark the zona 
pellucida 
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 It can clearly be shown that peroxisomes are present in very high abundance not only 
in the endocrine cells of the ovary, but also in the oocyte itself. This observation holds true for 
all stages of follicular development and oocyte maturation. Primordial follicles are very small 
and enclose even smaller oocytes, whereof the cytoplasm is extremely small. The primordial 
follicle is in a dormant or quiescent state and biologically almost inactive, which makes the 
low number of peroxisomes not surprising. As the follicle develops into a primary follicle and 
the oocyte matures and increases in size, the cytoplasm becomes densely populated with 
peroxisomes of various sizes. This development continues through the secondary to the 
tertiary Graafian follicle. The specificity of all stainings can hereby clearly be seen through the 
obvious void surrounding the secondary and tertiary follicles, which marks the zona pellucida, 
a glycoprotein polymer capsule surrounding the oocyte and containing no cellular organelles. 
In several oocytes Pex14p-positive structures were found similar in shape compared to those 
described by Nenicu et al. (2007) in late spermatids (Fig. 3.1_10). They are significantly larger 
in size than those in late spermatids and can be viewed without the necessity of electron 
microscopy. It is most likely that they are indicative of the oocyte within an atretic follicle and 
represent the rearrangement of the peroxisomal compartment during cytoplasmic 
restructuring while the cell undergoes apoptosis. 
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Fig. 3.1_9: Immunofluorescence labeling of Pex14p in various stages of follicular development. All images were 
taken at 63x magnification, inserts of the oocytes are in 126x magnification. 
 
 The structures found in late spermatids before phagocytosis of the cytoplasmic 
droplet by Sertoli cells were described by light as well as electron microscopy and 
characterized as catalase-positive double membrane loops. They can also be shown through 
staining against Pex14p and are also present in seminiferous tubules from a male cat (Fig. 
3.1_10). These images also show the quality and sensitivity of the new Pex14p-staining 
method, as the paraffin blocks of the cat testis are over-20-year-old specimens from our 
regular histology course. The tissue was immersion fixed in Lilie’s formol and refixed in 
Bouin’s fixative rather than taken from animals freshly perfused with PFA. This also goes for 
sections taken from cat ductus epididymidis (Fig. 3.1_10). 
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Fig. 3.1_10: Pex14p in mouse and cat testis during different stages of spermatogenesis as well as in the cat 
epididymis; all images were taken at 63x magnification 
 
3.1.5 Steroid hormone producing cells 
 Peroxisomes are highly abundant in all cells involved in steroid hormone synthesis, 
albeit with interindividual differences in density. Most of these peroxisomes are also 
extremely rich in catalase, in some cases leading to more intense signals than in Pex14p-
staining (Fig. 3.1_11). This is probably due to high mitochondrial activity, namely side-chain 
cleavage during steroid synthesis as well as necessary for protection of steroidogenesis 
against H2O2. Interestingly, peroxisomes in many steroid secreting cells do not exhibit a 
punctuate pattern, but rather a tubular one at higher magnification (Fig. 3.1_11).  
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3.1.5.1 Ovary and testis: As previously shown by Nenicu et al. (2007), peroxisomes are 
present in Leydig cells of the testis as well as in the basal compartment of the germinal 
epithelium and in peritubular myoid cells (Fig. 3.1_11). Catalase signals are extremely high 
within Leydig cells (Fig. 3.1_11). 
 These results are mirrored by the analogous cells of the female gonad, namely the 
theca and granulosa cells within the ovary. Pex14p can be clearly seen in both the granulosa 
and the corona radiata epithelium. The signal is highest in the apical parts of the superficial 
layers of the granulosa cells. Outside the follicle, however, the signal is even more intense 
within the cells of the theca organ (Fig. 3.1_8). 
 The signal distribution for catalase is similar to that of Pex14p, however with clearly 
visible differences regarding intensity. While the signal within granulosa and corona radiata 
cells is slightly weaker than in stainings for Pex14p, the signal intensity within the theca cells, 
on the other hand, surpasses that of Pex14p. 
 The theca cells also clearly show the tubular peroxisomal pattern found in most 
steroid hormone producing cells (Fig. 3.1_11). 
 
 
Fig. 3.1_11: Pex14p and catalase in steroid hormone producing cells of the mouse testis (top row) and ovarian 
theca organ (bottom row); lc: Leydig cell, st: seminiferous tubule 
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3.1.5.2 Adrenal cortex (Figs. 3.1_12 & 3.1_13): The differences in peroxisomal distribution 
between the three layers of the adrenal cortex can already be seen at low magnification in 
both Pex14p- and Catalase-stainings. Levels are lowest within the zona fasciculata, slightly 
higher in the zona reticularis and markedly higher in the zona glomerulosa. These differences 
can also be seen at higher magnifications as well as in the staining for ABCD3, which is 
similarly distributed to Pex14p in the adrenal cortex. Higher magnifications of the zona 
glomerulosa also show the presence of peroxisomes in the cells of the surrounding adrenal 
fibrous capsule. Comparable to the layers of Bowman’s capsule in the kidney, catalase- and 
ABCD3-stainings were negative within the adrenal fibrous capsule (not shown here). Finally, 
the tubular pattern of peroxisomal distribution can also be seen at higher magnifications, 
similar to ovary and testis.   
 
 
Fig. 3.1_12: Immunofluorescence labeling of Pex14p, catalase and ABCD3 in the mouse adrenal gland; ac: 
adrenal capsule, am: adrenal medulla, zf: zona fasciculate, zg: zona glomerulosa, zr: zona reticularis 
 
 The extreme difference between Pex14p- and catalase-signals of the cells of the 
adrenal medulla shall be described together with the differences in other cells originating 
from the neural tube and crest. 
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3.1.6 Peroxisomes in cells originating from the neural tube and crest 
 The differential distribution of Pex14p and catalase within the developing mouse CNS 
as well as between primary cultured neurons and astrocytes was recently reported by co-
workers (Ahlemeyer et al., 2007). Furthermore, the sharp contrast between catalase-positive 
bodies in the developing nervous system and lack thereof in corresponding areas of the adult 
brain has also been described by Arnold and Holtzman (1978) and Holtzman (1982). 
 
3.1.6.1 Adrenal medulla (Figs. 3.1_12 & 3.1_13): Apart from cells of the central and 
peripheral nervous system, the chromaffine cells of the adrenal medulla originate from the 
neural crest and can be viewed upon as somewhat analogous to catecholaminergic cells of 
peripheral sympathetic ganglia, including their being supported by Schwann cells. They also 
share the extremely high dissonance of neurons regarding the number of peroxisomes 
labeled with Pex14p compared to the nearly undetectable amounts of catalase. The few 
positive catalase signals within the adrenal medulla (Fig. 3.1_12) are likely to come from 
peroxisomes in either endothelial cells of the large medullary vessels or from Schwann cells 
surrounding the adrenergic chromaffine cells.   
 
 
Fig. 3.1_13: Immunohistochemical overview of the mouse adrenal gland 
 
3.1.6.2 Primary neurons before and after treatment with a peroxisome proliferator (Fig. 
3.1_14): On the basis of the aforementioned, the reactions of Pex14p (as indicator of total 
number of peroxisomes) and catalase to the treatment of primary neurons from mouse 
neocortex with a peroxisome proliferator were examined. It is obvious that baseline catalase-
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signals are lower compared to those for Pex14p. Interesting, however, is the fact that catalase 
does not increase linearly to Pex14p upon treatment with ciprofibrate. This means that not 
only is catalase less abundant at baseline, but also that peroxisome proliferation in neurons 
does not lead to a proportionate increase in catalase-containing peroxisomes. 
 
Fig. 3.1_14: Primary cultured neurons from the mouse neocortex treated for 24 hrs with a vehicle (left column) 
or the peroxisome proliferator ciprofibrate (right column) 
  
3.1.6.3 Peroxisomes in the human brain: To further examine the distribution of peroxisomes 
in the central nervous system as well as to establish the value of the novel Pex14p marker, an 
attempt at labeling of peroxisomes in the human brain was made. This was done on samples 
taken from human autopsies. It has to be mentioned that human brain autopsy material is 
notoriously difficult to process, firstly, due to the brains tendencies for fast and early autolysis 
and, secondly, due to the accumulation of larger lipofuscin granules within the cytoplasm of 
the neurons (arrows in Fig. 3.1_15). Lipofuscin is a yellow brown pigment composed of lipid-
containing residues lysosomal digestion, which begins to accumulate in neurons during aging. 
It seriously complicates explorative immunostaining of aged neuronal tissue due to its filling 
out great part of the neuronal cytoplasm. In cases of direct or indirect immunofluorescence, 
lipofuscin also hinders the signaling in that it is comprised of various different lipid 
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derivatives, in turn containing a large amount of unconjugated pi-electrons and therefore 
strongly fluoresces at every excitation wavelength, outshining the fluorochromes of interest.  
 
 
Fig. 3.1_15: Lipofuscin granules in a human CA neuron fluorescing at different excitation wavelengths 
 
Lipofuscin is not susceptible to photobleaching, but can be quenched by staining with 
Sudan Black B (SBB) (Schnell et al., 1999), which, however, also seriously reduces the intensity 
of the signal of the respective flourochromes and often leads to unspecific background (Fig. 
3.1_16, q.v. Materials & Methods). 
 
 
Fig. 3.1_16: Granule cells from a human hippocampus showing specific and unscpecific (lipofuscin) fluorescence 
signals with and without SBB-pretreatment 
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 By carefully adapting the staining protocol and maximizing antigen retrieval, as well as 
through careful reduction of exposure times during photography and through ex post facto 
augmentation of the images with Adobe® Photoshop® peroxisomes in the human brain could 
successfully be labeled using IF and IHC procedures, but without significant contortion or 
falsification of the images (Fig. 3.1_17). 
 It could herefore be shown that peroxisomes are definitely present in neurons of the 
human cerebellum, hippocampal formation and lateral geniculate body (CGL) of the 
thalamus. 
 Notice the proportionality of peroxisomes to the sizes of the respective neurons. This 
can be shown in granule cells of the dentate gyrus compared to pyramidal cells from the 
cornu ammonis or a neuron from one of the magnocellular layers of the CGL. The same 
phenomenon can be used to distinguish the relatively larger Golgi cells within the granule cell 
layer of the cerebellar cortex (Fig. 3.1_17, asterisks). 
 It is also noteworthy that peroxisomes appear in distinctively larger number in places 
of dendritic fission, as shown by Purkinje cells from the cerebellar cortex (Fig. 3.1_17, arrows). 
This is in accordance with the supposition of Arnold and Holtzman (1978) that peroxisome 
content is related to cellular enlargement and the formation of neuronal processes. Finally, 
the Pex14p-staining can also be used to show that, although peroxisomes appear to be 
relatively sparsely distributed in the actual axons, their number is markedly increased within 
the initial axonal segment or axon hillock (Fig. 3.1_17, arrowhead). 
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Fig. 3.1_17: Immunofluorescence and immunohistochemical labeling of Pex14p in various cell types and regions 
of the human brain; top left: granule cells from the hippocampal dentate gyrus, middle left: CA neurons from the 
hippocampal cornu ammonis, bottom left: neuron from the magnocellular region of the lateral geniculate body 
(CGL), top left: Purkinje cell perikaryon and larger dendrites from the cerebellar cortex (arrows show 
peroxisomal clusters at sites of dendritic branching), middle right: Purkinje cell perikaryon (arrow head shows 
peroxisomes in the initial axon segment/axon hillock), bottom right: Golgi cells (asterisks) in the granule cell 
layer of the cerebellar cortex 
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3.1.6.4 Overview of the microscopic anatomy of the human hippocampal formation: Since 
the human hippocampal formation is extremely large and intra- as well as interindividually 
diverse and the various sectors are difficult to differentiate in staining methods not 
specifically developed for brain, parallel sections were stained with the modified Kluver-
Barrera method. The microscopic anatomy of the human and mouse hippocampal formation 
share certain similarities, wherefore it shall be exemplarily illustrated here (Figs. 3.1_18 & 
3.1_19). 
 Due to the hemispheral rotation during brain ontogeny the human hippocampus in its 
entirety is roughly C-shaped reaching from the septal area (hippocampus precommissuralis) 
via the stria of the induseum griseum (hippocampus supracommissuralis) to the hippocampus 
proper (hippocampus retrocommissuralis). The first to parts of the hippocampus will not be 
discussed here. The hippocampal formation is comprised of two intertwined inverse 
archicortices, namely the dentate gyrus (DG) and Amun’s horn (cornu ammonis, CA), whereby 
the latter continues seamlessly into the subiculum. The cornu ammonis was divided by Rafael 
lorente de Nó into four fields, CA1 through CA4, whereby CA1 follows the subiculum and CA4 
was described as laying in the hilum of the dentate gyrus (Lorente de Nó, 1934). Studies by 
David Amaral and Ricardo Insausti, however, showed that the field CA4 does in fact not 
belong to Amun’s horn, but is the plexiform layer of the dentate gyrus (Amaral, 1978; Insausti 
& Amaral, 2004). This new nomenclature has, unfortunately, not yet been incorporated into 
all revisions of standard anatomy text books.  
 Since the cornu ammonis is an inverse cortex, the pyramidal cells have their apices 
away from the surface, wherefore the white matter lies directly beneath the external glial 
limiting membrane and is referred to as the alveus. It condenses into fringe-like structures, 
the fimbriae, which continue in the fornix, one of the major output pathways of the cornu 
ammonis. The major input into the hippocampal formation is comprised of myelinated axons 
from the entorhinal cortices, the perforant path (tractus perforans). 
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Fig. 3.1_18: Modified Kluver-Barrera staining of the human retrocommissural hippocampal formation; CA: cornu 
ammonis, CGL: lateral geniculate body 
 
 Being archicortical, both the dentate gyrus and the cornu ammonis are trilaminar in 
nature, whereby the cornu ammonis features efferent pyramidal cells and the dentate gyrus, 
as the primary input part of the hippocampal formation features spiny stellate cells. 
Additionally both cortices are comprised of a vast variety of interneurons. The dentate gyrus 
is also relatively inverse, wherefore its molecular layer borders directly on the perforant path, 
which lies within the molecular layer of the cornu ammonis. The granular layer of the dentate 
gyrus is followed by the plexiform layer, sometimes referred to as the hilum of the denate 
gyrus. In general, all fields of the cornu ammonis share the same stratification, with the 
exception of the field CA3. Beneath the alveus is the stratum oriens, followed by the 
pyramidal layer. The axons of the pyramidal cells mainly of fields CA3 give of so-called 
Schaffer collaterals on their way to the alveus, thereby forming the stratum radiatum. Since 
these collaterals terminate mostly in the field CA1, the end of the stratum radiatum marks the 
border between the cornu ammonis and the subiculum. The deepest layer (originally the 
most superficial layer in hippocampal ontogeny) is the stratum lacunosum-moleculare with 
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the perforant path. In addition hereto, the field CA3 features a small stratum between the 
pyramidal cell layer and the stratum radiatum, which is comprised mainly of unmyelinated 
mossy fibres from the granule cells of the dentate gyrus and is therefore called the stratum 
lucidum. The borders between the fields of the cornu ammonis are not sharp, but can be 
differentiated approximately through the morphology of the pyramidal layer. Whereas the 
field CA2 features a single band of densely packed pyramidal cells, both CA3 and CA1 have 
more loosely distributed pyramidal neurons, which make up two distinguishable layers within 
the field CA1. The border between CA3 and the plexiform layer of the dentate gyrus (formerly 
CA4) is marked by the end of the stratum lucidum. The fuzzy transition between CA1 and the 
subiculum, as described above, can be distinguished through the gradual disappearance of 
the stratum radiatum (Insausti & Amaral, 2004).  
 
 
Fig. 3.1_19: Modified Kluver-Barrera staining showing the microscopic anatomy of the human hippocampal 
formation; A: alveus, CA: cornu ammonis, asterisks show the approximate borders between the CA fields, DG sg: 
granule cell layer of the dentate gyrus, DG sm: molecular layer of the dentate gyrus, DG sp: plexiform layer of the 
dentate gyrus, sl: stratum lucidum of the CA, slm: stratum lacunosum-moleculare of the CA; so: stratum oriens of 
the CA, sp: stratum pyramidale of the CA, sr: stratum radiatum of the CA 
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3.1.7 Labeling of peroxisomes with QuantomDots (QDots®) (Fig. 3.1_20) 
 The usually rather small size of peroxisomes makes it better for morphometric 
purposes to use IF-techniques rather than IHC, as the spatial resolution of an IF fluorochrome 
signal is usually higher than that of an organic dye or substrate like DAB commonly used in 
IHC. The disadvantage of fluorochromes for morphometry, however, is (a) the sometimes 
insufficient strength of the signal (in IHC this could be remedied by extending the 
development time of the color-dye reaction) and (b) the susceptibility to photobleaching of 
the fluorochromes, even though this has become easier thanks to fading and bleaching agents 
as well as to the new generation of AlexaFluor® fluorochromes.  
 Even so, the possibility of labeling peroxisomes with a fluorescent marker with a signal 
yield higher than that of AlexaFluor®, which is also unsusceptible to photobleaching, is 
offered by nanocrystal technology in the form of QDots. 
 QDots are significantly more difficult to handle and markedly larger in size than 
classical fluorochromes (q.v. Materials & Methods), wherefore labeling was performed on 
mouse (Hepa 1-6) and human (HepG2) hepatoma cell lines. QDots are all excited by UV-light 
and differ in size and therefore in the wavelength of their emitted photons, for which they are 
also denominated. Both small Qdot 525 as well as significantly larger QDot 655 nanocrystals 
were successfully established for labeling of Pex14p in Hepa 1-6 and in HepG2 cells.  
 
Fig. 3.1_20: Labeling of Pex14p in mouse (Hepa 1-6) and human (HepG2) hepatoma cell lines using different 
sized QuantomDot nano-crystals 
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3.2 Analyzing peroxisomal reactions to increased dopamine 
 
3.2.1 Morphological analyses of Pex14p and catalase in the hippocampus of schizophrenic 
patients vs. controls (Fig. 3.2_1): 
 Labeling of catalase in hippocampal sections taken from different brains of patients 
diagnosed with schizophrenia showed no detectable signal for catalase as was the same in 
sections from control patients. As expected, catalase is not present in high enough abundance 
in the adult brain to detect through immunohistochemistry. Since many results report 
decreased amounts and activity levels of catalase in schizophrenics it is not surprising that no 
differences can be detected between schizophrenia and control cases. The differences 
between Pex14p signals are also very subtle, albeit that the number as well as size of 
peroxisomes appear to be slightly reduced in schizophrenic patients compared to controls. 
The remaining peroxisomes do, however, seem to be a little more densely packed in 
proximity to the nucleus, which would be in line with atypical neurodegeneration, wherein 
neuronal processes become stunted thereby also leading to a reduced number of organelles 
in the cells with remaining organelles located in the perikaryon. 
 
 
Fig. 3.2_1: Immunohistochemistry using DAB with nickel-enhancement of Pex14p and catalase in the dentate 
gyrus of post-mortem brain sections of schizophrenic patients and controls 
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 Unfortunately no information was available regarding the subtype or duration of 
schizophrenia or the (especially pharmaceutical) therapy regimens in the patients from whom 
the samples were obtained, wherefore these results were interpreted with great care and not 
many inferences could be drawn regarding the differences and lack thereof between groups. 
 
3.2.2 Effects of increased dopamine and haloperidol on primary murine neuronal cultures 
 To examine the effects of increased extracellular dopamine on peroxisomal 
abundance and catalase levels in a more controlled fashion, primary murine neurons were 
cultured and treated with different concentrations of dopamine for 24 hours. Unlike in the 
human brain sections, the differences in catalase levels are striking, especially in the few 
astrocytes that are present in these cultures. Catalase appears to be increased in a dose-
dependent fashion in dopamine-treated cultures compared to vehicle-treated controls (Fig. 
3.2_2). 
 Peroxisomal abundance and distribution changes in a fashion similar to that 
hypothesized from literature reports on atypical neurodegeneration as well as the findings 
from human hippocampal sections. Peroxisomes appear to be smaller in size, less abundant 
and distributed closer to the nucleus. They appear almost absent in both neuronal and 
astrocyte processes in comparison to vehicle-treated controls. Although the amount of MAP2 
signal (blue) appears similar in the 100 M dopamine culture to the vehicle-treated cells, the 
reduced signal density between the labeled neuronal processes indicates a loss of smaller 
dendritic processes that usually form a fine network in culture, which can be visualized 
through increasing the intensity of the appropriate laser. The reduction of these smaller 
processes, that were shown to express various synaptic proteins in experiments performed in 
another context (data is therefore not shown here), and the loss of peroxisomes therein as 
well as in the larger dendrites through incubation with dopamine is again in accordance with 
the model of atypical neurodegeneration caused by excess dopamine. 
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Fig. 3.2_2: Triple IF staining for MAP2 (neurons), GFAP (astrocytes) and Pex14p or catalase in primary murine 
cortical cultures treated for 24 hrs with different concentrations of dopamine or a vehicle 
 
 To further examine this, neuronal survival was measured in all cultures, showing that 
dopamine leads to a slight increase in cell death. This increase is, however, neither significant 
nor dose-dependent considering the high concentrations of dopamine some cultures were 
exposed to (Fig. 3.2_3). It can therefore be assumed that dopamine cultivation may lead to 
the death of a certain basal amount of cells, but that the majority of cells do not undergo 
apoptosis even if dopamine levels are increased tremendously. 
 In contrast hereto, parallel incubations of cells with haloperidol causes a dose-
dependent increase in cell death that reaches around 90% in the highest concentrations (Fig. 
3.2_3).  
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Fig. 3.2_3: Neuronal death in primary murine cortical cultures after 24 hrs of incubation with increasing dosages 
of dopamine or haloperidol 
 
 In morphological staining this can also be seen clearly in higher dopamine 
concentrations. Additionally, haloperidol leads to a marked dose-dependent increase in 
catalase content in the surviving cells, especially in astrocytes (Fig. 3.2_4). This increase is 
higher than that found in dopamine-treated cells. The abundance of peroxisomes decreases 
in the few surviving neurons, but increases in astrocytes. The remaining peroxisomes in 
neurons appear to be larger in size compared both to vehicle- as well as dopamine-treated 
cultures (Fig. 3.2_2). It therefore can be held that the effects of (typical) neuroleptics on the 
nervous system are pronouncedly different to those of dopamine, wherefore findings from 
pharmacologically treated patients should be interpreted with great care. 
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Fig. 3.2_4: Triple IF staining for MAP2 (neurons), GFAP (astrocytes) and Pex14p or catalase in primary murine 
cortical cultures treated for 24 hrs with different concentrations of haloperidol or a vehicle 
 
3.2.3 Effects of increased dopamine on primary murine astrocyte cultures 
 Since the influences of dopamine (and haloperidol) on both Pex14p and catalase were 
different between neurons and astrocytes, with astrocytes generally showing more 
pronounced reactions to either substance, the question emerged whether these findings 
were inherent to astrocyte metabolism or dependent on neuron-astrocyte interaction. From 
the general function of astrocytes as important factors i.a. in maintaining homeostases 
important for neuronal survival, it would be expectable that the reactions of astrocytes are 
dependent on signaling from neurons and should therefore be less pronounced, if not absent 
in cell cultures containing no neurons. 
 To examine the verisimilitude of these expectations, cultures of pure murine 
astrocytes were established and treated with different concentrations of dopamine for 24, 48 
and 72 hrs. For reasons of conciseness, the results from the cultures treated for 48 hrs shall 
not be shown here. For more detail see Fischer, 2010. 
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3.2.3.1 Morphological analyses: The absence of neurons was controlled through 
immunolabeling for GFAP, MAP2 and nuclear counterstaining (Fig. 3.2_5). Apart from the high 
amount of GFAP-positive cells, no signal was detected for MAP2, wherefore it can be 
assumed that no neurons survived the cultivation procedure. The nuclei not belonging to 
GFAP-positive cells are likely to belong to fibroblasts which survive from (mainly) remnants of 
the pia mater and, unlike neurons, survive and multiply under the cultivation conditions. The 
effects of the fibroblasts on the validity of results are discussed extensively in Fischer (2010). 
It is considered unlikely that these connective tissue cells have a greatly falsifying effect. 
 
 
Fig. 3.2_5: Double IF labeling for MAP2 and GFAP in primary murine astrocyte cultures with nuclear 
counterstaining. Red cells are astrocytes. The lack of blue cells shows that no neurons are present in the 
culture. Nuclei outside of red cells belong to fibroblasts. 
 
 The effects of dopamine-incubation can be seen clearly through a distinct dose-
dependent discoloration of the medium even after 24 hrs (Fig. 3.2_6). This discoloration, due 
to changes in pH of the medium, is most probably caused by autoxidation of dopamine, 
dopamine metabolism of the cultivated cells and/or both. 
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Fig. 3.2_6: Dose-dependent discoloration of the medium of primary murine astrocytes after 24 or 72 hrs of 
incubation with dopamine 
 
 The effects of dopamine-treatment on astrocyte viability were negligible with on 
average only 3 % of cells undergoing apoptosis in all cultures, even those treated with a 
vehicle (Fig. 3.2_7). The range of nuclei with apoptotic morphology is slightly shifted from 
2,5 – 3,2 % (vehicle) to 2,8 – 3,6 % (dopamine), whereby this difference is neither significant 
nor dose-dependent. It can therefore be assumed that, even more so than in cultures 
containing neurons, dopamine does not induce apoptosis. 
 
 
Fig. 3.2_7: Comparison of astrocyte nuclei after 72 hrs of treatment with a vehicle or the highest concentration 
of dopamine shows the equally low rate of cell death under both conditions 
  
 Morphological analyses of GFAP and catalase immunoreactivity show little differences 
between vehicle-treated controls and cultures incubated with dopamine (Fig. R34). This also 
indicates that the reactions of astrocytes to dopamine-treatment, as observed in cell cultures 
with both neurons and astrocytes, are specific to neuron-astrocyte interactions. The only 
circumstance under which differences could be observed in pure astrocyte cultures were in 
those samples treated with 200 and 500 M for 72 hrs. The concentrations of RNA 
extractable from these preparations were markedly reduced compared to the other cultures. 
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In immunostainings the same cultures showed a reduction in outgrowing cellular processes, 
GFAP immunoreactivity and catalase content. It is probable that these cells exhibit a sort of 
“cellular sickness behavior”, during which the entire metabolism is reduced and shifted 
towards cellular survival at the expense of reduced anabolic activity. This again would be in 
line with the concept of atypical neurodegeneration. 
 
 
Fig. 3.2_8: Double IF labeling of catalase and GFAP in primary murine astrocytes incubated with a vehicle or 
different concentrations of dopamine for 24 or 72 hrs 
 
3.2.3.2 Analyses of gene expressions: In order to assess the capacity of the cultivated 
astrocytes to take up and metabolize the dopamine from the medium, RNA was extracted 
from untreated cell cultures and RT-PCRs were performed for all known dopamine 
synthesizing and catabolizing enzymes and the dopamine active transporter (DAT). Results 
clearly show that all genes encoding for the aforementioned proteins are actively expressed 
in the cell cultures (Fig. 3.2_9). 
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Fig. 3.2_9: RT-PCRs for the dopamine synthesizing and metabolizing enzymes as well as the dopamine active 
transporter from primary murine astrocytes; Th: tyrosine hydroxylase, Ddc: DOPA decarboxylase, Mao: 
monoamino oxidase, Comt: catechol-O-methyl transferase, transcripts 1 & 3 
 
 Additionally, the expression of genes coding for various dopamine receptors was 
examined. The number of mRNA copies, however, appeared to be very much lower leading 
to unspecific background amplification. Therefore, in these cases nested PCRs were 
performed. The results again show that the cultivated astrocytes contain RNAs of all five 
dopamine receptors, whereby the expression of dopamine receptor D5 is lower by far than 
that of the other receptors (Fig. 3.2_10). It can therefore be established that the cultured 
astrocytes are capable of taking up and metabolizing dopamine as well as that dopamine 
may bind to dopamine receptors expressed by the astrocytes, thereby leading to the 
activation or inhibition of intracellular cAMP-dependent metabolic pathways. 
 
 
Fig. 3.2_10: Nested RT-PCRs for the dopamine receptors from primary murine astrocytes 
 
 RT-PCRs for the mRNA of the 28S rDNA gene functioned as housekeeping controls and 
show that equal amounts of RNA were used for first strand synthesis as well as that equal 
amount of amplified cDNA were loaded onto the gel (Fig. 3.2_11).  
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Fig. 3.2_11: RT-PCRs for 28S rDNA (housekeeping gene) from primary murine astrocytes treated with different 
concentrations of dopamine or a vehicle for 24 or 72 hrs, showing equal amounts of RNA were used for first 
strand synthesis and equal amounts of amplified cDNA were loaded onto the gel 
 
 Expression profiles of the genes coding for the two major dopamine receptors (D1 and 
D2) as well as the dopamine active transporter (DAT) show that incubation with high 
concentrations of dopamine, even after 72 hrs, does not influence the number of mRNA 
copies transcribed from these genes in pure astrocyte cultures (Fig. 3.2_12). 
 
Fig. 3.2_12: RT-PCRs for dopamine receptors D1 and D2 as well as the dopamine active transporter from primary 
murine astrocytes treated with different concentrations of dopamine or a vehicle for 24 or 72 hrs 
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 Dopamine incubation in vitro does also not affect the expression of genes encoding for 
catabolizing enzymes after 24 hrs or 48 hrs (data not shown here). After 72 hrs, however, 
MAOA expression still remains unchanged, but a slight increase in mRNA copies for MAOB as 
well as COMT can be observed in dopamine treated cultures. This increase does not appear to 
be dose-dependent, with the exception of MAOB expression in the two highest 
concentrations (200 M & 500 M), wherein a reduction of band size can be observed (Fig. 
3.2_13). Why this reduction in mRNA copies is not mirrored by MAOA or COMT gene activities 
is not clear. 
 
Fig. 3.2_13: RT-PCRs for dopamine metabolizing enzymes from primary murine astrocytes treated with different 
concentrations of dopamine or a vehicle for 24 or 72 hrs 
 
 Expression analyses of selected peroxisomal genes also show no activation differences 
after 24 hrs of dopamine incubation. While the same goes for the genes encoding for catalase 
and ABCD3 after 72hrs, the gene number of mRNA copies transcriped from the PEX14 gene 
increases slightly after 72 hrs in cultures incubated with higher concentrations than 0.1 mM 
dopamine (Fig. 3.2_14). This shows that peroxisomal proliferation does not automatically 
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induce the expression of all peroxisomal membrane bound or matrix enzymes, but rather 
appears to be a differentially regulated process. This is in accordance with findings of 
peroxisomal heterogeneity within this thesis and also with the results from primary murine 
neurons cultivated with a peroxisome proliferator for 24 hrs, wherein Pex14p levels increased 
in a non linear fashion compared to catalase levels. Finally the lack of increase in catalase 
expression could be indicative of the high efficiency of this enzyme, meaning that the increase 
in ROS caused by dopamine incubation can still be degraded by the relatively high basal level 
of catalase already present within the astrocytes. 
 
Fig. 3.2_14: RT-PCRs for selected peroxisomal proteins from primary murine astrocytes treated with different 
concentrations of dopamine or a vehicle for 24 or 72 hrs) 
  
3.2.4 Effects of MK-801-treatment in male pubescent C57Bl/6J mice 
 To examine the effects of increased mesolimbic dopamine in vivo wildtype animals 
were injected intraperitoneally with the NMDAR-antagonist MK-801, since it has been shown 
in literature that this group of drugs leads to an activation of mesolimbic pathways. Excised 
animal brains were used either for morphological analyses or for the extraction of RNA with 
subsequent RT-PCR. 
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3.2.4.1 Analyses of gene expressions: In order to ensure maximum reliability and validity of 
results from experiments downstream of RNA isolation, the nucleic acid integrity was 
measured through MOPS/FA gel electrophoresis. With the exception of one sample from the 
liver of an animal treated for 49 hrs (which was not used for further analyses) the integrity of 
all RNA samples was considered more than sufficient. An exemplary gel shows clear bands for 
18S and 28S rRNAs, whereby the 28S band is larger than the 18S band (Fig. 3.2_15). 
 
 
Fig. 3.2_15: Exemplary MOPS/FA gel showing the integrity of extracted RNAs 
 
 Since it was not possible to record and quantify parameters of behavior which could 
identify the development of a schizophrenia-like phenotype (e.g. prepulse inhibition, latent 
inhibition, vertical activity or rearing behavior), animals were observed by blind raters and 
could always be accurately identified as control or experimental animals respectively. 
Additionally, the expression of serine racemase mRNA was examined after 1 hour of 
treatment as a metabolic internal positive control, since it has been shown that MK-801 leads 
to an increase in serine racemase expression. Using two different pairs of primers it was 
shown that animals treated with MK-801 did indeed have a markedly higher expression of 
serine racemase compared to vehicle-treated controls (Fig. 3.2_16). 
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Fig. 3.2_16: RT-PCRs for serine racemase using two different primer pairs as metabolic internal positive control 
of MK-801 treatment 
 
 The application of equal amounts of RNA for first strand synthesis was controlled 
through parallel analyses of a housekeeping gene, 28S rDNA, which encodes for 28S rRNA. 
 After 1 hour of treatment with MK-801 increases in gene expression in the forebrain 
were observed for serine racemase and D-aspartate oxidase and to a small extent for PEX14. 
Due to the non-quantitative nature of gel electrophoresis, especially the latter finding should 
be interpreted with care. No differences were observed in catalase, Nrf2 or any of the liver 
samples (Fig. 3.2_17). 
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Fig. 3.2_17: RT-PCRs of selected genes from forebrain and liver of animals treated with MK-801 or a vehicle for 
1 hour 
 
 Housekeeping controls for the expression profile of the 28S rDNA-gene show that 
equal amounts of RNA were used for first strand synthesis and that subsequently equal 
amounts of amplified cDNA were loaded onto the gel (Fig. 3.2_18). 
 Expression profiles of serine racemase are somewhat ambivalent. Even though, as 
expected, signal intensity is higher after 25 and 73 hrs in the MK-801-treated group, the 
expression appears to also increase after 49 and 73 hrs in the vehicle-treated animals. 
Especially after 49 hrs the intensity appears to be higher in the vehicle- rather than the MK-
801-treated animals. 
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Fig. 3.2_18: RT-PCRs of serine racemase and 28S rDNA (housekeeping gene) from the forebrain of animals 
treated for 25, 49 or 73 hrs with MK-801 or a vehicle as controls for the MK-801 treatment and the use of equal 
amounts of RNA for first strand synthesis as well as amplified cDNA for gel loading 
 
 
 Expression profiles of MAOA and COMT genes are similar in that there appears to be 
a slight decrease in MK-801-treated animals after 25 hrs followed by an upregulation of gene 
expression after 49 hrs. The major difference between these two genes shows up after 73 
hrs, where MAOA expression does not appear to be altered between groups, whereas COMT 
expression seems slightly decreased. The expression patter of MAOB, however, differs 
markedly from that of the other two degrading enzymes in that levels decrease in both 
groups from 25 over 49 to 73 hrs of treatment. Additionally the expression in the MK-801-
treated animals is lower in comparison to controls at all given time points. 
 
Fig. 3.2_19: RT-PCRs of the genes coding for dopamine metabolizing enzymes from the forebrain of animals 
treated for 25, 49 or 73 hrs with MK-801 or a vehicle 
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 Both antioxidant enzyme expression levels appear to increase after treatment with 
MK-801 (Fig. 3.2_20). In the case of catalase there appears to be no difference detectable 
between vehicle treated groups (25, 49 or 73 hrs), but in the appropriate MK-801 treated 
brains the signal intensity is always higher, with the most pronounced increase found after 
49 hrs. The differences in SOD2 expression levels are more complex. After 25 hrs the 
difference between control and MK-801 brains is minimal, but after 49 and 73 hrs it 
becomes apparent that SOD2 expression is induced in animals treated with MK-801. 
Interestingly, however, the levels in the 73 hrs group are lower both in vehicle and MK-801 
treated animals compared to the 49 hrs group, even though the expression is still relatively 
higher after MK-801 treatment. A possible explanation herefore could be that the increase in 
expression after 49 hrs creates a surplus of enzyme, wherefore not as many new mRNA 
copies need to be transcribed. Alternatively the stability of the mRNA could be altered, 
whereby each strand could serve as template for the translation of relatively more protein 
copies. In any case, the amount of enzyme present, as examined through immunolabeling, is 
equal in all vehicle-treated groups and always relatively higher in the MK-801-treated 
animals (see below). Unfortunately this explanation does not account for the reduction in 
band intensity in the vehicle treated animals after 73 hrs.  
 
Fig. 3.2_20: RT-PCRs of the genes coding for the antioxidant enzymes catalase and SOD2 from the forebrain of 
animals treated for 25, 49 or 73 hrs with MK-801 or a vehicle 
 
 Marker proteins of peroxisomes (Pex14p) and astrocytes (GFAP) show differential 
expression patterns. While treatment with MK-801 appears to have little to no effect on the 
expression of the PEX14 gene it appears to lead to an activation of astrocytes as shown 
through the rapid increase in GFAP expression after 25 hrs of treatment (Fig. 3.2_21). The 
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bands of all three vehicle-treated groups are relatively similar, whereas the expression of the 
gene in the MK-801 groups increases dramatically, but is then reduced in the 49 and 72 hrs 
groups. Since GFAP is a cytoskeleton protein, which can be seen in higher abundance in MK-
801-treated animals in the morphological analyses as well, an increase in gene expression 
early after treatment with MK-801 would lead to higher protein content in the astrocytes. 
Therefore an ongoing increased level of expression should not be necessary. The reduction 
of mRNA copies in the animals treated with MK-801 for 49 and 73 hrs could therefore be 
explained by the fact that the early increase after 25 hrs might be sufficient over a longer 
time, thereby negating the necessity for further increases in gene expression. 
 
Fig. 3.2_21: RT-PCRs of the genes coding for peroxisomal (PEX14) and astrocyte (GFAP) marker proteins from 
the forebrain of animals treated for 25, 49 or 73 hrs with MK-801 or a vehicle 
 
3.2.4.2 Morphological analyses: Immunolabeling of catalase in the hippocampus of vehicle- 
and MK-801-treated animals show shows results concurrent to those found in the 
expression analyses of the CAT-gene. Whereas the increase in enzymatic catalase cannot be 
observed in situ after 25 hrs, after 49 hrs the signal intensity is recognizably higher in the 
MK-801-treated animal compared to the vehicle-treated controls (Fig. 3.2_22). Since 
catalase is generally not found in high abundance in the mammalian nervous system, the 
increases are obviously only subtle. Unfortunately results for catalase from the animals 
treated for 73 hrs could not be obtained.  
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Fig. 3.2_22: Triple IF labeling for catalase, MAP2 and GFAP in the hippocampal formation of animals treated for 
25 or 49 hrs with MK-801 or a vehicle 
 
 Immunostainings for Pex14p show that even after 73 hrs treatment of animals with 
MK-801 does not lead to noticeable alterations in peroxisomal abundance or distribution 
(Fig. 3.2_23). While treatments of primary murine neurons with a peroxisome proliferator as 
well as with dopamine showed that 24 hrs are sufficient time for both peroxisomal 
proliferation as well as redistribution from peripheral processes to the larger dendrites and 
perikarya, it would appear that the intrinsic increase in dopamine within the hippocampus 
caused by MK-801 is markedly lower than the concentrations used in experiments on 
cultured cells. Whether an ongoing treatment over the course of several weeks would finally 
lead to peroxisomal redistribution as found in vitro is presumable, but can only be 
speculated upon from the data at hand. 
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 Interestingly, however, these sections clearly show an increase in GFAP 
immunoreactivity, especially in the images taken from animals sacrificed after 25 and 49 hrs. 
This increase is mirrored by an increase in number of mRNA copies of the GFAP-coding gene, 
as shown through RT-PCR experiments.   
 
IF staining for mitochondrial manganese superoxide dismutase (SOD2) show a 
noticeable increase in protein content in all animals treated with MK-801 compared to 
vehicle-treated controls (Fig 3.2_24). This increase appears to be time-dependent, since 
SOD2 levels increase with treatment duration. Whereas the protein content at first only rises 
within the perikarya of the neurons and astroytes (as can be illustrated nicely in the 
relatively small and densely packed neurons of the dentate gyrus), after 73 hrs there appears 
to be an increase in immunoreactivity not only in perikarya, but also in the surrounding 
neuropil. 
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Fig. 3.2_23: Triple IF labeling for Pex14p, MAP2 and GFAP in the hippocampal formation of animals treated for 
25, 49 or 73 hrs with MK-801 or a vehicle 
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Fig. 3.2_24: Triple IF labeling for SOD2, MAP2 and GFAP in the hippocampal formation of animals treated for 
25, 49 or 73 hrs with MK-801 or a vehicle 
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4. Discussion, summary and conclusions 
 
4.1 Peroxisomal localization with Pex14p as a novel marker protein 
 
It could be shown clearly that peroxisomal protein content is highly variable within as 
well as between distinct cell types and tissues, especially when comparing the abundance and 
distribution of proteins involved in specific peroxisomal metabolic function, like catalase or 
ABCD3, with proteins involved in peroxisomal biogenesis, like peroxins 13 or 14. It could 
further be illustrated that matrix enzymes like catalase are highly unsuitable for peroxisome 
marking on comparative morphometry since they are markedly altered by metabolic 
parameters, whereas peroxins, like Pex14p, give a far superior estimation of true peroxisomal 
abundance and distribution. 
It is therefore necessary to critically reexamine old publications which describe 
peroxisomal abundance solely on the base of (mainly histochemical) stainings of catalase. It 
was for example proposed by Arnold and Holtzman (1978) that even though 
microperoxisomes are abundant in the cells of the developing rat central nervous system they 
are no longer found in the fully developed adult rat CNS. In 1982 Holtzman published having 
observed heterogeneity of enzyme content between subgroups of peroxisomes, namely 
those containing high catalase and low levels of D-amino acid oxidase (DAAO) and those with 
low catalase, but high DAAO. A metabolically similar enzyme, D-aspartate oxidase (D-AspOx), 
is shown to be highly abundant in neurons, glial cells as well as the epithelia of the proximal 
tubules in the kidney in both rat and human samples. D-amino acids are knows to be of 
modulatory function in N-methyl-D-aspartate glutamate receptors (NMDAR), binding to a 
specific binding site at the NMDAR. Peroxisomes are described in kidney and liver as the only 
organelles known to contain D-AspOx (Van Veldhoven et al., 1991; Zaar et al., 1989; Zaar, 
1996). In this thesis it was, however, possible to show that peroxisomes can be found both in 
the adult brain as well as in distal tubules of the kidney, amongst other organs. It is therefore 
obvious that Pex14p is present in the membrane of different peroxisomal subtypes, as 
described by Holtzman, making it superior as marker protein compared to functional enzymes 
like catalase, DAAO or D-AspOx. 
The differences in peroxisomal distribution between distinct cells of the 
submandibular gland as well as within the same cells during the development of the gland 
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were described by Mooradian and Cutler in 1978 using a cytochemical demonstration of 
catalase through alkaline DAB.  These partially extreme differences are found not only in 
electron microscopy, but can also be seen in light and fluorescence microscopy using 
antibodies against catalase (Fig. 3.1_5). It is interesting to note that some cells in the ducts of 
the submandibular gland show what appears to be physiologically cytoplasmic catalase both 
in mouse as well as human samples. These findings were interpreted as differences in 
peroxisomal distribution by Mooradian, but appear to be mainly differences in catalase 
content of individual peroxisomes, as peroxisomal abundance shown through Pex14p appears 
relatively homogeneous within the mucous and serous parts of the gland, albeit obviously 
different between the serous and mucous cells. Finally the interpretation of cytoplasmic 
catalase is supported through the observation that, albeit that duct cells have slightly more 
Pex14p compared to primary secretory cells, the amount of Pex14p found within the duct is 
not nearly as high as that of catalase. This, according to peroxisome ultrastructure, is only 
possible, if catalase is in fact present outside of the peroxisomal membrane in these cells. 
Therefore, a membrane protein, like Pex14p, is again superior in its qualities as peroxisomal 
marker. Due to its role in the docking complex involved in both PTS1- and PTS2-linked matrix 
protein import, it cannot be found outside of peroxisomes, unlike metabolic enzymes which 
can leak or be mistargeted. Pex14p is also suitable for the labeling of peroxisomal membrane 
ghosts, which occur in specific peroxin knockouts, like the PEX5-knockout (Baes et al., 1997). 
The first extensive screening of various tissues and organs for peroxisomes (then 
called microbodies) again made use of the DAB-method for labeling of endogenous catalase 
(Hruban, et al., 1972). Albeit not necessary to discuss all findings in comparison to new 
findings within this thesis, some special points of interest may be emphasized. A main 
difference, which was also analyzed by co-workers (Ahlemeyer et al., 2007) is the abundance 
of peroxisomes in neural tissue, such as the cerebellar and cerebral cortices or the dorsal root 
ganglia, both of which are described by Hruban as having “occasional” microbodies with 
relatively weak DAB reaction. Analyses of the abundance of peroxisomes using Pex14p clearly 
show that peroxisomal abundance in neurons is relatively high in the somata and dendrites, 
as it also is in astrocytes, even though these peroxisomes appear to contain only very small 
amounts of catalase, wherefore they do not appear (strongly) when using the DAB reaction. 
Similarly Hruban et al. report a low number of DAB-detectable microbodies in 
testicular Leydig cells, various cells of the ovary, podocytes of the renal glomerula or 
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endocrine cells of the adrenal cortex. In all of these organs the results of this thesis show 
substantially higher numbers of Pex14p-positive peroxisomes compared to those found by 
others as well as compared to those found when staining for catalase. It would therefore 
appear that the advantages of Pex14p as peroxisomal marker are found in most organs and 
tissues and that there are only few organs in which catalase yields higher signal intensities 
compared to Pex14p. Examples hereof are liver or the corpus luteum. 
Online gene expression profile analyses (performed with BioGPS, www.biogps.gnf.org) 
show that PEX14 is expressed in similar amounts in most organs and cells types unlike ABCD3 
and especially CAT which show major differences between different organs and cell types. 
Furthermore PEX14 appears to be expressed in all analyzed samples, whereas catalase is not 
(Fig. 4_1). 
 
Fig. 4_1: Gene expression charts for PEX14, CAT and ABCD3; performed with BioGPS 
 
The importance of peroxisomes for healthy bodily functions is becoming more evident 
from year to year. Especially since the discovery that not only functional catalase is necessary 
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for peroxisomal defense against oxidative stress, as shown in patients suffering from X-ALD 
(Powers et al., 2005). The absence of the lipid transporter ABCD1 (formerly known as ALDP, 
adrenoleukodystrophy protein) leads to an accumulation of VLCFA, which in turn causes an 
imbalance in oxidative homeostasis in various tissues (Fourcade et al., 2008). Similar 
observations were made in mice after genetic knockout of the transporter ABCD2 (Fourcade 
et al., 2009). It has been shown under these circumstances that loss of peroxisomal 
antioxidant capacity, and thereby oxidative stress, is shown through an increase in 
mitochondrial manganese superoxide dismutase (SOD2). This relationship between 
peroxisomal and mitochondrial antioxidant defense appears to be vital for the equilibrium of 
oxidant and antioxidant chemicals within the body. For example, Baumgart et al. (2001) 
investigated the behavior of mitochondria in the Pex5p-knockout mouse, the first ever mouse 
model for Zellweger syndrome (Baes et al., 1997), to find proliferation of mitochondria with 
significant differences in ultrastructure, respiratory chain proteins and enzymes as well as a 
significant upregulation of mitochondrial SOD2. 
Also interestingly, Li et al. (2002) showed that a deficiency in the peroxisomal 
biogenesis protein PEX11  leads to a pathological picture similar to that found in patients 
suffering from or in mouse models for Zellweger syndrome (Baes et al., 1997; Faust & Hatten, 
1997; Maxwell et al., 2003), the severest form of peroxisomal biogenesis disorders. Upon 
closer examination, however, it could be shown that peroxisomal function was not 
significantly altered. Similarly hereto, it was shown that the neuronal migration defects 
prototypical to Zellweger syndrome were not caused by the inactivation of peroxisomal -
oxidation pathways (Baes et al., 2002). This was evaluated in mice carrying a defect in the 
gene encoding for multifunctional enzymes MFP1 and MFP2, the second step in peroxisomal 
-oxidation. These mice exhibited no noticeable changes in phenotype at birth.  
It therefore becomes quite obvious that peroxisomal function and involvement in 
various pathogenetic mechanisms are highly complex and far less understood than was 
believed initially. Peroxisomal function is essential as a protector against oxidative stress as 
well as lipid toxicity in many cell types and tissues. This function is, however, not solely 
dependent on single enzyme or protein actions, e.g. catalase, ABCD1 or MFP1/MFP2. 
Furthermore, peroxisomal function is also not solely dependent on functional peroxisomal -
oxidation or lipid import. This can also be shown through the knockout of another 
peroxisomal biogenesis protein encoding gene, namely PEX13 encoding for the peroxin 13 
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(Pex13p). Mice lacking the gene PEX13 exhibit a phenotype similar to that found in Zellweger 
Syndrome (Maxwell et al., 2003), as do mice lacking the gene PEX2 (Faust and Hatten, 1997; 
Faust et al., 2002 & Faust, 2003). 
A possible reason for the usefulness of Pex14p lies in its protein structure and how it is 
embedded into the peroxisomal membrane. The human orthologue was identified by Will et 
al. (1999) and analyzed and described in detail by Oliviera et al. (2002). They find major 
similarities between the Pex14proteins of human, rat and mouse. Overall the protein (in rat) 
has 377 aminos acids, whereof only the first 130 N-terminal amino acids serve as a true 
membrane protein. The remainder of the protein including the C-terminus is completely 
exposed to the cytosol. It is yet unclear, whether the N-terminus of the protein reaches the 
luminal side of the organelle or is in fact also exposed to the cytosol, as proposed earlier by 
Shimizu et al. (1999). It can, however, be concluded that since more than two thirds of the 
Pex14protein are actually cytoplasmic it can easily be accessed and bound to by antibodies 
against epitopes contained within this part of the amino-acid sequence. This optimal 
accessibility makes the protein highly suitable as a marker for comparative morphometry. 
Additionally it could be suggested that Pex14p would be a marker usable for cells and 
tissues of many different species, since, additionally to the species shown in this thesis (Homo 
sapiens, Mus musculus, Rattus norvegicus, Felis catus, and Papio hamadryas), the PEX14 gene 
and proteins sequence are also conserved in Pan troglodytes, Canis lups, Gallus gallus, Danio 
rerio, Drosophila melanogaster, and Anopheles gambiae (HomoloGene: 37936, NCBI). It is 
most likely that many more species share sequence homologies for PEX14 as well as Pex14p. 
 
Over all, the key pathogenetic mechanisms underlying most peroxisomal diseases 
appears to be oxidative stress, defined as a disequilibrium of reactive oxygen species (ROS) 
and antioxidant capacities of the cell. Both the production of ROS as well as the forms of 
antioxidant defense are multifaceted, wherefore it can be assumed that differences in 
peroxisomal content are adaptive mechanisms for combat of different form of oxidative 
danger. It was therefore important to find a common marker for all peroxisomes, which was 
found in Pex14p. In doing so, it is now possible to catalogue the distribution of peroxisomes in 
all tissues and to assess the exact differences in protein and enzyme content by tissue. 
The labeling of peroxisomes in morphological studies for example is by its very nature 
a diagnosis. The usage of a diagnostic tool (in this case a marker protein) for the prediction of 
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an unknown condition (in this case the existence of peroxisomes) is obviously prone to two 
kinds of errors (incorrect negative diagnosis and incorrect positive diagnosis) as well as likely 
to yield two forms of correct results (correct negative diagnosis and correct positive 
diagnosis). A diagnostic testing of this kind, as is done in every case of organelle-labeling 
through a marker protein, is therefore assessable in its quality through Bayes’ theorem and is 
dependent on the one hand on the sensitivity of the diagnostic tool (in this case the 
antibody’s capability of binding to the correct antigen) and on the other on its specificity (in 
this case the capability of the antibody not to bind to other antigens). By respecting the base 
rate of the diagnostic condition (in this case the amount of specific antigens in the cell or 
tissue sample) it is possible to estimate the positive (PPP) and negative predictive power 
(NPP) of the diagnosis, meaning both the validity of the statement that the marker 
successfully labels all of the respective organelles (PPP) as well as that of the statement that 
everything which is not labeled is also not the organelle in question (NPP). This theoretical 
reasoning easily goes to show the value of Pex14p as a marker for peroxisomes: Pex14p is (to 
date) known to be part of every intact peroxisomal membrane. The Pex14p-antibody has 
been shown through Western blotting to have a highly specific affinity for its antigen. And 
finally, the antibody exhibits a high sensitivity for its respective antigen, as shown through 
studies on partially decayed tissue samples from human body donors to the gross anatomy 
course (Fig. 3.1_6). One can therefore argue that Pex14p is not only suited best as a marker 
protein for peroxisomes due to its cell biological properties, but also due to its probabilistic 
assets, meaning that not only the labeling as such is excellent, but also the validity of the 
diagnostic conclusion based on this labeling. 
 These findings provide the possibility for future explorative and morphometric 
studies on alterations of the peroxisomal compartment in all tissues and cell types und 
different experimental conditions as well as in various human disorders, like schizophrenia. 
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4.2 Dopamine neurotoxicity, schizophrenia and peroxisomal metabolism 
 
 Although studies analyzing the protein abundance and activity of various peroxisomal 
enzymes, like catalase, DAAO or D-AspOx, find differences both between schizophrenic 
patients and controls as well as the result of dopamine neurotoxicity in vitro, no data exists in 
literature regarding the abundance or distribution of peroxisomes as an organelle in 
morphological and morphometric analyses. As could be shown in figure 3.2_1 the low amount 
of catalase in the healthy brain of humans makes the immunohistochemical labeling very 
difficult and does not allow for comparative morphometric analyses between schizophrenia 
patients and controls. Stainings for Pex14p, however, open the door to the localization of 
peroxisomes in the human brain and make more detailed in situ analyses of peroxisomal 
behavior in schizophrenia possible. The minute differences in peroxisomal size and 
distribution as shown also in figure 3.2_1 are, however, very subtle and should not be 
overinterpreted, due to the lack of information regarding the medical histories and case 
histories of the patients analyzed in these experiments. This holds true not only for the 
schizophrenia cases, but also for the controls, of whom not more information was available 
other than that they had never been diagnosed with schizophrenia and did not show any 
other detectable neuropathological alterations. To investigate the differences regarding 
peroxisomal abundance and distribution more detailed and especially controlled analyses are 
necessary. These, however, usually prove hard to accomplish, since sufficient numbers of 
standardized cases (e.g. first-episode patients or patients treated with known 
pharmaceuticals for known spans of time etc.) are generally not available. 
 It was therefore necessary to perform in vitro and animal studies in order to control as 
many confounding variables as possible.  
 
 4.2.1 Effects of dopamine treatment on primary murine neuronal and astrocyte cultures 
All analyses were performed under the assumptions mentioned in the chapter on 
dopamine metabolism, namely that the causal factor underlying the schizophrenia phenotype 
is mesolimbic hyperdopaminergia, that dopamine is neurotoxic by leading to the formation of 
ROS and that systemic injections of NMDAR-antagonists (like MK-801) in turn cause 
mesolimbic hyperdopaminergia. As illustrated also in the aforementioned chapter there is 
sufficient evidence in literature to support all these assumptions. Unfortunately the complex 
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interactions known to exists between various bodily functions and organs as well as between 
functional parts of the brain and systems of neurotransmission make it highly improbable that 
even the best animal model, be it through drug challenges or knock outs/downs of possible 
candidate genes, will be able to explain all of the differences found between schizophrenics 
and healthy controls or the differences within the rather heterogeneous group of phenotypes 
characterized under the diagnosis of clinical schizophrenia or related disorders. This is 
exacerbated by the still rather vague knowledge regarding the etiopathogenesis of 
schizophrenia spectrum disorders. The main advantage of in vitro or animal research, 
however, is the possibility to perform qualitative research through (relatively) controllable 
alterations to a cell culture or animal environment, metabolism or genome and use the 
gathered information to form more precise hypotheses, which can then be translated, 
operationalized and tested in human samples. The results of the second part of this thesis 
should therefore be viewed as well as interpreted in this light, namely as qualitative and 
hypothesis-generating, rather than quantitative and hypothesis-testing. 
 Incubation of primary murine neuronal cultures with different concentrations of 
dopamine showed a resulting dose-dependent increase in catalase abundance especially in 
astrocytes and neuronal perikarya. This allows the conclusion that hyperdopaminergia indeed 
leads to an increase in H2O2-production in both cell types. It also suggests that initially cells 
are able to activate compensatory antioxidant pathways, which raises the question whether 
or not these antioxidant defense mechanisms are sufficient to prevent oxidative stress as 
defined by disequilibrium between ROS production and ROS degradation. Unfortunately it 
was not possible within this thesis to measure the levels of oxidative damage and compare 
them to the activation of antioxidant pathways. Additionally the influences on other 
(peroxisomal, mitochondrial and cytosolic) antioxidant defense mechanisms like the 
peroxiredoxins, superoxide dismutases or the glutathione system have yet to be examined in 
this experimental setting. The lack of a major increase in cell death even in the cultures 
treated with extremely high dopamine concentrations suggests that the effects of dopamine 
neurotoxicity need to be prolonged in order to influence neuronal survival, as is hypothesized 
in Parkinson’s disease. This is also in line with findings of little cell death and gliosis in post-
mortem brains of schizophrenic patients. It is therefore arguable, if dopamine neurotoxicity 
over a specific time span may lead to neuronal degradation resulting in a Parkinsonian 
phenotype, that the underlying mechanisms in the schizophrenic brain must be different. This 
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is further supported by findings on cell death and catalase abundance in primary murine 
neuronal cultures treated with haloperidol. In these experiments there was also a dose-
dependent increase in catalase, which was, however, markedly higher compared to 
dopamine-treated cultures and was accompanied by an increase in cell death, which was also 
dose-dependent. Since haloperidol is known to lead to a Parkinsonian phenotype in patients 
it can therefore be seriously questioned, whether the causal relationship between disorder 
and oxidative stress reported in literature is the same for schizophrenia and Parkinson’s, even 
though both conditions involve dopamine neurotoxicity. And since oxidative stress is far 
better established as a causal factor for Parkinson’s, it would seem that the relationship in 
schizophrenia is probably different, likely vice versa, in that schizophrenia is not caused by 
oxidative stress, but rather that schizophrenia results in oxidative stress. 
 The influences of ROS production in schizophrenia may, however, play an important 
role in the maintenance of the disorder and also, in part, the expression of specific symptoms 
like progressive loss of gray matter volume as well as cognitive decline, even after the 
cessation of psychosis. The reduction of peripheral processes of both neurons and astrocytes 
(Fig. 3.2_2) would be in line both with the aforementioned argument and with the findings of 
atypical neurodegeneration. The novel technique of peroxisomal labeling with Pex14p 
additionally shows a reduction and redistribution of peroxisomes from the peripheral 
processes to the perikarya upon treatment with dopamine. It can therefore be argued that, 
albeit that dopamine does not lead to neuronal death, it probably leads to a reduction of 
dendritic arborization and synaptic density, thereby influencing the balance between 
neurotransmitter systems. As mesolimbic pathways project into various areas involved in 
functions that are attenuated in schizophrenia, like the NAcc, the hippocampus or the 
prefrontal cortex, and as these regions are known for their glutamate transmission, it is 
therefore safe to argue that a reduction of synaptic connectivity in these regions will also 
affect the glutamate system.  These results therefore suggest in vitro quite clearly that there 
probably is a link between “dopaminergic noise and glutamatergic silence” (Bernd Gallhofer, 
conference statement, 2010). Since both facets are discussed heavily in schizophrenia 
research, these findings support an integrative model, whereby frontal hyperdopaminergia 
causes hypoglutamatergia, rather than the idea of two separate concepts in which dopamine 
and glutamate are independent entities. 
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 Since the observed differences in Pex14p and even more so catalase content were 
most pronounced in astrocytes and since astrocytes are important cells for the regulation of 
NMDAR-linked glutamate transmission, the effects of dopamine incubation on pure primary 
murine astrocyte cultures were examined. This also links back to peroxisomal metabolisms, as 
two enzymes important for NMDAR-cofactor metabolism, namely DAAO and D-AspOx, are 
localized solely in peroxisomes and are both shown to be altered in activity and abundance in 
schizophrenia. The genes encoding these proteins are both considered candidate or risk 
genes in schizophrenia research. Figures 3.2_5 and 3.2_6 showed that astrocyte cultures were 
devoid of neurons and that increasing concentrations of dopamine lead to a dose-dependent 
discoloration of the medium. It can therefore be assumed that there was a chemical reaction 
caused by dopamine. This does not, however, influence levels of cell death, similar to 
neuronal cultures, even in markedly higher concentrations and over the course of 24, 48 or 72 
hrs of incubation. Since the cultured astrocytes were able to take up dopamine and react with 
dopamine through receptor binding, it can be assumed that the treatment not only leads to 
an increase of extracellular, but also intracellular dopamine concentrations as well as 
metabolic cAMP-dependent pathways. No differences were observed in the expression 
profiles of dopamine receptors, the dopamine active transporter or dopamine synthesizing 
enzymes. This can be explained through several possible arguments: Firstly, the reactions of 
neurons and astrocytes are heavily dependent on each other, whereby astrocytes react to 
neurotransmitter/cAMP-mediated intracellular increase in Ca2+-levels with a production of 
signal molecules for the regulation of synaptic transmission (Newman, 2003; Volterra & 
Meldolesi, 2005). It could therefore be assumed that the lack of cross talk between neurons 
and astrocytes in these cultures significantly alters the astrocytes’ metabolism. This argument 
is probably especially relevant for dopamine synthesizing enzymes. Since this is not primarily 
a function of astrocytes it is not surprising that expression levels of this group of enzymes are 
not altered in cultures without neurons. As is shown in figure 3.2_9 the basal expression 
levels of both enzymes are relatively low to begin with. Secondly, other experimental setups 
involving various stimulation or inhibition of different dopamine receptors generally show 
few to no differences in receptor expression levels, albeit that some studies report 
differences in receptor protein abundance (Maus et al., 1993; Horiuchi & Felder, 1996; 
Autelitano & van den Buuse, 1997; Lammers et al., 1999a; 1999b; Unger et al., 2008). It would 
therefore appear that short-term alterations of dopamine receptor density do not require 
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alterations of gene expression, but are regulated on the post-transcriptional level. Thirdly, the 
amount of time necessary for alterations in expression profiles for dopamine receptor genes 
might be longer than 72 hrs. Finally, Hirrlinger et al. (2002) showed that blocking of dopamine 
receptors in cultured astrocytes did not influence the oxidation of intracellular GSH to GSSG 
upon treatment with astrocytes. It could therefore be argued that the detoxification of excess 
dopamine by astrocytes in vitro is not necessarily dependent on dopamine receptor binding. 
   
 In general it has to be emphasized that RT-PCR, as performed in this thesis, is neither a 
quantitative method nor is it capable of reliably detecting subtle differences between 
expression levels. For the detection of finer alterations in a more reliable fashion quantitative 
PCRs or other methods of expression profiling, like microarrays or SAGE (serial analysis of 
gene expression) need to be performed. 
 The fact that the expression levels of the three dopamine degrading enzymes are 
barely changed can be interpreted in different ways. The slight increase shown in MAOB 
expression, but not in MAOA, taken in light with the initially higher basal expression rate of 
MAOA, allows for the hypothesis that enzymatic content of the cultured astrocytes is 
sufficient for the degradation of the increased levels of dopamine. Since detoxification of 
metabolites of neuronal activity is one of the primary functions of astrocytes it would be 
necessary for these cells to express all necessary enzymes regularly and in ample quantities. 
Due to the fact that dopamine is degraded by both MAOs equally, the high basal expression 
levels of MAOA would therefore only necessitate the observed slender increase in expression 
of MAOB and COMT. As described above, the chemical interaction between neurons and 
astrocytes in vivo is known to play an important role in the regulation of astrocytal function. 
Since these are missing in these in vitro cultures it could be argued that the cells have no 
reason for a further transcription of the genes in question. The increased dopamine levels 
obviously do not appear to be life threatening to the cultured cells as can be shown through 
the lack of increase in cell death even in highest concentrations after 73 hours, although 
these latter cultures do begin to show signs of reduced over-all metabolic function. 
 An alternative explanation to lack of necessity to increase numbers of mRNA copies 
could be again that major alterations to the dopamine degrading system occur on a post-
translational level. To examine this hypothesis it would be necessary to examine the stability 
of the mRNA copies, the enzyme content of the cells as well as the activity of the enzymes 
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and compare these values between groups. It could be possible that, regardless of relatively 
little change in gene expression, either or all of these values may still increase. 
 The effects of dopamine incubation on genes coding for selected peroxisomal proteins 
are also hardly visible. PEX14 is the only gene that appears to be induced in concentrations of 
1 M dopamine and higher after 72 hrs of incubation, albeit only slightly. Since Pex14p as an 
integral membrane protein is a part of every peroxisome, the elevation of the expression of 
the PEX14 gene can be considered as indicative of peroxisomal proliferation in these cultures. 
The lack of increase in ABCD3 expression shows that peroxisomal proliferation is a selective 
process, wherein new peroxisomes could cater adaptively to those functions required in a 
given cell or tissue. Since ABCD3 is a transporter for very long chain fatty acids (VLCFAs) into 
the peroxisomal matrix, it is not required in cells confronted with an increase in dopamine 
related ROS production. The expression of the enzyme more relevant in this context, catalase, 
is, however, also not induced in a detectable fashion. This could be due to the limitations of 
the method, but could also mean that the level of catalase present in the atrocytes as well as 
the basal level of catalase are already sufficient for the degradation of the increased levels of 
ROS expected to be induced by dopamine treatment. Due to the high efficiency of catalase, 
the latter argument does not appear unlikely. Furthermore, the argument of enzyme activity 
also needs to be considered, similar to the enzymes involved in degradation of dopamine. To 
answer this with any given amount of certainty additional enzyme activity assays would need 
to be performed. Since catalase activity is reduced by almost 75% in the developing mouse 
cortex between postpartum days 2 and 49 (Ahlemeyer, 2007) it would not be unlikely that 
initial demands regarding an increase in H2O2-degradation could be compensated for by 
activity increases of catalase rather than an immediate increase in the expression of new 
protein. Since dopamine was shown to increase the activity of Nrf2 (Shih, Erb & Murphy, 
2007), which in turn regulates a variety of antioxidant mechanisms, it would be interesting to 
compare the expression levels of the CAT-gene to those of other Nrf2-activated genes in 
order to address the question of selective and differential antioxidant activation. This would 
then also raise the question on molecular mechanisms of this differential activation, since 
H2O2 is not only an activator of Nrf2, but also the direct substrate of catalase. This differential 
activation mechanism is not only a possibility for interindividual regulation of various genes 
within the same cell, but also for intraindividual differences in expression patterns in or 
without the presence of neurons. This could possibly be regulated through the level of Keap1 
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(kelch-like ECH-associated protein 1), a major regulator of Nrf2 activity, within the different 
cultures. Since Nrf2 is expressed constitutively its activity is controlled through degradation 
by ubiquitylation, which is promoted by Keap1 (Nguyen, Nioi & Pickett, 2009). The increase in 
catalase as shown in figure 3.2_2 in astrocytes cultivated in the presence of neurons in 
comparison to pure astrocyte cultures (Fig. 3.2_8) suggests higher levels of H2O2 in the first 
cultivation condition. Whether this comes from neurons via passive diffusion or is produced in 
the astrocytes at higher levels due to neuronal signaling is unclear, but in any case the 
increase in H2O2 would lead to a higher level of degradation of Keap1, a protein high in 
cystein residues (Nguyen, Nioi & Pickett, 2009), the thiol moieties of which are prone to 
oxidation by hydrogen peroxide and other oxidizing agents. Since Keap1 is only expressed in 
moderate amounts in the brain to begin with, compared to other tissues (online expression 
pattern analysis performed with BioGPS), it could be assumed that the added degradation of 
Keap1 through an increase in H2O2 in intact neuron-astrocyte interaction would therefore 
lead to a potent activation of Nrf2. It is therefore a possibility that the differential regulation 
of catalase expression, or rather the relative lack of regulation in pure astrocyte cultures, 
could be lead back to reduced enzymatic dopamine degradation or to increased H2O2 
degradation or the added effects of both in comparison to cultures with neuron-astrocyte 
interactions. Therefore, interesting aspects would be to research the expression levels of 
Keap1 in schizophrenic patients and the therapeutic effects of Keap1-inhibitors or Nrf2-
agonists as potential palliatives. 
 In closing, albeit apparent that astrocytes are by far more robust to increased levels of 
dopamine compared to neurons, incubation with the highest concentrations of dopamine 
(200 M & 500 mM) for 72 hrs resulted not only in a decrease of general levels of 
transcription (data not shown here, see diploma thesis: Fischer, 2011), but also in a reduction 
of protein content not only for catalase, but also for GFAP (Fig. 3.2_8). Since cellular survival is 
not decreased in these cultures it could be assumed that the apparent reduction in overall 
cell activity is due to a kind of “cellular sickness behavior”. 
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4.2.2 Effects of treatment of male pubescent C57Bl/6J-mice with the NMDAR-antagonist 
MK-801 
 1 h after treatment of animals with MK-801 a clear increase in the expression of the 
gene for serine racemase could be observed (Fig. 3.2_16). This is considered as internal 
positive control for the effectivity of systemic (i.p.) MK-801 administration in the brain, in 
addition to the observations of expected phenotypical behavior in the animals by blind 
independent raters. It can therefore be assumed that MK-801-treatment managed to induce 
the desired pharmacological schizophrenia phenotype within this set of experiments. 
 Additional RT-PCRs showed increases in the expression of D-AspOx and to a lesser 
extent PEX14. Since MK-801 rapidly induces serine racemase expression, the elevated levels 
of D-serine are likely to lead to an increase in D-amino acid degrading enzymes. This was 
shown by Yoshikawa et al. (2004b) for D-amino acid oxidase and would also be expected in 
the case of D-aspartate oxidase, not only due to the fact that both enzymes have synergistic 
function, but are both also found exclusively in peroxisomes (Zaar et al., 2002). When 
comparing the time courses of the increases in expression of serine racemase (Yoshiakwa et 
al., 2004a) and D-amino acid oxidase (Yoshikawa et al., 2004b), the time delay in transcription 
induction between the two genes (maximum expression in serine racemase after 1 h vs. 4 hrs 
for D-amino acid oxidase) could also support the hypothesis that DAAO expression is not only 
induced directly by the increase in dopamine due to the CRE in the promoter and first intron 
of the DAAO gene (Fukui & Miyake, 1992), but also due to the secondary activation via the 
aforementioned increase in D-serine. It is therefore probable that similar mechanisms also 
lead to the increased expression of the D-AspOx gene. The most important aspect is, 
however, that MK-801 induced hyperdopaminergia leads to an increased expression not only 
of D-amino acid oxidase, but also of D-AspOx. It can therefore be assumed that the influences 
between the dopaminergic and glutamatergic systems are bidirectional: NMDAR blockade 
leads to an increase in mesolimbic dopamine, as is established in literature, while 
hyperactivity of the mesolimbic dopamine system in turn leads to an increase in enzymes 
degrading important cofactors of NMDAR-mediated glutamate transmission. This would give 
rise to a vicious circle in patients whose hyperdopaminergia is not caused by administration of 
a drug and is therefore not transient. It also gives rise to the question regarding the chicken 
and the egg: Is it the initial increase in dopamine transmission leading to frontal glutamate 
deficiency, which in turn exacerbates the underlying hyperdopaminergia? Or is the other way 
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around, meaning that initial frontal glutamate hypofunction disinhibits mesolimbic dopamine 
pathways thereby leading to a neurotoxic effect which not only reduces the density of 
synaptic spines on peripheral dendrites carrying NMDARs, but also reduces the availability of 
important NMDAR cofactors? More research is necessary to answer this question. It may also 
be possible that both possibilities could be found in patients, whereby the end-effect would 
be the same. 
 The slight increase in PEX14 expression could be due to a rise in dopamine-related ROS 
levels, but could also be linked to the aforementioned activation of transcription in the genes 
of the two peroxisomal enzymes D-AspOx and DAAO. As the difference in band size is only 
slight it should not be overinterpreted. Since neither the expression of Nrf2 nor CAT is 
induced it is unlikely that ROS levels will have risen substantially 1 h after treatment with MK-
801. The constitutive expression of Nrf2 and the primary regulation through Keab1 as 
described above as well as the high efficiency spectrum of catalase and lack of information 
regarding changes in the activity of the enzyme, however, do not exclude the possibility of 
dopamine-related ROS production after MK-801 treatment. It can therefore probably be 
ascertained that after 1 h there is no oxidative stress, in a sense of disequilibrium between 
ROS production and cellular ROS defense. Since the time is, however, sufficient to induce a 
schizophrenia phenotype in the treated animals, the hypothesis found in literature that 
oxidative stress is a primary cause of schizophrenia, comparable to Parkinson’s disease, 
becomes ever more doubtful. 
 The lack of markedly changed expression levels in the liver samples after 1h of MK-801 
treatment compared to vehicle-treated animals shows that the systemic administration of the 
drug has differential and specific effects in the brain and does not support a primary 
mechanism of ROS production of MK-801 itself. Since drugs blocking NMDAR channels are 
commonly shown to reduce oxidative stress caused by glutamate excitotoxicity it therefore 
becomes most likely that the proposed ROS production after administration of MK-801 is due 
to secondary mechanisms like dopamine neurotoxicity. 
 The inconsistencies in the expression patterns of serine racemase after 25, 49 and 73 
hrs in both groups (Fig. 3.2_18) are not easy to interpret. On the one hand Yoshikawa et al. 
(2004) showed that 8 hrs after MK-801 administration expression levels of the serine 
racemase genes had returned to baseline, but on the other hand Hashimoto et al. (2007) 
reported a significant increase in serine racemase expression after chronic treatment (14 
4. Discussion, summary and conclusions  140 
 
 
days) with MK-801. Since the expression of serine racemase appeared to be highest after 49 
hrs in the vehicle-treated group it could be possible that other factors strongly influence the 
transcription of the gene and mask the effects of the MK-801 treatment. It has been 
suggested that the protein content of the diet fed to experimental animals could be one such 
factor with influence on the serine metabolism (Antflick, Baker & Hanson, 2010). Whether 
this could be relevant regarding the results presented in this paper cannot be excluded, but 
can also not be ascertained without further research. Another possibility could be an 
undetected inflammation in one or some of the control animals, as inflammation has also 
been shown to increase serine racemase expression (Wu & Barger, 2004). 
 The influences of MK-801 on the expression patterns of dopamine-degrading enzymes 
are surprising. It would be expected that increase in prosencephalic dopamine through MK-
801 would lead to a reactive increase in MAO and COMT transcription, as is found after 49 hrs 
of treatment (Fig. 3.2_19). After 25 hrs of treatment as well as after 73 hrs (with the 
exception of MAOA) the numbers of mRNA copies are, however, reduced in the MK-801 
treated animals compared to controls. A possible explanation herefore may be levels of 
plasma glucocorticoids, which have been shown to differentially regulate the expression 
patterns of all three dopamine degrading enzymes (Edelstein & Breakefield, 1986; Carlo et al., 
1996; Lindley, She & Schatzberg, 2005). Although these findings are more than ambiguous 
they all commonly show major influences of glucocorticoids on both expression and activity 
of MAOs and COMT and also show that MAOA and MAOB are differentially regulated and do 
not necessarily follow a parallel course. Since rodents are animals prone to flight it is 
commonly accepted that the act of catching and immobilizing them during injection will be 
perceived as extremely stressful and cause high releases of corticosterone, the primary 
glucocorticoid in rodents, from the adrenals. It is therefore possible that the reduction or lack 
of induction of dopamine degrading enzymes could be caused by increases in the activity of 
the hypothalamic-pituitary-adrenal axis. This can be seen especially in the reduction of MAOB 
expression over time in both the MK-801- as well as the vehicle-treated groups. The reduction 
in transcription levels in the MK-801 animals at all time points regarding MAOB and after 
25hrs in MAOA and COMT as well as after 73 hrs in COMT could therefore be caused by the 
increase in locomotion activity due to drug treatment, which in turn should raise the 
glucocorticoid production. Again, as previously mentioned, possible posttranscriptional 
modifications, e.g. increases in enzyme activity, might also play an important role in the 
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degradation of increased levels of dopamine. On the whole it would seem that the levels of 
dopamine are probably not too high after 73 hrs so that massive increases in the expression 
levels of MAOs and COMT are not (yet) necessary. This would seem to be supported by the 
fact that no morphological signs of increased neuronal death could be observed in any of the 
immunolabeling experiments (Figs. 32._22 through 3.2_24), thus one could argue that, 
although MK-801 leads to a sufficient increase in dopamine to cause a schizophreniform 
phenotype in the animals, after 73 hrs the levels are not yet high enough to cause marked 
neurodegeneration. This argument also supports the hypothesis, that neuronal damage 
caused by oxidative stress is not a primary cause of schizophrenia.  
 Both the expression patterns (Fig. 3.2_21) as well as the immunolabeling results (Fig. 
3.2_23) show little to no increase in PEX14 expression levels or Pex14p abundance. Since 
results from the differential distribution of Pex14p and catalase in various organs including 
the brain show that many peroxisomes are present in neuronal tissue which do not contain 
catalase, it would therefore not be surprising that the slight increases in catalase protein 
abundance and gene expression (Figs. 3.2_22 & 3.2_20) do not require a proliferation of 
peroxisomes, since obviously many peroxisomes exists that can be filled with newly 
synthesized catalase. This again shows the heterogeneity of the peroxisomal compartment. It 
could, however, be reasonable to assume that chronic elevation of prosencephalic dopamine 
levels would at some point lead to peroxisome proliferation. Since degradation of H2O2 
through catalase occurs in peroxisomes, a forced proliferation through treatment with 
peroxisome proliferators (like PPAR -agonists; Shintu et al., 2009) might still prove 
therapeutically relevant in schizophrenia. As catalase has an immense substrate turnover it 
would therefore be probable that an increase in peroxisomes, even if catalase levels were to 
remain unchanged, would therefore still lead to a more efficient ROS degradation, if only 
through an increased capability of sequestering the ROS inside the increased number of 
peroxisomes, thereby preventing damage to other intracellular proteins, fatty acids and 
nucleic acids. 
 The increased expression of GFAP after 25 hrs of MK-801 treatment is expected, since 
similar findings have been reported both for NMDAR-antagonists (O’Callaghan, 1994; Fix, 
Wightman & O’Callaghan, 1995) as well as for various substances increasing dopamine levels 
or dopamine transmission including (meth)amphetamine (Sheng, Cerruti & Cadet, 1994; 
Armstrong et al., 2004), D2-receptor agonists (Sands & Chronwall, 1996) and MAO-inhibitors 
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(Revuelta et al., 1997). Since GFAP is an intermediate filament in the astrocyte cytoskeleton 
and not a functional protein, it is not surprising that an initial increase in expression levels 
after 25 hrs is sufficient and further increases after 49 and 73 hrs are not required. This can 
also be seen in the immunolabeling results, where increased protein abundance can still be 
observed after 49 and 73 hrs, even though expression patterns have fallen back to baseline 
(Figs. 3.2_23 & 3.2_24). 
 Finally, the increases in both catalase and SOD2 protein levels (Figs. 3.2_22 & 3.2_24) 
as well as in the expression levels of the coding genes (Fig. 3.2_20) show that the apparently 
heightened ROS levels caused by dopamine neurotoxicity are compensated for by antioxidant 
defense mechanisms. Whether this increase is sufficient to attenuate ROS-mediated cell 
damage cannot be said, due to the fact that direct ROS measurements or evaluations of 
peroxidation (by)products could not be performed. It is, however, unlikely that the MK-801-
treated animals exhibit significant oxidative stress, since the tissue sections showed no signs 
of morphological differences that would suggest severe neurodegeneration. It can therefore 
be assumed that compensatory inductions of antioxidant enzymes are capable of making up 
for the increase in dopamine-related ROS. In any case, the antioxidant defense mechanisms 
include many more elements than catalase and SOD2 that have not been assessed within this 
thesis. It would therefore again appear that animals do not exhibit significant levels of 
oxidative stress, although they are confronted with increased ROS levels, since they are still 
capable of activating and increasing antioxidant defense pathways. Most studies on patients 
regarding oxidative stress and schizophrenia show the opposite findings, namely a decrease in 
cellular antioxidant defense and an increase in morphological as well as biochemical signs of 
oxidative damage compared to matched controls. 
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4.3 Summary, conclusions and implications for further research 
 
 It could be shown that Pex14p is the optimal novel marker protein for peroxisomes in 
comparative as well as experimental morphometry, as it appears to be present in every 
healthy peroxisome, independently of enzyme content, cell or tissue type. The Pex14p-
antibody is highly specific and selective and can be used in IHC, IF, IGL as well as in 
combination with Qdots®. The epitope also appears to be very well accessible and highly 
stable even in tissues with progressed autolysis. It can therefore be used not only in 
experiments performed with freshly perfused animal tissues, but also be used in human 
tissues with moderately preserved ultrastructure. This is, however limited through other 
factors specific to aged human tissue, such as the accumulation of lipofuscin granules in the 
human brain. 
 Using Pex14p as a marker it was therefore now possible to examine the effects of 
increased dopamine on the antioxidant defense mechanisms using the peroxisome as model 
and studying its reaction to dopamine neurotoxicity in more detail. Cell culture experiments 
showed that dopamine, although not leading to marked increase in cell death, leads to a 
reduction of peroxisomal abundance in peripheral neuronal and astrocyte processes in line 
with the concept of atypical neurodegeneration, combined with an increase in catalase 
content especially in astrocytes. It can therefore be hypothesized that mesolimbic 
hyperdopaminergia and frontal hypoglutamatergia are not separate entities, but rather 
causally linked, in that dopamine neurotoxicity caused reduction of dendritic arborization and 
thereby loss of glutamatergic synapses. 
 When cultivated in the absence of neurons, however, it was shown that dopamine in 
concentrations far higher than were used for neurons and over significantly longer time 
periods has little effect on the cultivated cells. It can therefore be concluded that astrocytes 
play a decisive role in the protection of neurons against dopamine neurotoxicity and are by 
far more robust than neurons. For the antioxidant reactions to be induced, however, intact 
neuron-astrocyte interaction is necessary. This interaction and possible impairments thereof 
are therefore potent fields of research regarding the antioxidant capacity of the brain as an 
organ. 
 Finally, animals treated with the non-competitive NMDAR-antagonist MK-801 for 1, 
25, 49 and 73 hrs showed a schizophrenia-like phenotype 10-15’ after systemic injection of 
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the drug, but no marked differences in PEX14 or CAT expression 1 h after treatment. There 
was, however, an increase in D-AspOx expression, thereby showing in vivo that MK-801-
induced hyperdopaminergia may in turn lead to NMDAR-hypofunction. 
 Continued treatment with MK-801 over 25, 49 and 73 hrs showed differential effects 
on the expression on genes coding for dopamine degrading enzymes. A slight increase in gene 
expression was observed after 49 hrs in MAOA and COMT, while MAOB-levels continuously 
decreased. This could be interpreted in such a fashion that the increased levels of dopamine 
can still be degraded by the existing amount of enzymes, whereby increases in enzyme 
activities are a probable mechanism herefore. Both RT-PCRs and immunolabelings showed no 
conclusive evidence of peroxisomal proliferation within the aforementioned time frame, 
although levels of expression and protein abundance for the two antioxidant enzymes 
catalase and SOD2 increased in the MK-801-treated animals. It can therefore be concluded 
that antioxidant pathways of the brain are still active and can be adapted to increased ROS 
production caused by dopamine neurotoxicity, thereby questioning the proposition that 
oxidative stress is a primary cause of schizophrenia. 
 In conclusion the preliminary results of the exploratory experiments performed within 
this thesis suggest that that schizophrenia is a not disorder caused by oxidative stress, a 
condition in which antioxidant defense mechanisms are relatively hypofunctional, that 
dopamine hyperfunction and glutamate hypofunction are not separate entities, but may 
induce and increase each other in vivo and that dopamine induced neurotoxicity plays an 
important role in the upkeep and exacerbation of the core pathogenic mechanism of 
schizophrenia on the one hand and on the other via the induction of ROS-production leads to 
an increase in atypical neurodegeneration which could play an important role in the 
development and persistence of cognitive symptoms in schizophrenic patients. The results 
lead to the postulation of an integrative model regarding the etiopathogenesis and upkeep of 
schizophrenia based on dopamine neurotoxicity and dopamine-glutamate-interactions.  
 
 
Fig. 4_2: Schematic illustration of the proposed integrative “mesolimbic bottleneck model” of schizophrenia 
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4.3.1 Implications for further research 
In order to further examine the verisimilitude of the aforementioned hypothesis (q.v. 
Fig. 4_2) the results from this thesis need to be replicated in larger samples. Furthermore the 
effects of systemic treatment with MK-801 need to be evaluated over longer time spans in 
order to differentiate between acute and chronic effects of increased activity of the 
mesolimbic dopamine system. Especially regarding findings of decreased antioxidant defense 
in patients suffering from schizophrenia, it would be relevant to ascertain if and when the 
antioxidant defense systems of the brain (which appear to be functional during acute and 
short-term treatment with MK-801) become hypofunctional when confronted with 
chronically elevated dopamine levels. In this respect there is also a strong necessity for 
research into the confounding effects of neuroleptic treatment, since results from this thesis 
show that haloperidol has a markedly higher potential for (oxidative) damage than dopamine 
(q.v. section 3.2.2). It is therefore likely that oxidative stress as found in patients is partly 
caused or at the least exacerbated through treatment with antipsychotic medication, 
especially typical neuroleptics like haloperidol. 
The possibility of palliative treatment of schizophrenia with antioxidant medication is 
therefore another question worth examining based on the findings of this thesis. The animal 
research application for this thesis, approved by the regional board for animal protection, 
incorporates treatment of animals for up to 14 days as well as a second set of experiments in 
which animals are to be treated with a peroxisome proliferator (rosiglitazone) prior to 
injections with MK-801. It is therefore planned to expand upon the preliminary research as 
laid out in this thesis in order to answer some of the aforementioned questions regarding 
both acute vs. chronic MK-801-treatment as well as palliative treatment with drugs 
augmenting antioxidant capacity.  
Additionally a number of targeted experiments need to be performed using 
quantitative methods like real-time RT-PCR (qRT-PCR), microarrays, ELISA (enzyme-linked 
immunosorbent assay) and enzyme-activity assays in larger samples in vivo, in animals and in 
human patients.  
Finally it would be of great interest to examine possible effects of altered dopamine 
transmission in non-clinical samples. Since, on the genotype level, polymorphisms of 
candidate genes for schizophrenia that were also analyzed within this thesis, like DAAO 
(Stefanis et al., 2007) or COMT (Avramopoulos et al., 2002), have also been shown to be 
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associated with the trait of schizotypy, examinations of the genes’ expression patterns could 
show correlations with self-reported schizotypy levels, especially when other factors, like self-
reported life-events or gene methylation patterns would be taken into account additionally. 
Since Stefanis et al. (2004) report that variations in the COMT Val158Met polymorphism are 
associated with schizotypy, but not with cognition, the question arises, whether or not 
atypical neurodegeneration caused by dopamine neurotoxicity might play a role in the 
transition from subclinical schizotypy to clinical schizophrenia. There is an ongoing dispute on 
the question, if schizotypy and schizophrenia are represented by the same continuum or if 
there is a clear dichotomy between the two concepts (conference statement by Gordon 
Claridge, Oxford). It would therefore be interesting to examine the levels of antioxidant 
defense, neurotoxicity and atypical neurodegeneration in schizotypy in order to establish, 
whether these are also continuously distributed and correlated with schizoptypy or whether 
they make the difference between schizoptypy and schizophrenia in a sense that atypical 
neurodegeneration only presents in clinical schizophrenia, but is absent in persons with high 
schizotypy. This would mean that persons high in schizotypy may be prone to develop 
schizophrenia (e.g. through the experience of negative life-events), but that the latter 
condition would then involve additional processes leading to manifest damage to the brain. 
Should this be the case, the question would arise, what the nature of this discontinuity 
between schizotypy and clinical schizophrenia on the neurophysiological, neurochemical and 
neuropathological level would be. It is, however, in the opinion of the author more likely that 
schizotypy and schizophrenia are presented both phenotypically as well as a 
neuropsychologically on the same continuum, wherefore the research into the 
neurophysiological and -chemical correlates of schizoptypy could answer many of the open 
questions in schizophrenia research, but without the additional confounding influences of 
many of the variables (e.g. antipsychotic medication) commonly associated with clinical 
schizophrenia.  
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Appendix A – Materials and methods: Detailed descriptions 
 
A.1 Cell culture  
 
A.1.1 Mixed primary murine neuronal cultures 
Briefly, the cortices were digested for 20’ with 0.1% papain. Afterwards, the 
sedimented tissue sample was gently triturated three times with Pasteur pipettes of 
subsequently smaller opening sizes. The supernatants were removed, transferred to 
neurobasal medium containing 1% trypsin inhibitor and 1% BSA and then centrifuged at 200 
g for 10’ at room temperature (RT). Cell pellets were gently resuspended and the cells were 
seeded onto 35 mm poly-L-lysine-coated Petri dishes containing a coverslip at a density of 3 
x 105 cells. Neurons were cultured in neurobasal medium plus B27 supplement for 6 days 
before experiments. 
 
A.1.2 Primary astrocytes cultures 
Each culture was taken from an entire litter of newborn C57Bl/6J mice. Animals were 
sacrificed through decapitation, after which the brains were excised and the cerebella, bulbi 
olfactorii as well as all non-neuronal tissue was removed. Cortices were digested in a water 
bath for 20’ at 37°C in samples of two or three in 2 ml of 0.1% Papain (Sigma) in neurobasal 
medium (neuronal base medium, PAA) with 0.02% bovine serum albumin (BSA). After 20’ 
the papain solution was removed by pipetting and 1 ml warm medium was added to the 
pellet and the sedimented tissue sample was gently triturated eight times each with three 
Pasteur pipettes of subsequently smaller opening sizes. The supernatants were removed, 
transferred to neurobasal medium containing 1% trypsin inhibitor and 1% BSA and then 
centrifuged at 200 g for 10 min at room temperature (RT). The supernatant was removed 
through pipetting and 5ml warm medium were added. The samples were triturated several 
times and pipette into a glass beaker, mixed again by pipetting and decanted into an 
uncoated FalconTM-culture flask (75 cm2), which already contained 10 ml medium (final 
volume was 25 ml).   
 Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) Low Glucose 
(1g/l) with L-glutamine at 37°C in a Hera Cell 240 incubator (Heraeus) with 5% CO2. 10% 
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(vol/vol) fetal calf serum (FCS), 1% penicillin-streptomycin (100x, PAA) and 1% sodium 
pyruvate (100 mM, PAA) were added to the medium to achieve optimal concentrations of 
amino acids, vitamins and ATP-generation substrates and germicides for the astrocytes in 
the culture. This treatment along with the lack of coating of the culture flask did not allow 
other cells like neurons, oligodendrocytes, microglia, endothelial cells or smooth muscle cells 
from vessels to survive. This method of cultivation along with the length of cultivation did, 
however, allow for the common contamination (Schmitz, 2007) with fibroblasts.  
 The medium was changed on the first day after preparation. Between removal of old 
and addition of new medium (25 ml) cells were washed with 25 ml cold (4°C) PBS (pH 7.4). 
Hereafter cells were cultured for 8-11 days until reaching confluence with medium changes 
every 2-3 days, however, with the omission of the PBS-washing step. Upon reaching 
confluence cells were passaged into Petri dishes (20 cm2). Here for 3 ml of Hank’s Balanced 
Salt Solution (HBSS, PAA) containing 0.05% porcine trypsin were added for 30’’, removed by 
pipetting and another 1 ml 0.05% porcine trypsin in HBSS was added and incubated for 3’. 10 
ml warm medium were added and the entire contents were pipetted into a glass beaker and 
mixed by pipetting. Cells were seeded with 2x104 cells per cm2. To achieve this seeding 
density cells were counted in a Neubauer Improved Counting Chamber and the necessary 
amount of medium was added to allow for the intended seeding concentration. 6 ml were 
pipetted into each Petri dish and the remainder of the suspension in the beaker was mixed 
through pipetting prior to each seeding. Petri dishes intended for subsequent indirect 
immunofluorescence labeling contained an additional uncoated cover slip. Cells were 
cultivated for another 3 days after passaging with a medium change as described above 
(including a washing step in PBS) on the first day after passaging. After the third day medium 
was changed once again (without the PBS washing step) and a defined amount of dopamine 
was added (see section 2.2.2.2 on dopamine treatment). 
 
A.2 Morphological staining techniques 
 
A.2.1 Histological staining 
A.2.1.1 Modified Kluver-Barrera staining: Sections were incubated over night at 60°C 
followed by 3 changes of xylene (5’ each) to remove the paraffin. Afterwards sections were 
rehydrated through a descending series of ethanol (2 x 99%, 1 x 96°; 5’ each) and then 
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incubated in a sealed cuvette in luxol fast blue for 1.5-2 hrs at 60°C. After a brief wash in 
ethanol (96%) sections were hydrated in ultrapure water for 5’ and then differentiated in 
0.1% NaOH (aq) for 20-30’’. The differentiation was stopped by placing the sections in 
ultrapure water and controlled under the microscope. Nuclei and Nissl bodies (rough 
endoplasmic reticulum, rER) were counterstained with acidophilic cresyl violet at room 
temperature for 8-15’, followed by a short rinse in ultrapure water. Sections were then 
dehydrated in an ascending graded ethanol series (70 %, 99%, 1 x 3’ each) and then 
transferred to a 50:50 solution of 99% ethanol and xylene, followed by three changes of pure 
xylene (3 x 3’). Sections were then mounted in DePeX. Kluver-Barrera stains myelin sheaths 
blue, nuclei, nucleoli and Nissl bodies (rER) violet and neuropil cyan. 
 
A.2.2 Indirect Immunohistochemistry (IHC), Immunofluorescence (IF) and 
ImmunoGoldLabeling (IGL) 
A.2.2.1 Principle of indirect immunolabeling: Immunolabeling techniques are based on the 
binding of antibodies (immunoglobins, usually IgG) to specific protein sequences (epitopes) 
in situ within biological materials. Antibodies are raised by treating animals with specific 
antigens of interest. The variety of possible epitopes within an antigens protein sequence 
leads to the creation of multiple antibodies from different parent immunocytes with the 
capacity of recognizing the protein of interest (antiserum containing various polyclonal 
antibodies) within the host animal. These antisera can either be used directly for 
immunobeling procedures or can alternatively be purified further through various methods 
(mostly forms of chromatography and/or precipitation) to include only antibodies against a 
single epitope. Since these antibodies are made in the host animal by clones of one unique 
parent cell, they are referred to as monoclonal antibodies. These antibodies are then labeled 
with either enzymes that catalyze color producing reactions, organic fluorescent dyes 
(fluorochromes) or electron-dense metals (usually gold particles) and therefore be 
visualized. Since the antibody binding to the specific epitope of the target protein is directly 
labeled, this method is referred to as “direct immunolabeling”. 
 In indirect immunolabeling techniques a secondary antibody is introduced, which 
does not bind to the protein of interest, but to the Fc (fragment crystallizable) domain of the 
primary antibody. In this case not the primary, but the secondary antibody is labeled as 
described above. This method increases the sensitivity of labeling compared to direct 
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immunolabeling, since more than one secondary antibody can bind to each primary 
antibody, thereby intensifying the signal yield and ideally reducing the signal to noise ratio. 
For this method it is therefore important that the secondary antibody is raised against the 
species-specific Fc domain of the primary antibody. E.g.: If the primary antibody is raised in 
rabbit (the most commonly used species for these purposes), then the secondary antibody 
must firstly be raised in any species other than rabbit and must secondly be of anti-rabbit 
binding capacity. In some cases the secondary antibody is not a complete Ig-molecule, but 
consists only of labeled IgG-Fab (fragment antigen-binding)-domains. 
 
 
Fig. A.2_1: Principle of indirect immunolabeling (modified from www.di.uq.edu.au/indirectif) 
 
 The most commonly used methods of visualizing labeled antibodies as mentioned 
above shall be explained briefly, since they were all used within this thesis. 
Enzyme linked immunolabeling techniques (e.g. enzyme linked immunosorbent assays 
(ELISA) or immunohistochemistry) involve the catalyzation of a color reaction through an 
enzyme bound to the (secondary) antibody. The most commonly used enzymes are alkaline 
phosphatase or horseradish peroxidase. This method is often slightly modified for the 
purpose of additional signal amplification. Hereby the enzyme is not directly bound to the 
antibody, but rather both the secondary antibodies as well as the enzyme are biotinylated 
and bound to each other using (strept)avidin. The resulting avidin-biotin complex (ABC) is 
known for its high affinity interaction, thereby making it ideal for utilization in scientific 
research. In a final step a specific organic dye is introduced (e.g. 3,3’-diaminobenzidine, DAB), 
which is then converted by the enzyme resulting in a color reaction. In the case of DAB the 
color reaction is brown, but can be intensified by nickel ammonium sulfate to form a black 
product.  
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Fig. A.2_2: Indirect immunohistochemistry principle using the ABC system with DAB or DAB with nickel (NiDAB) 
intensification as reaction substrates (modified from Hoffman, Le & Sita, 2008) 
 
 Immunofluorescence and immunogold staining both involve direct visualization of 
agents bound to the secondary antibody (or Fab-domains of secondary antibodies). 
Fluorescent agents (mostly organic fluorochromes or alternatively crystalline 
semiconductors/quantum dots) are excited by photons of a specific wavelength. These 
photons are absorbed by orbital electrons leading to an increase in quantum state of the 
excited electrons. When these fall back into their ground state another photon is released 
(usually of longer wavelength than the absorbed photon) leading to a fluorescent signal.  
 Using primary antibodies (against different proteins) raised in different species and 
secondary antibodies labeled with fluorescent markers of different emission spectra it is 
possible to perform multiplex immunostainings. 
 Finally, immunogold labeling works upon the same principle as in 
immunofluorescence with the difference of electron dense colloidal gold particles 
conjugated to secondary antibodies rather than fluorescent materials (quantum dots can be 
used both in both immunofluorescence a well as in immuno-electron microscopy). 
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Depending on the size of the gold particles they can either by visualized directly or be 
enhanced using silver or gold ions which are reduced to metallic silver/gold in a reaction 
catalyzed by the colloidal gold particles. This leads to an increase in size of the colloidal gold 
particles (q.v. Fig. A.2_2).  
 
 
Fig. A.2_3: Principle of gold enhancement. Using nanogold particles of different initial size allows for multiplex 
IGL-stainings (modified from nanoprobes.com) 
 
This technique is used in cases where larger colloidal gold particles infringe upon the 
ability of the labeled antibody to penetrate into the ultracut section (see Fig. A.2_4). Using 
smaller particles (nanogold), which can then be enlarged during gold/silver enhancement 
solves this problem. During examination under the electron microscope electron dense 
materials like gold, silver or heavy metals (osmium, uranium or lead) deflect the electron 
beam leading to lack of excitation of these areas of the electron-detecting membrane, which 
shows as black signals. 
 
 
Fig. A.2_4: Size comparison between conventional IgG-coupled colloidal gold particle (left) and a nanogold-
Fab’-probe (right) (modified from nanoprobes.com) 
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A.2.2.2 IHC on paraffin-embedded tissue sections: Paraffin was removed from the tissue by 
over-night incubation at 60°C followed by xylene (3x5’), after which the sections were 
rehydrated through a descending graded ethanol series (2x99%, 1x96%, 90%, 80%, 70%, 50% 
and ultrapure water for 5’ each). Stainings for Pex14p, catalase, ABCD3 as well as 
mitochondrial Mn-superoxide dismutase (SOD2) were carried out according to a 
standardized protocol for indirect immunofluorescence on formalin-fixed paraffin-
embedded (FFPE) tissues (based on Grabenbauer et al., 2001 and Baumgart et al., 2003). 
Antigen retrieval was carried out through digestion with freshly prepared 0.01% trypsin 
solution (10’ at 37°C) followed by microwave irradiation (3x5’) at 800W in 10mM citrate 
buffer (pH 6.0) and subsequent cooling back to room temperature (30’-40’). Hereafter the 
sections were incubated with freshly prepared 3% H2O2 (in ultrapure water; for quenching of 
endogenous peroxidases). Washing buffer was 1xPBS (pH 7.4). Non-specific binding sites 
were blocked with 4% bovine serum albumin in PBS (PBSA, pH7.4) with 0.05% Tween 20 
(Sigma) and additional avidin. Primary antibodies were all raised in rabbit and diluted 1:1000 
in 1% PBSA with 0.05% Tween 20 and additional biotin. Antibodies against catalase and 
Pex14p were self-created by Denis Crane (SBPS, Griffith University Brisbane, Australia). The 
antibody against ABCD3 was a kind gift from Alfred Völkl (Dept. of Anatomy and Cell Biology 
II, Ruprecht-Karls-University, Heidelberg). The SOD2- antibody was acquired from Biozol 
Diagnostica GmbH, Germany. 
The secondary antibody against rabbit was biotinylated and visualized through an 
ABC (avidin-biotin-complex)-protocol with the substrates being either Vector®NovaRED™ or 
DAB with nickel enhancement. Nuclei were counterstained with hematoxylin, after which 
slides were dehydrated through a graded series of ascending ethanols and mounted in 
DePeX. 
 
A.2.2.3 Multiplex IF on human and murine brain tissue sections: Main steps were the same 
as described above. During primary antibody incubation three antibodies were used, 
whereof one was raised in rabbit against either Pex14p, catalase or SOD2 (see above). The 
other were an antibody against microtubule associated protein 2 (MAP2, raised in chicken, 
Novus Biologials) and an antibody against glial fibrillary acidic protein (GFAP, raised in 
mouse, Chemicon). MAP2 is expressed in the perikarya and dendrites of most neurons, 
whereas GFAP is expressed exclusively in astrocytes. These antibodies therefore served as 
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cell markers. Secondary antibodies were donkey anti-rabbit AlexaFlour 488 (green emission, 
Molecular Probes), horse anti-mouse Texas Red (orange-red emission, Vector) and anti-
chicken AlexaFlour 633 (deep red emission, Molecular Probes). Cells were only 
counterstained with Hoechst 33258/33342 solution, since TOTO-3 iodide has a similar 
emission wavelength to AlexaFlour 633. Antibodies against Pex14p and catalase were diluted 
1:2000, the antibody against SOD2 was diluted 1:1000. Secondary antibodies were all diluted 
1:300. 
 
A.2.2.4 Multiplex IF on murine primary neuronal and astrocyte cultures: Medium was 
removed from the Petri dishes by pipetting, whereupon cells were washed briefly with three 
changes of warm (37°C) PBS prior to fixing in 4% PFA in PBS for 20’. The fixing solution was 
then removed and cells were washed 3x5’ with PBS. After this cells were incubated for 10’ 
with 1% glycin (Roth) in PBS to assure quenching of unsaturated aldehydes through possibly 
repolymerized PFA. Cells were then permeabilized for 10’ with 0.3% Triton X-100 (Sigma) in 
PBS with 1% glycin, followed by washing 3x5’ in PBS. After removal of PBS the cover slips in 
the Petri dishes were encircled with a PAP-pen (Super PAP Pen IM 35800, Beckman-Coulter) 
to assure that following incubation solutions remain in place over the cells. Blocking solution 
(1% PBSA with 0.05% Tween 20) was added and Petri dishes were incubated at room 
temperature in a humind chamber for 30’, where after blocking solution was removed by 
pipetting and substituted with primary antibody incubation solution. Primary antibodies 
were against Pex14p or catalase, MAP2 and GFAP (see above) and incubated in a humid 
chamber at room temperature for 1h, followed by 3x5’ washing in PBS and subsequent 
incubation with secondary antibodies (see above) for 30’. Hereafter cells were washed again 
3x5’ prior to counterstaining of nuclei with Hoechst 33258/33342 solution (1:750 in PBS). 
After a final 3x5’ washing in PBS cover slips were removed from the Petri dishes with a 
tweezer and mounted onto SuperFrost Plus microscope slides using two parts Mowiol 4-88 
and one part n-propyl gallate.   
 
A.2.2.5 IF using QuantumDots® on mouse and human hepatoma cells: The steps up to and 
including the incubation with the primary antibody against Pex14p are identical to those 
described above in the IF protocol for cell cultures. QuantumDots (QDots, Invitrogen) 
fluorescence was, however, found to be highly dependent on pH of washing buffers and 
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mounting media. Therefore several different modifications of the IF protocol for cell cultures 
were performed and subsequently changed stepwise in order to achieve the final optimal 
protocol for IF using QDots (data not shown here). Since QDot fluorescence was strongest in 
a hydrophobic medium (DePeX) and relatively poor in most aqueous media (including 
Mowiol 4-88 and various buffered glycerol solutions of different pH, with the exception of 
carbonate buffered glycerol, pH > 10) these modifications included the addition of several  
dehydration steps in order to allow for mounting in a hydrophobic medium. The incubation 
with the primary antibody was therefore followed only by a single washing step with PBS, 
where after the pH had to be adjusted to that of the optimal QDot incubation buffer (see 
below). The cells were therefore washed twice in 50mM borate buffer (pH 8.3). QDots were 
diluted 1:500 in 1% bovine serum albumin in 50mM borate buffer with 0.05% Tween 20 
(final optimal QDot incubation buffer). After 30’ of incubation with QDots cells were washed 
several times in borate buffer and then dehydrated and washed (simple dehydration proved 
insufficient for removing unbound QDots) further in a graded ascending ethanol series and 
finally cleared in three changes of xylene prior to mounting onto object slides using DePeX 
mounting medium. QDots are optimally excited by UV-light, wherefore no nuclear 
counterstaining was performed, so as not to outshine the QDots’ signals. 
 
 
Fig. A.2_5: Size comparison between organic fluorophore (left) and Qdot ® (right) antibody conjugates (adapted 
from invitrogen.com)  
 
A.2.2.6 IGL for electron microscopy: All washing and incubation steps were performed on 
drops pipetted onto a specially cast rubber panel. Grids with cryo-ultrathin section were 
washed 3 times in 1xPBS to remove the pick-up solution (2.3M sucrose and 2% methyl 
cellulose). After this all grids were washed in 1xPBS with 0.1% glycin to quench the 
aldehydes from the fixation. Blocking of non-specific binding sites as well as dilution of both 
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primary and secondary antibodies was achieved with 1% BSA-c (Aurion) in normal donkey 
serum without the addition of any detergents. Primary antibodies against Pex14p and 
catalase were diluted 1:2000 (twice as strongly as for light microscopy to reduce unspecific 
background). The secondary antibody against rabbit was coupled with AlexaFour 488 
fluorogold and diluted 1:200. The reaction was fixed after incubation with 1% 
glutardialdehyde (GDA) in PBS for 10mins and the aldehydes were again quenched with 
washes in PBS with 1% glycine. Fluorogold particles were intensified with a silver 
enhancement kits (Nanoprobes, NY, USA; Aurion, Netherlands) and grids were then washed 
thoroughly with deionized water. Resin grids were then contrasted with a saturated aqueous 
solution of uranyl acetate, washed in water and left to dry, whereas cryo-grids were 
conveyed onto two successive drops of nine parts 2% methyl cellulose and one part 
saturated aqueous uranyl acetate. On the second drop the grids were contrasted for 5’ and 
then looped out on a sheet of filter paper and left to dry. 
 
A.3 Reverse transcription polymerase chain reaction (RT-PCR) 
 
A.3.1 Pinciple of RT-PCR 
The basic principle of Polymerase Chain Reaction (PCR) is taken from in vivo DNA 
(deoxyribonucleic acid) duplication during mitotic division of a parent cell into two daughter 
cells. This process, however, depends not only on the activity of DNA-dependent 
polymerases, but also requires the involvement of primarily three other enzymes, namely 
helicase, primase and topoisomerase. Helicase is important for the unwinding of the DNA 
double helix, thereby leading to the formation of the replication fork. Primase is an RNA 
(ribonucleic acid) polymerase which builds short strands of RNA complementary to the origin 
sites of replication. In this context a fourth enzyme, DNA ligase, becomes important, since 
DNA replication, which always goes from 3’ to 5’, on the lagging strand leads to the 
formation of short amplicons (Okazaki fragments) which need to be spliced together to form 
a complete strand of daughter DNA. After replication topoisomerase cuts the parent DNA 
strand and “unwinds” physical stresses which evolve during denaturation of the parent DNA 
by helicase, so that both strands may reanneal to each other without breaking. 
In vitro two of these enzymes (primase and topoisomerase) are not necessary, since 
primers are designed specifically not to bind to origins, but rather to encompass a sequence 
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of the DNA of interest, which is to be amplified. These primers are therefore not synthesized 
during the amplification reaction, but in separate reactions (usually performed by service 
providers). Topoisomerase is also not necessary, since DNA breakage due to physical stress 
may still occur, but unlike in vivo does not pose any further risk to the host. The simplest in 
vitro method of DNA amplification is therefore called helicase dependent amplification 
(HDA), a process involving only parent DNA, site-specific primers and the two enzymes DNA-
polymerase and helicase. HDA is therefore, unlike PCR, an isothermal reaction. 
An alternative to enzyme-dependent separation of DNA strands was found in physical 
denaturation through elevation of the temperature to >90°C. This method was described in 
theory without any evidence of practical application by Kjell Kleppe in 1971, but the 
invention of the actual PCR-method is generally accredited to Kary Mullis in 1983 (described 
in Mullis, Ferré & Gibbs, 1994). First experiments did not, however, involve thermostable 
DNA polymerase, but the Klenow fragment of DNA polymerase I from Escherichia coli 
(lacking nuclease activity compared to the entire enzyme) (Klenow & Henningsen, 1970; 
Klenow & Overgaard-Hansen, 1970). Since the Klenow fragment is also inactivated through 
the temperature elevation necessary for denaturation of DNA, this method involved adding 
new polymerase in each cycle in order to achieve exponential amplification. This problem 
was also solved (and a patent was filed by Mullis and coworkers in 1987) by using a 
thermostable DNA polymerase which had been isolated just over a decade ago (Chien, Edgar 
& Trela, 1976) from the thermophile Thermus aquaticus (Brock & Freeze, 1969). The enzyme 
is therefore commonly known as Thermus aquaticus polymerase (Taq). 
PCR using Taq consists of repetitive cycling between three steps which occur at 
different temperatures. The first steps is the denaturing of the parental DNA strands and 
occurs at >90°C. In many PCR-designs (like in this thesis) an additional single denaturation 
step is included before the first cycle. Within the cycles, denaturation is followed by cooling 
of the reaction mix to optimal primer annealing temperature (depending on primer-melting 
temperature as a function of C/G vs. A/T content of the primer). The final step is the actual 
elongation and thereby duplication of the amplicon at optimal activity temperature of the 
Taq used. These cycles are repeated (usually between 30 and 45 times) and followed by a 
single final elongation step, after which the reaction is terminated by cooling the reaction 
mix to 4°C. 
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In each cycle the amount of amplicons is doubled, leading to fast exponential 
growths of the number of template copied. Due to this, the name polymerase chain reaction 
was chosen. Albeit that chain reaction normally involve the generation of reaction products 
which in turn lead to further reactions of themselves, as is not the case in PCR, each reaction 
product becomes an integral part of the next reaction cycle, wherefore the term chain 
reaction is applicable. Furthermore, due to the fact that amplicons of parental DNA lack 
sequences outside of the primer range (apart from the first amplicons, which are elongated 
beyond the 5’-end of the sequence complementary to the second primer binding region), 
the majority of PCR products have identical number of base pairs (bps) and can therefore be 
analyzed and compared to amplicons of different sizes by means of gel electrophoresis. 
Reverse transcription polymerase chain reaction (RT-PCR; not to be mistaken for Real 
Time PCR) is also taken from in vitro metabolic processes. Normal transcription involves the 
generation of a complementary strand of ribonucleic acid (in most cases messenger RNA, 
mRNA) by RNA polymerase. During this process the aforementioned enzyme binds to 
specific response elements (or promoters) of genomic DNA and transcribes it, this being the 
first (and in cases of non-coding RNAs also the last) step of gene expression. In retroviridae, 
however, this process also works in reverse, whereby the RNA-containing virus uses an RNA-
dependent polymerase (so-called reverse transcriptase) to synthesize a complementary 
single stranded DNA (cDNA) out of an RNA template. The most commonly known 
retroviridae are the human immunodeficiency virus (HIV), the hepatitis B virus (HBV) and 
several strands of leukaemia viridae or other oncoviridae.  
RT-PCR uses these enzymes (mostly mutations of reverse transcriptases isolated from 
Moloney murine leukaemia virus [MMLV] or avian myeloblastosis virus [AMV]) to analyze 
the number of mRNA copies of specific gene, thereby giving an indication of the amount of 
expression of the gene(s) in question. After extraction of RNA, the first step of RT-PCR is the 
incubation with reverse transcriptase to form complementary strands of cDNA (first strand 
synthesis, FSS), which can then be introduced into and amplified in standard PCR reactions. 
Many forms of reverse transcriptase have an additional RNase H-activity, which selectively 
degrades RNAs only in RNA/DNA-hybrids, thereby increasing the purity of the cDNA. 
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Fig. A.3_1: Principle of RT-PCR (modified from Kendall & Riley; 2000)  
 
Apart from this, reverse transcriptases also differ regarding their optimal activity 
temperature. Generally, enzymes with a higher temperature optimum perform better during 
FSS, since RNAs (unlike DNA) possess complex secondary and tertiary structures, which may 
not be fully denatured at lower temperatures. A final point of differentiation between FSS-
reactions depends on the choice of priming. As in DNA polymerases, reverse transcriptase 
also requires a short nucleotide sequence complementary to the origins (primer). Commonly 
two varieties of primers are used during FSS: Olido(dT)-primers, which anneal selectively to 
poly(A)-tails of mRNAs, and random polymer (often hexa-, octa- or nonamers) primers, 
which bind to any complementary sequence of the RNA, thereby not only being limited to 
mRNAs. The enzyme used in this thesis, SuperScript® II Reverse Transcriptase (Invitrogen), is 
an in vitro mutation of MMLV and possesses reduced RNase H-activity, a temperature 
optimum of 42°C and was primed using oligo(dT)-primers. 
General remarks: Prior to RNA extraction all surfaces and gloves were treated with 
chaotropic agents (RNaseZap, Sigma) to avoid RNase contamination. Metal tools (scissors, 
tweezers and scalpels) were incubated for 60’ in 70% ethanol. RNA extraction were 
performed using appropriate kits from Qiagen (RNeasy Mini Kit for cells and tissues; RNeasy 
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Protect Animal Blood Kit for blood samples), wherefore buffer compositions cannot be 
described. Buffer names are those given by Qiagen. 
A.3.2 RNA extraction protocols 
A.3.2.1 RNA extraction from animal tissues: After animals were sacrificed through cervical 
dislocation livers and brains were excised. Brains were cut between mesencephalon and 
diencephalon resulting in two samples: Brain stem and forebrain. Samples were rapidly 
placed into a stabilizing agent (RNA later, Qiagen), quick frozen in liquid nitrogen and stored 
at -80°C. On the day of extraction tissues were thawed and the RNA later was removed by 
pipetting, where after tissues were incubated for 30’ at room temperature with 600 l 
buffer RLT + 6 l -mercaptoethanol ( -ME) in order to lyse the tissue and reduce protein 
disulfide bonds. The tissue was homogenizes in a two-step process. The first step was 
manual homogenization through a needle and syringe method, using 19 G needles for the 
livers and 21 G needles for the brain samples. For the second step 300 l of the pre-
homogenate were respectively mixed with 600 l buffer RLT + 6 l -ME and centrifuged in a 
QIAshredder homogenization column at max. speed for 2’. The lysate was centrifuged for 3’ 
at max. speed, where after the supernatant was removed carefully through pipetting and 
600 l ethanol (in RNase-free water) were added and mixed. 700 l of the sample were 
pipetted onto an RNeasy spin column and centrifuged for 15’’ at >8000 g. The flow-through 
was discarded and the remainder of the sample was pipetted onto the column and 
centrifuged for 15’’ at >8000 g. 700 l buffer RW 1 were added to wash the column and 
centrifuged for 15’’ at >8000 g. The flow-through and collection tube were discarded and the 
column was transferred into a new collection tube. 500 l buffer RPE were pipetted onto the 
column to wash it, followed by 15’’ centrifugation at >8000 g. The flow through was 
discarded and another 500 l of buffer RPE were added, where after the column was 
centrifuged for 2’ at >8000 g with open lid to dry the silica membrane. The RNA was eluted 
using 50 ml RNase-free water in the first and 30 ml RNase-free water in the second 
centrifugation step (each 1’ at >8000 G). RNA was stored at -80°C. 
 
A.3.2.2 RNA extraction from animal whole blood: Blood was collected from the animals 
after cervical dislocation by introducing a syringe into the aorta. 100 l of blood were 
pipetted into 300 l RNA Protect Animal Blood Reagent (Qiagen), inverted 10 times and 
incubated for 2 hrs at room temperature prior to quick freezing in liquid nitrogen. On the 
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day of the extraction samples were thawed and samples from the same animal were pooled 
into 1.5 ml RNase-free reaction tubes. Tubes were centrifuged at 5000 g for 3’, the 
supernatant was decanted and 1 ml RNase-free water was added. The tubes were vortexed 
until the pellet was clearly dissolved and centrifuged at 5000 g for another 3’. The 
supernatant was removed by decanting and 240 l buffer RSB were added and the tube was 
again vortexed until the pellet had dissolved. The sample was pipetted into a new tube along 
with 200 l buffer RBT and 20 l proteinase K, vortexed shortly and incubated on a thermo-
shaker (set at 600 rpm) at 55°C for 10’ to allow for proteinase digestion. The sample was 
then pipetted onto a QIAshredder spin column and centrifuged for 3’ at 19.999 g. The 
supernatant of the flow-through was mixed with 240 l ethanol (absolute) in a new tube, 
mixed by vortexing and then pipetted onto an RNeasy MinElute spin column and centrifuged 
for 1’ at >8000g. The flow-through was discarded and the column was washed with 350 l 
buffer RW1 by centrifugation at >8000 g for 15’’. For on column DNase digestion 80 l of 
DNase I incubation mix (prepared freshly from 10 l DNase I stock solution and 70 l buffer 
RDD) was pipetted onto the silica membrane and incubated at room temperature for 15’. 
Hereafter the column was washed again with 350 l buffer RW1 by centrifugation for 15’’ at 
> 8000 g. Membrane bound RNA was washed from residual guanidinium-isothiocyanate salts 
using 500 l buffer RPE (which had previously been diluted in ethanol as described by the 
provider) by centrifugation for 15’’ at > 8000 g, followed by adding 500 l ethanol (80% in 
RNase-free water) onto the membrane and centrifugation for 2’ at >8000 g. The silica 
membrane was dried by placing the column into a new collection tube and centrifugation for 
2’ at 19.900g with open lids. RNA was eluted with 30 l of elution buffer REB for 1’ at >8000 
g.  
 
A.3.3 RNA denaturation, quantification and quality control 
 All RNA eluates were denatured through incubation for 5’ at 65°C. RNA was 
quantified using a spectrophotometer (BioRad Smart SpecTM 3000). RNA was diluted in 
RNase-free water (1:50 for tissue RNA; 1:25 for whole blood RNA), which was also used for 
blanking the spectrophotometer. An appropriate volume of the RNA eluate (containing 1 mg 
of RNA) was mixed with 0.5 l RNA loading dye (see appendix B) and run through a 
denaturing agarose-MOPS/FA-gel electrophoresis. Here for 1 g agarose was dissolved in 100 
ml RNase-free MOPS-buffer (20 mM 3-(N-morpholino)propanesulfonic acid (MOPS), 5 mM 
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sodium acetate, 1 mM ethylenediaminetetraacetic acid (EDTA), pH 7.0) and boiled briefly 
twice in a microwave at max. power. 1 l ethidium bromide (EtBr) was added and the gel 
was allowed to polymerize in an RNase-free tray with an RNase-free 15-well spacer. The gel 
was run for 30-45’ at 80 V in an RNase-free electrophoresis chamber containing 1x RNase-
free FA/MOPS gel running buffer (2.5 M formaldehyde (FA), 20mM MOPS, 5 mM sodium 
acetate, 1 mM EDTA, pH 7.0). Gels were analyzed in a BioRad Gel Doc 2000 using the 
QuantityOne® (Version 4.3.0, BioRad) software. RNA-integrity was considered sufficient if 
both the 18S and 28S rRNA bands were clearly visible, the 28S rRNA band was roughly twice 
as strong as the 18S rRNA band and there was little smearing between the bands from other 
RNAs. 
 
A.3.3.1 DNase digestion: Since the RNeasy Protect Animal Blood System includes on column 
DNase digestion, post hoc DNase digestion was only carried out for RNA extracted from cells 
and tissue samples. 
 3 g RNA were mixed by pipetting in an RNase-free reaction tube with 3 l DNase I 
(Amp Grade, 1 U/ l, Qiagen), 3 l 10x DNase incubation buffer (Qiagen) and an appropriate 
volume of RNase-free water to reach a reaction volume of 30 l. The mixture was incubated 
at room temperature for 15’ and the reaction was terminated by adding of 3 l EDTA (25 
mM) and heating to 65°C for 10’.  
 
A.3.4 First Strand Synthesis (FSS) with SuperScriptTM II reverse transcriptase 
 30 ml of the DNase digested sample were mixed by pipetting in an RNase-free 
reaction tube with 3 l oligo(dT)12-18-primers (oligo thymidine, 500 g/ml; bind to poly(A) 
tails of mRNA) and 3 l dNTPs (deoxyribonucleotide triphosphates, 10 mM of each) and 
incubated for 5’ at 65°C. The reaction tubes were then chilled on crushed ice and 12 l 5x 
first strand buffer, 6 l DTT (dithiothreitol, Cleland’s reagent, 01 M) and 3 l RNaseOUTTM 
RNase-inhibitor (40 U/ l) were added and the reaction mix was incubated for 2’ at 42°C. 
Subsequently 3 l of the SuperScriptTM II reaction mix (Invitrogen) were added and the first 
strand synthesis was run for 50’ at 42°C. The reaction was terminated through heat 
inactivation of the enzyme at 70°C for 15’. The resulting single stranded cDNA was stored at -
80°C. 
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A.3.5 Polymerase Chain Reaction (PCR) 
 PCRs were pipetted and run in DNase-free PCR-softstrips (0.2 ml, Biozym). Pipetting 
steps were all carried out either on crushed ice or PCR cool blocks. PCRs were run in an 
iCycler thermal cycler (BioRad). 
 PCR single reaction volume was 25 l, consisting of 5.2 l master mix, 1 g (0.5 g for 
samples taken from whole blood) cDNA (X l) and an appropriate volume of AAI (19.8-X l). 
For each primer pair a control samples was run containing just 5.2 l master mix and 19.8 l 
of AAI with the omission of cDNA. 
 The reaction master mix consisted (per sample) of 2.5 l 10x PCR buffer (Taq Buffer 
advanced with Mg2+, 5-Prime), 0.5 l dNTPs (10 mM each, 5-Prime), 1 l forward and reverse 
primers respectively (see above) and 0.2 l Taq DNA-polymerase (5 U/ml, 5-Prime). 
 The PCR protocol began with a single denaturing step at 94°C for 1’ 30’’. Repetitive 
PCR cycles consisted of denaturing at 94°C for 30’’, annealing at optimal temperature (see 
appendix B) for 30’’ and elongation at 72°C for 2’. The protocol ended with a single extension 
step at 72°C for 7’. PCRs were run with optimal number of cycles regarding template and 
primer pair (see appendix B). 
 
A.3.5.1 Agarose-Gel Electrophoresis: PCR amplification products were mixed with 2ml DNA 
loading dye (Blue/Orange 6x loading dye, Promega) and analyzed through agarose-gel 
electrophoresis. 1 g of agarose (2 g for cell culture experiments) was dissolved in 100 ml 1x 
TAE (tris acetate EDTA) buffer and boiled twice briefly in a microwave at maximum power, 
where after 1ml EtBr was added and the gel was allowed to polymerize in a gel tray with an 
appropriate spacer. The gel was run for 30-60’ at 120 V in 1x TAE buffer. Each gel contained 
at least one lane filled with a 1kb DNA ladder (Promega).  
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Appendix B - Recipes and Primers 
 
B.1 Recipes 
 
Borate buffer, 50 mM 
 19.07 g sodium tetraborate (borax) 
 3,09 g boric acid 
 fill to 1 l with ultrapure water 
 adjust to pH 8.3 with boric acid 
 
Citrate buffer 
 stock solution A (1mM citric acid monohydrate; 2.1010 g/100 ml ultrapure water) 
 stock solution B (50mM trisodium citrate dehydrate; 14.705 g/500 ml ultrapure water)  
 15 ml stock solution A 
 85 ml stock solution B 
 fill to 1l with ultrapure water 
 adjust pH to 6.0 and store at 4°C 
 
Cresyl violet solution (0.1%) 
 dissolve 0.5 g cresyl violet in 500 ml acetic acid (1%) 
 
DAB stock solution 
 dissolve 1 g DAB (Sigma, D5637) in 44.4 ml PB (0.1M, pH 7.4) 
 filter and store in aliquots (1 ml, 22.5 ml DAB) in the dark at -20°C 
 
DNA ladder mix 
 40 l DNA ladder (1kb DNA Ladder, Invitrogen) 
 20 l Blue/Orange 6x Loading Dye (Invitrogen) 
 40 l aqua ad iniectabilia (Braun) 
 store in 10 l aliquots at -20°C 
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Formvar solution (for coating of grids) 
 rinse an Erlenmeyer flask with chloroform and add 1.2 g Formvar (Sigma F-6146) 
 slowly add 80 ml chloroform while stirring until Formvar is dissolved completely 
 fill to 100 ml with chloroform, seal and store in the dark 
 
Glycine solution (1%) 
 dissolve 0.5 g glycine (!) in 50 ml 1x PBS (pH 7.4) 
 prepare freshly 
 
Hematoxylin nuclear counterstaining solution 
 dissolve 1 g Mayer’s hemalaun in 1l ultrapure water 
 0.2 g sodium iodate 
 50 g potassium alum 
 50 g chloral hydrate 
 1 g citric acid 
 solution is ready to use 
 
Hoechst 33258/33342 (Sigma) nuclear counterstaining stock solution 
 dissolve 50 mg bis-benzimide (Hoechst 33258 or 33342) in 100 ml ultrapure water 
 store at -20°C 
 
Luxol fast blue solution (0.1%) 
 dissolve 1 g Luxol fast blue, MBS, in 1 l ethanol (96%) 
 add 5 ml acetic acid (10%)  
 
Methyl cellulose solution (for ultracryo microtomy) 
 heat 196 ml ultrapure water to 90°C 
 add 4 g methyl cellulose and stir 
chill on ice to 10°C 
seal container and stir over night at 4°C 
mature solution (without stirring) for 3 days at 4°C 
centrifuge at 100 000 x g for 95’ 
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Methyl cellulose/uranyl acetate solution (for ultracryo microtomy) 
 mix saturated, freshly filtered uranyl acetate solution with the methyl cellulose 
 solution (ratio 1:10)  
 always prepare uranyl acetate and final solution freshly 
 
10x MOPS (3-(N-morpholino)propanesulfonic acid) gel buffer 
 200mM MOPS (41.9 g/l) 
 50mM sodium acetate (6.8 g/l) 
 10mM EDTA (20 ml 0.5M EDTA/l, pH 8.0) 
 fill to 1 l with RNase-free H2O 
 pH titrated to 7.0 with NaOH (aq) 
 
1x MOPS gel buffer 
 100 ml 10x MOPS gel buffer 
 900 ml RNase-free H2O 
 
1x MOPS/FA running buffer 
 100 ml 10x MOPS gel buffer 
 20 ml formaldehyde (37%) 
 880 ml RNase-free H2O 
 
Mowiol 4-88 mounting medium 
 add 20 g Mowiol 4-88 (Polysciences) to 80 ml 1x PBS, pH 7.4 
 stir over night 
 add 40 ml glycerol and stir over night 
 centrifuge at 15 000 x g for 1 hour 
 withdraw supernatant and store at 4°C or -20°C 
 
NaOH solution (0.1%) for modified Kluver-Barrera differentiation  
 0.5 ml NaOH (50%) 
 fill to 250 ml with ultrapure water 
 always prepare freshly 
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Nickel/DAB solution 
 45 ml PB (0.1M, pH 7.4) 
 100 l freshly prepared ammonium chloride solution (18 mg/100 l PB) 
 900 l 0.05M nickel sulphate solution 
 900 l glucose solution (10%) 
 1 ml DAB stock solution 
 stir and filter 
 before use add 150 l freshly prepared glucose oxidase solution (0.18 mg/150 l PB) 
 
n-propyl gallate solution (anti-fading agent) 
 add 2.5 g n-propyl gallate (Sigma) to 50 ml PBS, pH 7.4 
 stir for 1 hour 
 add 50 ml glycerol and stir over night 
 store at 4°C  
 
1x PB (phosphate buffer), 0.2M 
 stock solution A (sodium dihydrogen phosphate, 27.6 g/l) 
 stock solution B (disodium hydrogen phosphate, 35.7 g/l) 
 mix 19.0 ml of solution A and 81.0 ml of solution B 
 store at 4°C 
 
10x PBS (phosphate buffered saline) 
 87.6 g sodium chloride 
 22.8 g dipotassium hydrogen phosphate 
 6.8 g potassium dihydrogen phosphate 
 fill to 1 l with ultrapure water 
 
1x PBS 
 dilute 10x PBS in ultrapure water, adjust pH to 7.4 with NaOH(aq)/NaCl(aq) and store at 4°C 
 
1% PBSA (for ICH/IF) 
 2 g (BSA) 
 100 l Tween 20  
 fill to 200 ml with 1x PBS (pH 7.4) 
 store at -20°C 
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1% PBSA (for IGL) 
 1 g BSA 
 fill to 100 ml with 1x PBS (pH 7.4) 
 store at -20°C 
 
4% PFA (paraformaldehyde) in PBS 
 dissolve 12 g PFA in 100 ml ultrapure water (ca. 60°C) and clear with NaOH(aq) 
 add 6 g sucrose and 30 ml 10x PBS 
 fill to 250 ml with ultrapure water and adjust pH to 7.4 with NaOH(aq)/NaCl(aq) 
 fill to 300 ml with ultrapure water 
store at -20°C 
 
QDot incubation buffer 
 1 g bovine serum albumin (BSA) 
 50 l Tween 20 
 fill to 100 ml with 50mM borate buffer (pH 8.3) 
store at -20°C 
 
RNA loading dye 
 16 l saturated aqueous bromophenol blue  
 80 l 0.5M EDTA, pH 8.0 
 720 l formaldehyde (37%) 
 3084 l 10x MOPS gel buffer 
 2 ml glycerol (100%) 
 fill to 10 ml with RNase-free H2O 
 
Rüdeberg staining for semithin sections 
 0.1 g methylene blue 
 0.1 g thionine (!) 
 1.78 g disodium hydrogen phosphate 
 fill to 70 ml ultrapure water and add 30 ml glycerol 
 pipette onto semithin section and stain on heating plate (70°C) for 1-10’ 
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Sucrose solution, 2.3M (infiltration solution for ultracryo microtomy) 
 80 g sucrose 
 fill to 100 ml with 0.1M PB 
 stir over night until all sucrose is dissolved 
 
Sudan Black B (0.1%) 
 1 g Sudan black B 
 add 100 ml ethanol (70%) and boil to dissolve Sudan black B 
 cool and filter 
 
50x TAE (Tris-acetate-EDTA) buffer 
 242 g tris(hydroxymethyl)aminomethane (Tris, Merck) 
 57.1 ml glacial acetic acid 
100 ml ethylenediaminetetraacetate (EDTA; 0.5M, pH 8.0; Fluka) 
fill to 1l with ultrapure water and adjust pH to 8.0 
 
1x TAE buffer 
 dilute stock solution 50:1 with ultrapure water 
 final concentrations: 40mM Tris, 20mM acetic acid, 1mM EDTA 
 store at 4°C 
 
Trypsin solution (0.01%) 
 add 0.01 g trypsin to 100 ml 1x PBS (pH 7.4) 
 prepare freshly before use 
 
Uranyl acetate solution (saturated, aqueous) 
 dissolve 4% uranyl acetate in ultrapure water 
 filter before use 
 always prepare freshly 
  
  
  
B.2 Primers 
Table B_1: Final selection of primer pairs and respective PCR conditions. Primers were chosen from a number of primers designed for each template and analysed regarding 
optimal temperature and number of cycles (q.v. section 2.5.4).  
Template Forward primer Reverse primer 
Annealing 
temperature 
Number of 
cycles 
28S (tissue samples) CGAAATGCAAGCACGGAGAGT CTGGGTCAGTGGAGAGTGTCTCA 61°C 35 
28S (astrocytes) AAAGCGGGTGGTAAACTCCA   GGTTTCACGCCCTCTTGAAC 62°C 43 
CAT ATGGTCTGGGACTTCTGGAGTCTTC GTTTCCTCTCCTCCTCGTTCAACAC 65°C 35 
COMT1t1 CATTCTGGCCCATAAATGCT GGGGGTCAGAGTGAGTGTGT 62°C 35 
COMT1t3 TTGGACCTGCCTCCTCTAAA CTCATCAGGCTGAGTGGTCA 52°C 35 
D-AspOx CGTTGGAGCTGGCGTGATAGG TCCAGCCACGGGAGGTAGGC 66°C 35 
DAT CATGCTGCTCACTCTGGGTA GACAGAGGCTTCTTTGTGGC 62°C 35 
DDC ATCATGGAAAAGCTGGTTGC TGTGCAAATTTCAAAGCGAG 54°C 43 
DRD1 AGAGGGACTTCTCCTTTCGC AATAATGGGGTTCAGGGAGG 62°C 35 
DRD1 nested AGAGGGACTTCTCCTTTCGCATCCT AGGGAGGAATTCGCCCAGCCA 68°C 30 
DRD2 GATGTGCACAGCAAGCATCT ACACACCAAGAACAATGGCA 62°C 35 
DRD2 nested TGCACAGCAAGCATCTTGAACCTGT ACACACCAAGAACAATGGCAAGCA 66°C 30 
DRD3 TCCCTCAGCAGTCTTCCTGT CGTGAGTCAAGAAGAAGGGC 52°C 35 
DRD3 nested CCCTCAGCAGTCTTCCTGTCTGC GTCAAGAAGAAGGGCAGCCAAC 66°C 30 
DRD4 TGTCGGACCCTACTCAGGGT AACTACCACCGGCAGGACTC 68°C 30 
DRD4 nested CCCTACTCAGGGTCCCTTCTTCCC ACCGGCAGGACTCTCATTGCCT 68°C 30 
DRD5 ACCAAGACACGGTCTTCCAC ATTTCCTCAAGGCCCTTTGT 52°C 35 
DRD5 nested CCAAGACACGGTCTTCCACAGGG GGCCCTTTGTTCTGCGAGTTCCC 66°C 30 
GFAP GAGGAGTGGTATCGGTCTAAGTTTG GCCGCTCTAGGGACTCGTT 61°C 35 
MAOA ACCAGAGCTTCCACCTGAGA TGAAAACTTCAGGACTGGGG 62°C 35 
  
Table B_1 (continued) 
MAOB GAGCAACAAAAGCGATGTGA AACTGAACCCAAAGGCACAC 61°C 35 
Nrf2 CCACTGGTTTAGCCATCTCTCC GTGGACATTAGCCCTTCCAAAC 66°C 35 
PEX14 CACTGGCCTCTGTCCAAGAGCTA CTGACAGGGGAGATGTCACTGCT 56°C 36 
SerRac1 TCAAATAGCAGGGCGCAATCT GGTAAGGAGCTGGCCGTTCA 56°C 35 
SerRac2 CCTGCAGTGATAGCTGGACA AAGCCAATGCTGGATTTGAC 56°C 35 
SOD2 ATGCAGCTGCACCACAGCAA ACTTCAGTGCAGGCTGAAGAG 62°C 35 
TH CCACGGTGTACTGGTTCACT GGCATAGTTCCTGAGCTTGT 62°C 43 
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